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Nie, Haichen. Ph.D., Purdue University, December 2016. Acid-Base Reactions in 
Different Solid-State Forms. Major Professor: Stephen Byrn. 
 
Most drug substances are reported to be either weak acids or weak bases. Hence, acid-
base reactions are commonly observed in pharmaceutical systems with samples including 
salts, amorphous solid dispersions, and in formulated products. Salt formation of active 
pharmaceutical ingredients (APIs) is widely recognized as one of the most commonly 
used approaches to modify the solubility and dissolution rate. Formulating poorly water-
soluble weak acids or weak bases into salts can not only increase bioavailability, but also 
improve the stability and manufacturability of APIs by changing their solid-state 
properties. However, from a formulation perspective, acid-base reactions might occur 
between APIs and ionizable excipients, which would induce deleterious form conversions 
or chemical degradation of the APIs during storage or manufacturing. Therefore, 
understanding the fundamentals of acid-base reactions is critical to design a robust 
formulation and to avoid drug-excipients incompatibility issues in multicomponent 
pharmaceutical products.  
This research is divided into two parts to comprehensively understand the acid-base 
reaction in different solid-state formulations. The first part focuses on utilizing acid-base 






dispersion system. The key moiety of each component, the binding motif, and the 
underlying mechanism of solid state acid-base interactions are illustrated in this part. In 
the second part, the focus is on the salt disproportionation, an adverse effect of an acid 
base reaction between drug and excipients in different formulations. The impact of 
properties of different excipients, hygroscopicity of formulation, and reaction products on 
the kinetics and extent of disproportionation are investigated herein. Furthermore, 
feasible formulation approaches are developed to effectively slowdown salt 
disproportionation process during storage and manufacturing.  
The overall goal of this research is to reveal the mechanisms of acid-base interactions in 
different pharmaceutical systems and to better understand the dominant factors 
influencing these reactions. An additional objective is to better understand proton transfer 
and interaction patterns between drug and excipient, and to develop effective formulation 
strategies to minimize the risk of salt disproportionation. Moreover, this thesis also 
reports efforts of developing new validated analytical methods to monitor and detect the 





CHAPTER 1. THEORY AND BACKGROUND  
1.1 Theories of acids and bases  
A large fraction of active pharmaceutical ingredients (APIs) can be categorized weak 
electrolytes. In order to further investigate the acid base reactions of these weak acids or 
bases in pharmaceutical systems, an understanding of the fundamental theories of the 
acid-base chemistry is required. 1  
1.1.1 Lewis theory of acid and base  
One of the classic theories of acid and base is called Lewis theory, which forms the basis 
of electron transfer. Before discussing this theory, we need to understand an electron 
deficient compound, which contains atoms with less than an octet of electrons. Hence, the 
completion of the octet provides the primary driving force to form the acid or base. Thus, 
Lewis acids are defined as substances that are capable of accepting electron pairs to form 
a new bond in a chemical reaction. On the other hand, a Lewis base is defined as a 
species donating the election pairs to the acid to form the new bonds.2 From a quantum 
mechanical perspective, a Lewis acid is referred as Lowest Unoccupied Molecular 
Orbital (LOMO) which provides the empty orbital to interact with Highest Occupied 





1.1.2  Brønsted-Lowry theory of acid and base 
Another classic theory of acids and bases is named the Brønsted-Lowry theory, which is 
commonly used in pharmaceutical sciences. In contrast to the Lewis theory, the Brønsted-
Lowry theory of acid and base focuses on the movement of protons rather than the 
electron transfer. The substance that donates the proton in the chemical reactions is 
defined as the Brønsted acid. After donating a proton, the Brønsted acid forms its 
conjugate base. In contrast, Brønsted bases are defined as species that accept protons. 
After gaining the proton from the Brønsted acid, the Brønsted base forms its conjugated 
acid.3 The strength of the Brønsted acid can be described by an equilibrium constant, 
which is discussed in the following section. 
1.1.3 Activity and equilibrium constant of water dissociation  
To derive the thermodynamic equilibrium constant, some thermodynamic parameters 
need to be clarified first. For instance, the chemical potential (µ) can be described by the 
following equation, where the standard state chemical potential is symbolized as µ0.  
                                           
0 ln [ ]RT a A                                         Equation 1.1 
The a[A] represents the thermodynamic activity, which is related to the temperature and 
concentration of the substances. The relationship of the activity of A (a[A]) and its 
concentration ([A]) can be expressed as Equation 1.2, where the activity coefficient is 
symbolized as γA. 
                                           
[ ] [ ]Aa A A                                           Equation 1.2 
On the basis of the chemical potential and the activity, the equilibrium constant for a 





situation, the activity of all species can be treated as 1. Therefore, the equil ibrium 
constant can be expressed by concentration (Equation 1.5).  
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                                Equation 1.5 
For an aqueous solution, the water dissociation process, which is also termed 
autoionization, can be described in a similar way.4  The equilibrium of water dissociation 
and its corresponding equilibrium constant, as described by concentration, can be 
expressed by Equation 1.6 and Equation 1.7. In aqueous solution, it is well established 
that the activity of water is constant due to its high concentration (55.55M). Therefore, 
equation 1.7 can be simplified to equation 1.8, where the Kw is defined as the 
autoionization/dissociation constant of water or ion product of water.5 It has been 
demonstrated that Kw is very small (1.007×10
-14). Hence, the Sørensen scale is general 
used to express the Kw as pKw, which has an approximate value of 14 at 25°C (Equation 
1.9). Similarly, [H3O
+] and [OH-] can be expressed by the Sørensen scale as in Equation 
1.10 and 1.11. Therefore, the relationship between the pH, pOH and pKw can be derived 
accordingly (Equation 1.12).  
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log( )w wpK K                                             Equation 1.9 
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1.1.4 Equilibrium constant of acid and base in aqueous solution 
The details of the ionization and equilibrium of acid-base systems will be discussed in 
section 2. In this part, the dissociation of an acid and base in aqueous systems will be 
described and the corresponding equations derived. According to the Brønsted-Lowry 
model, the equilibrium of an acid (HA) donating its proton to water can be expressed by 
equation 1.13. The equilibrium constant (Keq) and dissociation constant for the acid (Ka) 
can be expressed by equation 1.14 and 1.15 respectively. The dissociation constant (Ka) 
is a critical parameter that describes the strength of a Brønsted acid, and can help us to 
understand how well it will transfer a proton a Brønsted base. Typically, each acid has its 
dissociation constant which is expressed in the Sørensen scale as the pKa (equation 1.16). 
It should be noted that, although there is a term called pKb, the strength of basic 
compound is typically evaluated from the pKa of its conjugate acid.  
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log( )a apK K                                                   Equation 1.16 
Furthermore, based on the Equation 1.15, the [H3O
+] can be expressed by equation 1.17. 
Applying the Sørensen scale, Equation 1.18 is derived as the result, which is also called 
Henderson-Hasselbalch equation, and is very useful in describing buffers. For a base, the 
Henderson-Hasselbalch equation is given as Equation 1.19.  
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                                       Equation 1.19 
 
1.1.5 Relationship between chemical structure and acidity 
From a chemical perspective, there are two aspects of chemical structure that influences 
acidity of the compound. The first factor is the element effects. According to the periodic 
table, different elements with different electron density will affect bond strength, and the 
ability to donate or accept electrons. Therefore, substitution of a certain part of the 
organic compound could significantly affect the acidity. Secondly, the polar effect is very 
critical in influencing the acidity of the organic species.  For instance, halogens, or other 
electronegative groups, have electron withdrawing effects which can increase the acidity 





These factors and the chemical structure of the drug should be carefully assessed before 
selecting the counter-ions for the drug substance.  
For organic compounds, the carboxylic acid is the most common acid functional group. 
Structural features that impact acidity will be discussed below. The ionization 
equilibrium for a carboxylic acid is shown in Equation 1.20.  
                               2 3
RCOOH H O RCOO H O  
                         Equation 1.20 
The acidity of the carboxylic acid can be affected by both polar and resonance effects. 
The polar effects of the carbonyl group, which is sp2 hybridized and hence very 
electronegative, can significantly increase the acidity. Additionally, resonance effects can 
stabilize the conjugated carboxylate ions and increase the acidity of the carboxylic acid.  
1.2 Fundamentals of ionic equilibria 
Organic compounds can be categorized as electrolytes or non-electrolytes based on their 
capacity for ionization. It has been reported that two thirds of drug molecules belongs are 
weak electrolytes (weak acid or weak base), which means they have the potential to 
ionize and form salts with other electrolytes.6 Therefore, understanding the ionization 
equilibria of electrolytes provides a foundation for discussion of acid-base reactions in 
pharmaceutical systems including salt formation and salt disproportionation. 
1.2.1 Ionic equilibria of monoprotic electrolytes 
On the basis of the previous discussion of the Brønsted-Lowry theory of acids and bases, 
we understand that the acids are proton donors and bases are proton acceptors. Ionization 
in an aqueous system occurs when protons are transferred as H3O
+ from the donors to 
acceptors. A monoprotic acid (HA) and base (B) will be introduced as an example to 





For the mono-acid, the dissociation equilibrium is shown in Equation 1.21. [A-] and [HA] 
represent the ionized species and unionized species respectively. [AT] symbolize the 
summation of all the species containing A. The derived equations for calculating the 
fractions of ionized (fA
-) and unionized (f HA) species are shown as follows.  
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Similarly, for a mono basic compound, the equilibrium and the equations of fractions are 
demonstrated as follows.  
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According to the above equations for monoprotic electrolytes, it is clear that pKa is an 
essential parameter to determine the ionization of the drug substance and to provide 
critical information about the strength of the acid and base. Specifically, strong acids 
have low pKa values, and can donate protons even in solutions with high proton 
concentrations. On the other hand, strong bases typically have high pKa values indicating 
that they are capable of accepting protons even in solutions with low proton 
concentration. Knowing the pKa value of a drug substance is a prerequisite to calculate 
the fractions of the ionized and unionized species as a function of pH. A commonly used 
organic mono-acid, acetic acid (H3CCOOH, pKa=4.76) is used as an example to generate 
a species distribution diagram (Figure 1.1). This speciation diagram provides information 
to identify the regions with different percentages of ionization. To be specific, in the 
regions with two pH-units higher or lower than the pKa value, more than 99% of one of 
the species would exist in that region. For instance, when pH<2.76, the unionized form of 
acetic acid would be the dominant species in this pH range. In contrast, when pH>6.76, 
more than 99% acetic acid would exist in the ionized form. For the intermediate region 
(2.76 <pH <6.76), the unionized form decreases dramatically with increasing pH, while 
the ionized form is increasing rapidly. Thus, a small shift of pH will lead to a drastic 
change in the faction of ionized or unionized species. The pKa value occurs at the 
intersection of the distribution line for the two species, where the fraction of each species 






Figure 1.1 Speciation diagram of ionized and unionized acetic acid in aqueous solution 
1.2.2 Ionic equilibria of polyportic electrolytes 
Multi-step pH-dependent equilibria should be employed to describe the ionization of 
polyprotic electrolytes. For instance, maleic acid, a commonly used pharmaceutical 
excipient, is a diprotic acid with pKa,1=1.9 and pKa,2=6.07.
7, 8 The two-step dissociation 
equilibrium and the calculated fractions of ionized and unionized species are 
demonstrated as follows. [H2A], [HA
-] and [A2-] represents the unionized acid, the mono-
anion and the di-anion respectively.   
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   
                                    Equation 1.33 
Based on equations 1.30 to 1.33, the speciation diagram of the maleic acid (Figure 1.2) 
can be generated, whereby pKa,1 is determined as the intersection of distribution lines for 
mono-anion and the unionized acid, and pKa,2 is marked as the intersection of distribution 
lines for the mono-anion acid and the di-anion. 
 
Figure 1.2 Speciation diagram of maleic acid in aqueous solution 
1.2.3 Ionic equilibria of amphoteric electrolytes 
Amphoteric electrolytes are defined as substances containing both acidic and basic 






can be categorized as ordinary ampholytes and zwitterionic ampholytes based on the 
relative acidity of the different functional groups. For instance, 4-aminophenol is an 
ordinary ampholytes with a simple chemical structure. It has been reported that the pKa,1 
(amino group) and pKa,2 (phenol group) are 5.48 and 10.46 respectively.
9, 10 The 
equilibrium of 4-aminophenol and its speciation diagram are demonstrated as below 
(Figure 1.3). In the region, pH<3.48, the cation exists as the protonated amine and the 
neutral phenol is the dominant species. In contrast, at the region pH>12.46, the anion, 
neutral amine with phenolate group, is the dominant species. In the scenario of having a 
pKa difference of greater than 2 and pKa
acid ic larger than pKa
basic, it is noteworthy that the 
acidic group and basic group cannot be simultaneously ionized.    
 
Figure 1.3 Speciation diagram of 4-aminophenol in aqueous solution 
On the other hand, zwitterions are characterized by having no net charge when both 
acidic and basic functional group are ionized, and are treated as a special case of 






solution is titrated by a basic solution, the carboxylic acid group is initially deprotonated, 
followed by the deprotonation of NH3
+. The zwitterion is the dominant species in the 
range of pKa,1+2 to pKa,2-2 in the speciation diagram. For salt formation, we want to  
achieve complete ionization state of the drug in order to form a stable salt form.  
Therefore, understanding the pH-dependent equilibria for different types of drug 
substance is a prerequisite to investigate salt formation and disproportionation..   
1.3  Solubility behaviors of acids, bases and salts 
1.3.1 Fundamentals of pH-solubility profiles, Ksp and pHmax 
Understanding the solubility behavior of salts and their corresponding acids or bases is 
critical for salt selection procedures. Generally, the total concentration of an ionizable 
compound in aqueous solution can be described as the sum of the concentrations of the 
ionized form and the unionized form. The solubility of the unionized species is termed 
the intrinsic solubility. As discussed before, the degree of ionization for an organic weak 
electrolyte is pH-dependent. Hence, the solubility of the ionizable form changes 
accordingly to the pH and the physicochemical properties of the salt can be affected. The 
pH solubility profile is defined as the change of solubility of an ionizable compound as a 
function of pH, and can be readily measured by phase solubility methods. 11  To be 
specific, an excess amount of the salt and its corresponding acid or base are added to 
deionized water to obtain a suspension using the shake flask method. The pH of the 
suspension is adjusted and measured to establish equilibrium, applying stepwise titration 
with strong acid or base as needed. The supernatant solution phase is obtained by 
centrifugation of the suspension and subjected to concentration measurement, allowing 






should also be investigated at different pHs to identify the conversion from salt form to 
free acid or base, using powder x-ray diffraction (PXRD) or differential scanning 
calorimetry (DSC).12 
1.3.1.1 The pH-solubility profile of free acid and its salt 
The pH-solublity profile for flurbiprofen, a weak mono-acid, is discussed as an example 
(Figure 1.4) to further illustrate pH-dependent solubility behavior for an acidic weak 
electrolyte.13 In Region I of Figure 1.4 (pH<7.3), the free acid form of flurbiprofen is the 
dominant solid state form (saturated species). In Region II (red, pH>7.3), the sodium salt 
form of Flurbiprofen is the saturated species, i.e. the equilibrium species.  
 







For Region I, deriving from the equation 1.21 and 1.22, the equation of total solubility is 
demonstrated below.   
max
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        Equation 1.34        
In equation 1.34, the ST represents the total solubility at any pH value in region I. [HA] 
and [A-] symbolize the concentration of the unionized and ionized species respectively. 
The subscript s indicates the saturated species in that region. Ka represents the 
dissociation constant (Equation 1.22). Since the intrinsic solubility (S0) is defined as the 
solubility of the free form, [HA] is substituted by S0. Similarly, the pH-solubility curve 




[ ] [ ]
[ ] [ ] [ ] (1 ) (1 )T pH pH s s sp
a a
H H
S HA A A K
K K
 
      
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[ ][ ]spK A Na
 
                Equation 1.36 
The intersection of the two independent curves is termed pHmax, which defined as the pH 
of maximum solubility. For an acidic compound, when the pH value is higher than pHmax, 
the total solubility is calculated by the equation 1.35. On the other hand, when the pH 
value is lower than pHmax, equation 1.34 would be used to calculate the total solubility. 
When the pH is 2 units less than pKa, the solubility is independent of pH and maintained 
as the intrinsic solubility. 14 For the solid phase equilibrated with the solution, the free 
acid would be present at pH<pHmax, while the salt form would be the dominant species in 
the solid phase when pH>pHmax. The free acid and its salt can only coexist at the point of 
pHmax.
15 Inter-conversion between the free acid and its salt can take place when altering 






the pH value will lead to the conversion of the salt to its free acid. Hence, a lower pHmax 
would be favorable for salt formation of acidic substances.  
For equation 1.35, it is important to point out and discuss the term Ksp, which is defined 
as the solubility product of the salt. For a salt formed by sodium and mono-acid, Ksp is 
expressed as Equation 1.36. Since the [Na+] and [A-] are considered equal in the ideal 
situation, [A-]s can be substituted by the square root of Ksp. On the basis of the above 
discussions, the pHmax of weakly acidic compound is described by Equation 1.37.
16  










                          Equation 1.37 
1.3.1.2 The pH-solubility profile of free base and its salt 
The pH-solubility profile of a free base and its salt can be discussed in a similar way 
(Figure 1.5). The total solubility ST at Region I and Region II is addressed by Equation 
1.39 and Equation 1.40. In these two equations, [BH+] and [B] symbolize the 
concentration of the salt and the free base respectively. Similarly, the point where the two 
curves intersect is the pHmax, below which the saturated species would be salt, and above 
which the equilibrium species would be free form. Hence, a pH higher than the pHmax is a 
prerequisite for the conversion of the salt form to the free base form. Otherwise, no free 
base would be precipitated. The equilibrium around pHmax is described as follows. When 
altering the concentration of [H+], the equilibrium would move toward right or left 
accordingly. For instance, when base is added into the system, [H+] would be decreased. 
Therefore, the salt would convert to the free base. This process is called salt 






                                                            Equation 1.38 
For a basic compound, a higher pHmax value would be desirable to prevent conversion 
from the salt to its free from. The equation for pHmax for a basic compound is given by 
Equation 1.41.17 
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1.3.2 Effects of intrinsic solubility, pKa and Ksp on pHmax 
According to the above discussion, pHmax plays a critical role in salt formation and salt 
conversion. Hence, it is necessary to clarify the parameters which would affect the value 
of pHmax. Based on Equation 1.37 and Equation 1.41, we note that 3 factors contribute to 
the value of pHmax including pKa, intrinsic solubility (S0) and the solubility product of the 
salt (Ksp). The calculation of pHmax for a base would follow Equation 1.41. Thus for a 
basic electrolyte, factors influencing pHmax can be summarized as follows: 
(1) An increment of pKa by one unit would contribute to an increase of pHmax by one unit 
(Figure 1.6A) 
(2) An increase in the intrinsic solubility by one order of magnitude would result in an 
increase of pHmax by one unit (Figure 1.7A) 
(3) Two orders of magnitude increase in the solubility product of the salt (Ksp) or one 
order of magnitude increase in the solubility of salt (square root of Ksp) would lead to an 
reduction of pHmax by one unit (Figure 1.8A). 
14 
For an acidic electrolyte, one unit increment of pKa would lead to one unit increase in 
pHmax (Figure 1.6B). Increasing intrinsic solubility by one order of magnitude would 
contribute to a decrease of the pHmax by one unit (Figure 1.7B). In addition, two orders of 
magnitude increase in the solubility product of the salt (Ksp) could result in an increasing 
of the pHmax by one unit (Figure 1.8B). 
In summary, for a basic compound, the higher pKa, higher intrinsic solubility of the free 
base, and lower solubility of its salt would be favorable for forming a stable salt and 
make it more difficult to convert from the salt back to the free base. In contrast, for an 






intrinsic solubility of the free acid would favor the formation of a stable salt with a lower 
tendency to disproportionate. As we know, altering the solid state form of the free form 
and salt form will change the solubility of the resultant substance. Therefore, the kinetics 
and tendency of salt formation and disproportionation will be drastically different for 
different solid state forms.  This is a major topic that we want to investigate in the future 
studies. (Vide Infra)  
 
Figure 1.6 Effect of pKa on pHmax for base(A), acid (B) 
 







Figure 1.8 Effect of solubility product of the salt (Ksp) on pHmax for base(A), acid (B) 
Although Equation 1.37 and Equation 1.41 can be used to theoretically calculate pHmax, it 
should be noted that the pHmax has been reported as a range of pH values rather than as a 
single value. For instance, Serajuddin et.al reported a clear deviation of the pH-solubility 
profile and super-saturation behavior of drug substance around pHmax.
18 The discrepancy 
was attributed to inconsistent nucleation of the free base or its salt. To be specific, the 
differences of nucleation kinetics of different phases, attributed to kinetics barriers, can 
hinder the phase transformation. Hence, the differences of nucleation kinetics between 
the free base and the salt could be a dominant factor for salt formation or conversion from 
salt to free base. Interestingly, these differences account for some of the variability in salt 
disproportionation from compound to compound. 
1.3.3 Effects of counterion and common-ion effects 
1.3.3.1 Effects of counterion 
As we know, a salt is formed by combining the acidic or basic compound with certain 






substances. The details of salt formation and the underlying mechanisms will be 
discussed in the later sections of this document. The counterions used in salt formation 
are termed salt-forming agents. It has been reported that selecting different counterions 
will form salts with different physicochemical properties. For instance, Li et al. 
performed a series of studies for generating the pH-solubility profile of haloperidol by 
titrating with the different acid (Figure 1.9).19 According to Figure 1.9, the maximum 
solubility of the salt and the pHmax is determined by the acid used for the pH adjustment. 
In other words, the properties of the salt significantly related to the properties of the 
counterions selected for the salt formation including melting point, solubility, 
crystallinity, and hydrophobicity. 20, 21 
 
Figure 1.9 pH-solublity profiles of haloperidol with various salt forming agents19 
1.3.3.2 Common ion effects 
The common-ion effect is another factor which can impact the solubility of the salt. 
Direct evidence can be found from Figure 1.9, which shows that when the pH values 






and phosphate start to decrease gradually primarily due to the presence of excess 
counterions generated by the acid at lower pH. A pH-solubility profile measured after 
varying the NaCl concentration is demonstrated in Figure 1.10, which further illustrates 
the common-ion effect.22 In the absence of NaCl, the maximum solubility of the salt is 
higher than its solubility in the presence of NaCl. Moreover, as the concentration of NaCl 
increase, the maximum solubility decreases accordingly. Theoretically, this common ion 
effects can be explained by the following equilibria.  
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The (BH+Cl-)solid symbolizes the non-dissolved solid phase which is in equilibrium with 
the solution. [BH+]s is denoted as the solubility of the salt. [Cl
-], as the counterion, 
represents the concentration of chloride. When an excess amount of counterions is added, 
the equilibrium will move towards to the left side, and the solubility of the salt form will 
be decreased as a result. Without the addition of an excess amount of the counterion, 
[BH+]s=[Cl
-]=√Ks. However, in the present of an excesses amount of counterions, the 
solubility of the salts drastically decreases. The solubility of the salt can be derived using 
Equation 1.44. Furthermore, a more general equation showing counterion effects on salt 
solubility can be derived as shown in Equation 1.45.  According to previous studies, it 
has been demonstrated that the common ion effects mainly depends on the magnitude of 
the Ksp value.
23 For a salt with a higher value of Ksp, the common ion effect of salt 
solubility is less significant than that for a salt with a lower value of Ksp. When weaker 






lower pH, since the percentage of ionization for the weak acid would be decreased at 
lower pH. Therefore, fewer counterions would exist in solution. It is also critical to point 
out that hydrochloride salts will have more impacts from common ion effects especially 
in the GI tract, where [Cl-] will be present in large amounts. 24 
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Figure 1.10 Different pH-solublity profiles of a basic compound in presence of different 
concentration of NaCl22 
1.4 Hygroscopicity of pharmaceutical solids 
The presence of water can significantly influence the physicochemical properties of 
pharmaceutical solids either during storage or sample preparation. For instance, 
norfloxacin can undergo proton transfer induced by the water molecule. Therefore, tablet 
dissolution can be adversely affected by low relative humidity RH25 The extent of 






described hygroscopic.26 Generally, hygroscopicity is defined as the kinetic and 
thermodynamic processes by which solids adsorb and absorb atmospheric moisture. The 
kinetic component determines the rate of moisture uptake, while thermodynamic 
component determines the energy of this process.27 The hygroscopicity of the 
pharmaceutical ingredients can be described by the classification scheme proposed by 
Callahan (Table 1.1).28 
Table 1.1 Hygroscopicity classification scheme 
Class I Non-hygroscopic No obvious moisture increase below 90% RH; less 
than 20% increase in moisture content above 90% RH 
in one week 
Class II Slightly 
hygroscopic 
No moisture increase below 80% RH; less than 40% 
increase in moisture content above 80% RH in one 
week 
Class III Moderately 
hygroscopic 
Moisture content does not increase >5% below 60% 
RH; less than 50% increase in moisture content above 
80% RH in one week 
Class IV Very hygroscopic Moisture content will increase as low as 40–50% RH; 
greater than 20% increase in moisture content above 
90% RH in one week 
 
As discussed above, salt disproportionation is a solution mediated reaction which 
strongly associated with moisture and water activity. Therefore, A detailed discussion of 
the water activity and relative humidity (RH) are addressed herein to determine the 
storage conditions of salt candidates and to better understand hygroscopic behavior of 
pharmaceutical solids. The relative humidity is defined as the ratio of vapor pressure of 
water to the saturated vapor pressure of pure water at the given temperature, water 
activity a[H2O] can be calculated by knowing the saturated vapor pressure (P0) of pure 






to point out the water activity could be easily correlate to the relative humidity by 
multiply water activity with 100% (Equation 1.47 and 1.48). 







                                       Equation 1.46  
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a H O 
                                    Equation 1.48 
 
1.4.1 Water-solid interactions 
Apart from hydrate formation (beyond the scope of this reseach), water solid interactions 
also include moisture sorption behavior (surface adsorption, bulk material absorption), 
capillary condensation and deliquescence, which will be discussed in detail 
subsequently.29  It is important to note that adsorption is specifically relate to the surface 
area of the solid powder, while absorption refers to moisture that penetrates into bulk 
solids leading to potential hydrate formation  
1.4.1.1 Water vapor sorption  
Exposing the solids to water vapor leads to interaction between the water molecules and 
the surface of solid via different types of forces (van der Waals, ionic-dipole or hydrogen 
bonds). This moisture adsorption process can be thermodynamically described by 
Equation 1.49.30 The process of water molecule adsorption from the vapor phase is 
associated with a negative entropy change due to the increasing of the order of the system. 






adsorption process should be exothermic. The strength of interaction will therefore 
determine the reactivity of adsorption process.  
                                 
ads ads adsG H T S                                               Equation 1.49 
Based on these different interaction types, the moisture adsorption can be categorized as 
physisorption and chemisorption. Specifically, weaker interaction forces (like van der 
waals) will lead to the physisorption and contribute a heat of sorption in a range of -10 to 
-40 kJ/mol. 31 On the other hand, chemisorption involves stronger interactions (ionic or 
covalent bonds) between the adsorbates (H2O) and adsorbent (the solids), and typically 
has a heat of sorption in the range of -40 to -1000 kJ/mol. The details of these two types 
of adsorption behavior will not be discussed in this research.   
The water adsorption behavior and hygroscopicity of pharmaceutical solids are typically 
characterized by using dynamic vapor sorption (DVS) to generate moisture sorption 
isotherms, which are plots of the weight changes of the sample as function of RH.32, 33 
The experimental time is highly dependent on the type of sorption. Typically, the surface 
adsorption is faster than the bulk absorption.  
The moisture sorption behavior could be categorized into five different types (Figure 
1.11).34 To be specific, isotherm type I is limited to a monolayer of absorbate. A type I 
isotherm, typically due to chemisorption, is also named a Lagmuir isotherm, which shows 
a plateau due to the full occupation of the binding sites. A classic example of 
physisorption show type II isotherm. It mostly occurs for non-porous materials and the 
inflections indicate the formation of the first mono layer. For type III, the additional 
adsorption behavior is attributed to the formation of multilayers since the heat of 






difference between type II and type IV is the later one is mainly for the porous surfaces. 
Type V, having small adsorbate-adsorbent interaction, is generally associated with 
capillary condensation, which would be introduced together with deliquescence in the 
following session.  
It is import to note that, for some drug substances or excipients, the sorption or 
desorption isotherms may show hysteresis (Fig 1.12). Hygroscopicity studies on salt 
candidates can also show hysteresis. For instance, Figure 1.13 demonstrates the water 
sorption/desorption curves of three salts. Apparently, the hydrochloride salt shows 
marked hysteresis due to the formation of a strong hydrate. In contrast, the hydrogen 
malonate salt shows reversible sorption/desorption.35 This example illustrates the 
importance of determining the sorption isotherms for salt with different counterions 
during the preformulation process. Hysteresis indicates a non-equilibrium system, which 
can make determination of thermodynamic transition points difficult. In such cases, 
slurry equilibration should be employed to accelerate the transformation and measure the 







Figure 1.11 Five types of moisture sorption isotherms 34 
 
 
Figure 1.12 Water sorption/desorption isotherms A) sorption/desorption is reversible B) 







Figure 1.13 Water sorption/desorption isotherms for three salts (solid symbols: 
adsorption, empty symbols: desorption) 35 
 
1.4.1.2 Capillary condensation and deliquescence  
For capillary condensation, few reports have discussed its impact on pharmaceuticals 
solids. However, a brief understanding the fundamental concepts of capillary 
condensation would help us better interpret the sorption isotherms, especially for porous 
materials. The hysteresis discussed previously can also be attributed to capillary 
condensation. Typically, capillary condensation can be described by Kelvin’s equation, 
which is used to determine the vapor pressure above a curved surface.  
Deliquescence is more commonly observed for pharmaceutical solids, especially for salts 
and certain excipients.36, 37  When the RH of the environment higher than the critical 






aqueous layer on the solid surface formed by condensed water. This process is called 
deliquescence (Figure 1.14).38 Consequently, a saturated solution with a lower vapor 
pressure (Ps) than that of pure water (P0) would be formed as a film on the surface of the 
solid, which lead to further dissolution of the solids until the material is completed 
dissolved.   
 
Figure 1.14 Deliquescence process38 
For multi-component systems, the presence of a second deliquescence solid would 
decrease the critical relative humidity. The multi-component system is thus showing 
more hygroscopicity, and deliquescence occurs at a lower RH0 than for each individual 
component.39, 40 This phenomenon has also been observed for the disproportionation of 
pioglitazone in presence of the magnesium stearate. The disproportionation product, 
MgCl2, is a deliquescence solid, which can reduce the critical relative humidity leading to 






1.4.2 Effects of moisture on physicochemical stability and physical mechanical 
properties 
It has been reported that water adsorption can significantly enhance the molecular 
mobility of solids and therefore lead to higher solid state reactivity. For instance, some 
moisture-sensitive drug substances are reported to have greater reactivity to hydrolysis. 
Specifically, the water molecules can facilitate drug- excipients interaction for the 
following two reasons: First, water could mediate drug-excipient reactions by forming a 
water-layer termed a microenvironment in which conditions for reaction are favorable. 
For example, acid-base interaction and salt disproportionation are all water mediated 
reactions. Second, water can plasticize both the drug substance and the excipients to 
enhance the reactivity for the components involved in the reaction. For instance, water 
could mediate the acid-base reaction between the delavirdine methanesulfonate and 
cromscarmellose sodium. The salt would disproportionate in the water layer formed on 
the surface of a crystal as detected by solid state NMR.  Afterwards, the dissiocated 
methanesulfonate acid would interact with croscarmellose, as confirmed by IR 
spectroscopy.42 Moreover, another example was demonstrated by Jain et al. whereby the 
anhydrous lactose converted to the monohydrate form and therefore contributed to a more 
intimate drug-excipient interaction.43 
Moisture can also contribute to change in the physical-mechanical properties of 
pharmaceutical solids associated with different manufacturing process. For instance, 
incorporation of water molecule into the crystalline lattice of hydroxbenonic acid leads to 
plastic deformation. Moisture can also result in to the formation of agglomerates in bulk 






power would be changed accordingly. For amorphous materials, moisture sorption would 
affect tablet hardness due to the plastization effects of water. 44 
1.5 Acid-Base Reactions 
Based on the previous discussion of the acid and bases, we know that most 
pharmaceutical compounds are weak electrolytes. Hence, acid-base reactions can be 
widely encountered in pharmaceutical systems including salts, amorphous solid 
dispersions, and formulated products such as tablets, coated granules, capsule, suspension 
etc. It has been reported that most of the drug and excipient incompatibility issue is 
attributed to the acid-base reactions in drug product. Therefore, understanding the 
fundamental theory of acid-base reactions is critical to further investigate these 
pharmaceutical systems.   
1.5.1 Theory of acid-base reactions 
An equilibrium for a Brønsted acid and a Brønsted base reaction is demonstrated in 
Equation 1.50.  By comparing the pKa value of the acids involved in this reaction, we can 
estimate the direction of the reaction in this equilibrium. The equilibrium in the reaction 
of an acid and a base always favors the side of the equilibrium with weaker acid and 
weaker base. For instance, if acid and the base of the right hand side of equation 1.50 are 
weaker than the left side, the reaction lies to the right. The equilibrium constant (Keq) 
could be calculated accordingly by subtracting the pKa of the left side from the pKa of the 
right side. In this case, pKa of the HA is expressed as pKAH while pKa of the BH
+ is 
symbolized as pKBH. Hence, the relationship between Keq and pKAH, pKBH is 
demonstrated in equations 1.51 and 1.52.  
                                        
eqK






                                        eq HABH
pK pK pK                                              Equation 1.51 








                                                 Equation 1.52 
1.5.2 Salt formation and disproportionation 
1.5.2.1 Salt formation 
Salt formation is defined as one type of acid-base reaction involving either proton 
transfer or neutralization. Theoretically, each acidic or basic compound can be involved 
in the salt formation process. One important factor determining salt formation and 
stability is the strength of the acid or the base (acidity or basicity constant of the 
compound).45  Hence, the salt formation rule of thumb states that a ΔpKa value between 
acid and base (pKa base- pKa acid) larger than 2 to 3 will result in proton transfer and lead 
to the formation of salt.46-48 However, merely dependending on this rule is not enough to 
screen and optimize the salt formulation. Trial and error approaches for salt screening 
should also be employed to further evaluate the physicochemical properties of ionizable 
compound. The fundamental principles behind the trial and error approaches are utilizing 
the acid base reaction in solution and precipitating the targeted compounds with the 
appropriate counterions in their salt form. The solid extracted from the precipitation is 
subjected to solid state characterization for selecting solids with the desired 
physicochemical properties. 49, 50 
It has been reported that using salt screening methods typically involves using organic 
solvents due to the low aqueous solubility of drug substances. However, such methods 
can bring significant issues due to the fact that the pKa value may change in organic 






acid: the acetic acid shifts its pKa value by 5 units in the methanol solvent relative to in 
the aqueous system. Hence, the solvent effect for the salt formation should be carefully 
considered before screening. Furthermore, the salt forming agent selection needs to 
consider pH. One important condition for forming a salt is to adjust the pH to value lower 
than the pHmax of the basic compound and altering the pH to a value higher than the 
pHmax of the acidic compound. Commonly used salt forming can be found in detail from 
the references. 51 
In an aqueous system, acid-base reactions can be expressed and calculated using 
Equations 1.50 to 1.52. By calculating the value of the pKeq of this equilibrium, we can 
estimate the direction and the percentage of salt formation. Moreover, the functional 
group and the ionizable moiety of the acidic compound or the excipients need to be 
further investigated before the salt formation process. In my research plan, there are some 
validated methodologies that have been developed to understand the interaction pattern 
and the moiety involvement of the acid-base reaction.   
1.5.2.2 Salt disproportionation 
A primary potential risk of utilizing salt formation is that the salt form of API has the 
propensity to revert back to the unionized form/free base which is defined as salt 
disproportionation.52, 53 It has been reported that salt disproportionation has severe 
detrimental effects on pharmaceutical products including loss of potency, increased tablet 
hardness, and the reduction of dissolution rate and bioavailability. 12, 42, 54-56 
Disproportionation is also one type of acid base reaction and involves proton exchange. 






of water is known to be necessary for the disproportionation process, with higher water 
contents driving the process, indicating that it is a solution mediated reaction.12, 52, 57 The 
pH of maximum solubility (pHmax) and the microenvironmental pH are two pivotal 
parameters required to understand the likelihood of disproportionation.15, 56 The concepts 
of the pHmax have been illustrated in the previous section by evaluating the pH solubility 
profile. The microenvironmental pH can be greatly impacted by acidity/basicity of 
excipients used in formulations. For instance, excipients with high basicity can elevate 
the microenvironmental pH value and are generally reported as problematic components 
in formulations containing salts of weak bases.58-60 For a basic compound, when the pH 
value is higher than the pHmax the solid state phase in equilibrium will change from salt to 
free base, and disproportionation will occur. From a formulation perspective, contact 
surface, drug loading, excipients properties, and storage conditions could also have 
significant impacts on the disproportionation reaction.61  
1.5.3 Solid state acid-base reactions 
Solid state acid base reactions are commonly observed in pharmaceutical systems 
primarily due to the following two reasons. First, as we discussed before, most of drugs 
are either acidic or basic compounds. Second, formulating the drug as solid state 
pharmaceutical products, tablet or capsule, is a widely used strategy in the 
pharmaceutical industry. Moreover, most of the popular excipients involved in 
pharmaceutical products also have acidic or basic properties, which could induce the 
proton transfer and contribute to acid-base reactions with drug substances in the solid 
state. For instance, magnesium stearate, crosscarmellose sodium and A-Tab have been 






other hand, stearic acid and maleic acid are proton donors (Brønsted-acid), which can 
lead to stability issues with acidic pharmaceutical compounds. Such reactions would 
dramatically influence the physicochemical properties of the pharmaceutical compound, 
or even drastically change its bioavailability. For instance, magnesium oxide, one 
important impurity of magnesium stearate, was reported to interact with ibuprofe n during 
formulation development, changing the texture of the tablet. The magnesium salt of 
ibuprofen was generated as a reaction product.63 Stephenson et al. further demonstrated 
that this reaction is not a water mediated reaction and the reaction rate is strongly 
correlated to the crystal packing and meting point of the solid form. Furthermore, in 
multicomponent solid-state pharmaceutical products containing two drugs, the drugs may 
interact via an acid-base reaction. For instance, formulating phenylephrine hydrochloride 
together with aspirin may lead phenylephrine degradation due to the acid nature of 
aspirin. As a result, the solubility and bioavailability of phenylephrine will change 
accordingly. Hence, a compatibility test, a practice of screening the adverse component-
component interaction, should be employed in the preformulation stage to further explore 
the incompatibility issues between the drug and excipients or even between two drugs.  
Although pH in solid state is not well understood, it is important to maintain the desired 
microenvironmental pH in the solid state to stabilize the formulation. Therefore, 
numerous studies have been published on formulating pH-adjustment agents in the solid 
dosage forms to maintain the physical chemical properties and prevent proton transfer 






1.6 Research Overview  
The present research addressed two aspects of the acid-base reactions: salt formation and 
salt disproportionation. Chapters 2 and 3 focused on salt formation in solid dispersions, 
whereby acid-base interactions between drug and polymer to stabilize the amorphous 
form of the drug and increased the polymer drug-loading capacity. It was hypothesize 
herein that an acid-base interaction can be formed between certain drugs and polymers on 
the basis of salt formation rule which enunciates that a ΔpKa value between an acidic 
polymer and a basic drug substance (pKa base- pKa acid) larger than 2 to 3 will result in 
the proton transfer and salt formation. The overall objective of the first two chapters was 
to probe the interaction patterns between a model compound and polymeric carriers in 
amorphous solid dispersions and to further elucidate the underlying reaction mechanism 
by applying comprehensive spectroscopic investigations. 
Chapter 4 to 6 focused on the other direction of acid base reaction, which is 
pharmaceutical salt disproportionation. The main objective of chapter 4 was to 
investigate the impact of excipient counterion on the disproportionation reaction (both 
extent and kinetics), focusing specifically on the excipient properties as well as the 
characteristics of the reaction products. The second objective was to further understand 
the underlying mechanisms of proton transfer between drug salt and problematic 
excipients (i.e. metallic stearates). The hypothesis of chapter 3 was that both reactants 
and formed products can significantly affect the salt stability in formulation. Chapter 5 
aimed to develop effective formulation approaches to slowdown salt disproportionation 
process in solid formulation during storage and manufacturing. Moreover, the research of 






reactions in solid formulations.  The study presented in chapter 6 focused on develop 
innovative analytical approaches to detect the salt disproportionation in multi-component 
pharmaceutical products with low drug loadings. The logic flow of this research is 
summarized in Figure 1.15 
 







CHAPTER 2. INVESTIGATING THE INTERACTION PATTERN AND 
STRUCTURAL ELEMENTS OF A DRUG-POLYMER COMPLEX AT THE 
MOLECULAR LEVEL1 
2.1 Abstract:  
Strong associations between drug and polymeric carrier are expected to contribute to 
higher drug loading capacities and better physical stability of amorphous solid 
dispersions. However, molecular details of the interaction patterns and underlying 
mechanisms are still unclear. In the present study, a series of amorphous solid dispersions 
of clofazimine (CLF), an anti-leprosy drug, was prepared with different polymers by 
applying the solvent evaporation method. When using hypromellose phthalate (HPMCP) 
as the carrier, the amorphous solid dispersion system exhibits not only superior drug 
loading capacity (63% w/w), but also color change due to strong drug-polymer 
association. In order to further explain these experimental observations, the interaction 
between CLF and HPMCP was investigated in a non-polar volatile solvent system 
(chloroform) prior to forming the solid dispersion. We observed significant UV/Vis and 
1H NMR spectral changes suggesting the protonation of CLF and formation of ion-pairs 
between CLF and HPMCP in chloroform. Furthermore, Nuclear Overhauser Effect 
Spectroscopy (NOESY) and Diffusion Order Spectroscopy (DOSY) were employed to 
                                                 
1
 The content of this chapter is adapted with permission from Haichen Nie, Huaping Mo, Mingtao Zhang et 
al. Investigating the Interaction Pattern and Structural Elements of a Drug–Polymer Complex at the 







evaluate the strength of associations between drug and polymers, as well as the molecular 
mobility of CLF. Finally, by correlating the experimental values with quantum chemistry 
calculations, we demonstrate that the protonated CLF is binding to the carboxylate group 
of HPMCP as an ion-pair and propose a possible structural model of the drug-polymer 
complex. Understanding the drug and carrier interaction patterns from a molecular 
perspective is critical for the rational design of new amorphous solid dispersions.  
2.2 Keywords 
Clofazimine; Amorphous Solid Dispersion; Drug Polymer Interactions; Ionic Interaction; 








Formation of an amorphous solid dispersion (ASD), where drug molecules are dispersed 
into a polymer matrix, is a widely used formulation strategy to enhance the aqueous 
solubility and dissolution rate for drug candidates with inadequate bioavailability.64, 65 
These ASD systems replace strong intermolecular forces in the crystalline state with 
drug-polymer interactions. Understanding the interaction pattern between the drug and 
polymer is critical to formulating robust ASDs to overcome the limited drug loading 
capacity or recrystallization during storage.66, 67 However, it has been very challenging to 
determine the detailed molecular characteristics of ASDs, because amorphous mater ials 
lack long range order.68 Therefore, knowledge about the patterns of molecular 
interactions (strength, interaction type, and functional group involvement) between drug 
and polymers is still limited.69  
One structural element of particular interest is the strength of the drug polymer 
interaction in ASDs. Typically, dispersions with stronger intermolecular interactions are 
expected to be more physically stable by disrupting the crystallization tendency and 
reducing the molecular mobility.70, 71 Perhaps the most important intermolecular 
interactions between drugs and polymers are ionic interaction and hydrogen bonding. For 
instance, ionic interactions, a strong electrostatic interaction formed by protonated 
molecules, are reported as making significant contributions to increase both the drug 
loading and the physical stability of ASDs.72-74 On the other hand, the existence of an 
intra-molecular hydrogen bond in a drug molecule might have significant negative 
influence on physical stability.75, 76 These findings suggest that identifying the molecular 






extremely useful for selecting appropriate polymers without the reliance on empirical 
tests and screening.   
A variety of techniques have been applied to investigate drug-polymer interactions 
including spectroscopic characterizations and molecular modeling.77-80 High resolution 
solution state NMR, for instance, can provide structural insights into drug-polymer 
interactions at the molecular or atomic level in a non-polar volatile solvent system prior 
to forming the spray dried amorphous solid dispersions. By detecting the chemical shifts 
and line-shape changes, solution 1H NMR spectra provide important information about 
the changes of the electron densities around hydrogen atoms, which could be 
significantly affected by certain interactions.81, 82 Moreover, Nuclear Overhauser Effect 
Spectroscopy (NOESY) is an effective measurement for motional behavior of drug 
molecules associated with binding or aggregation. Therefore, it could be employed to 
evaluate the strength of drug-polymer associations and to investigate the ability of 
polymers to inhibit recrystallization in super-saturated solutions.83, 84 DOSY (Diffusion 
Order Spectroscopy) readily measures solution state self-diffusion coefficients of 
different size molecules without physical separations.85 Hence, it has the potential to 
evaluate molecular mobility of active pharmaceutical ingredients (APIs) in the presence 
of polymers.  
The primary objective of this investigation is to reveal the critical drug-polymer 
interaction pattern and to elucidate the underlying mechanisms involved in the formation 
of drug-polymer complexes from a molecular perspective. In addition, the second major 
objective of this study is developing new formulations for rare diseases. For leprosy, 






Organization, is poorly bioavailable and must be given in a high dose. 86, 87 Thus, CLF is 
used as a model compound for our studies of interaction pattern between drug and 
polymers.  CLF contains both a hydrogen bond donor and hydrogen bond acceptor, and 
also has a relatively high pKa value (8.51)88. These characteristics should enable CLF to 
form different types of interactions with various functional groups present on polymeric 
carriers both in solution state and in solid state. In this study, we chose HPMCP, HPMC, 
and PVP/VA as model polymers because the different chemical features of these 
polymers would enable the formation of various intermolecular interactions with CLF. 
One previous study has attempted to disperse CLF into polyvinylpyrrolidone matrix to 
form an amorphous system, but achieved a limited 10% drug loading. 89 In our study, we 
formulated an ASD of CLF and HPMCP with more than 60% (w/w) drug loading, and 
achieved a dispersion system with superior physical stability. By combining 
spectroscopic characterization and quantum chemistry calculations, we investigated the 
molecular interaction pattern of drug-polymer complex and the underlying binding 
mechanism in a non-polar solvent system to further explain the improved performance 







2.4 Experimental  
2.4.1 Chemicals  
Clofazimine (CLF) in crystalline form and phthalic acid (ACS reagent) were purchased 
from Sigma-Aldrich (St. Louis, MO). HPMCP (HP-55, Figure2.1B) was provided by 
Shin-Etsu Chemical Co., Ltd. (Tokyo, Japan). HPMC (METHOCELTM E15, 
Hypromellose, United States Pharmacopeia class 2910, Figure 2.1C) and PVP/VA 
(vinylpyrrolidone-vinyl acetate copolymer, Figure2.1D) were generously provided by 
Colorcon Inc. (West Point, PA) and BASF SE (Florham Park, NJ) respectively. 
Chloroform (CHCl3) and glacial acetic acid were purchased from Mallinckrodt Baker, Inc. 
(Paris Kentucky), and deuterated chloroform was obtained from Cambridge Isotopes 
Laboratories Inc. (Andover, MA).  
2.4.2 Preparation of solid dispersion  
A series of homogeneous solutions with the desired weight ratio between drug and 
polymers were prepared in chloroform. Sonication was applied as needed for solutions 
with HPMC. Solid dispersions were prepared either by rotary evaporation or spin coating. 
For rotary evaporation, chloroform was removed by a rotary-evaporator (Buchi, New 
Castle, DE) with a reduced pressure and immersed into water bath with a constant 
temperature (~50°C) for 2-3 minutes. Afterwards, in order to remove the residual solvent, 
samples were placed under vacuum at room temperature for a minimum of 12 hours. For 
spin coating, solvent was rapidly removed by adding several drops of the solution to a 
quartz microscope slide (VWR, Radnor, PA) which was rapidly rotated on a KW-4A spin 







2.4.3 Powder X-Ray diffraction (PXRD)  
The X-ray diffraction patterns of solid dispersions prepared by rotary evaporation were 
obtained using a Siemens D5000 X-Ray diffractometer equipped with a Cu Kα source. 
All the measurements were conducted at room temperature in Bragg–Brentano geometry 
with 2θ ranging from 4° to 40° using a 0.02° step size. The voltage and the current of the 
generator were set to 40 kV and 40 mA respectively.  
2.4.4 Ultraviolet-Visible spectroscopy 
For solution, UV spectra were recorded on a S.I. Photonics 400 Series UV/Vis 
Spectrophotometer (Tuscon, Arizona) equipped with a fiber optic dip probe (20 mm path-
length). Samples evaluated comprised mixtures of CLF (0.06 mg/mL) with various 
polymers (HPMCP, HPMC, PVP/VA) in chloroform at room temperature with a constant 
stirring rate. A Cary 300 Bio UV spectrometer coupled with WinUV software (Varian 
Inc., Palo Alto, CA) was used to analyze thin films of CLF dispersed with the polymers 
onto quartz slides. The wavelength range was set from 200nm to 800nm for both liquid 
and solid state samples.  
2.4.5 Solution NMR 
1D 1H NMR spectra were acquired on a Bruker 800 MHz Avance-III spectrometer 
equipped with a HCN single axis gradient probe at 25°C using standard sequences. CLF 
concentration (final) was maintained at 2 mg/mL in fresh deuterated chloroform (CDCl3), 
and other polymers (HPMCP, HPMCP or PVP/VA) were mixed with CLF at the desired 
(w/w) ratio for all applicable samples. Solutions were then transferred to 5 mm NMR 
tube for NMR data acquisitions. For NOESY, the mixing time was set to 300 ms. For 






coefficient measurement. For CLF with HPMCP, relaxation delay was 10 s, the total 
diffusion time (Δ) was fixed as 50 ms, gradient duration (δ) was 4 ms and strength varied 
from 1.07 G/cm to 50.8 G/cm; for CLF with HPMC or PVPVA, the corresponding time 
was 15 s, 50 ms, and 1.6 ms. Chemical shifts were referenced to residual solvent, CHCl 3, 
at 7.26 ppm. CLF proton chemical shift assignments in CDCl 3 solution were derived 
from COSY and NOESY, and confirmed by assignments made in d6-DMSO under the 
similar conditions. 
2.4.6 Computational methods 
Calculations of each system were carried out by using the Gaussian 09 software 
package91 at the density functional theory (DFT) level of the hybrid B3PW91 function 
and 6-311++g(2d,2p) basis set.77, 92, 93 The initial structure of CLF was obtained from the 
literature.94 All optimizations were completed without any geometrical constraints. The 
solvent effect of chloroform (=4.7113) was taken into account by applying a SCRF 
(self-consistent reaction field) through the polarizable continuum model (PCM)95. 
Frequency analysis of each compound was performed at the same level to achieve the 
optimized minima/zero imaginary frequency, so that Zero Point Energies (ZPE) and 
Gibbs free energies (at 298.15 K and 1 atm.) were obtained. The Gauge-Independent 
Atomic Orbital (GIAO) method was used to calculate NMR chemical shifts.96 UV/Vis 
spectra were simulated by utilizing the time-dependent density functional theory (TDDFT) 







2.5.1 Powder X-Ray diffraction 
Drug loading (DL) and physical stability of powdered ASD systems with acidic polymer 
(HPMCP) and neutral polymers (HPMC, PVP/VA) were characterized by powder X-ray 
diffraction (PXRD). When HPMCP was used as the carrier, an amorphous dispersion 
with 63% drug loading could be achieved (Figure 2.2A). However, for the dispersions 
formed by CLF and the neutral polymers, the drug loading capacities were significantly 
lower than that of the system with HPMCP. For example, the drug loading of CLF was 
limited to 10% when employing PVP/VA as the carrier (Figure 2.2C). Although the drug 
loading could be increased to 25% with HPMC, crystalline drug was clearly observed in 
dispersion system at a 50% drug loading (Figure 2.2B). 
ASD samples with HPMCP (63% DL), HPMC (25% DL), and PVP/VA (10% DL) were 
exposed to 40°C and 75% relative humidity (R.H.) for short term physical stability 
studies. The PXRD results show that ASDs formed with HPMC or PVP/VA 
recrystallized within a week. In comparison, the HPMCP dispersion system remained 
amorphous over two weeks (Figure A.1).  The above results indicate that HPMCP would 
be a more efficient carrier to form an ASD with CLF for its superior drug loading 
capacity and better physical stability.   
2.5.2 Ultraviolet Visible Spectroscopy   
When CLF was mixed with HPMCP in chloroform at a weight ratio of 1 to 5, visual 
observation indicated a color change from orange to dark purple. Accordingly, the 
ultraviolet-visible spectrum revealed that the wavelength of the broad peak centered at 






could be observed in the drug-polymer films prepared by spin coating (Figure 2.3A). A 
similar color-changing phenomenon was detected when glacial acetic acid was added to a 
CHCl3 solution of CLF. Based on the spectra shown in Figure2.3D, the wavelength of the 
broad peak in visible wavelength range has shifted 37 nm both in the solution and the 
solid state samples, which is very similar behavior to that observed when mixing CLF 
with HPMCP. In contrast, virtually no color change was detected when CLF was co-
dissolved with the neutral polymers (HPMC or PVP/VA) in the same solvent and the 
same weight ratio.  Predictably, the corresponding UV/Vis spectra did not change either 
for the solution or for the solid thin films produced by spin coating (Figure 2.3B and 
2.3C). These results are consistent with the formation of a protonated salt of CLF.   
2.5.3 Solution NMR  
2.5.3.1 1D 1H NMR spectra 
The peak assignments for each proton of CLF were made (Figure A.2) by evaluating 1D 
1H NMR, COSY, NOESY and 1H, 13C-HSQC (Figure A.3 to A.6. 1H NMR spectra of 
CLF with the ionic polymer (HPMCP) or neutral polymers (HPMC and PVPVA), and 
CLF alone are shown in Figure2.4. For the spectrum of CLF with HPMCP, not only are 
the 1H chemical shifts moved downfield, but line broadening also occurs for all the 
signals throughout the molecule. A similar change in the chemical shifts was observed 
when glacial acetic acid was added (Figure A.7). However, the spectra of CLF with 
HPMC and PVP/VA exhibited minimum changes of this type.  
To quantitatively investigate the influence of HPMCP on both chemical shifts and line-






HPMCP: CLF (w/w) ratio increasing from 0:1 to 5:1, and the corresponding 1D 1H NMR 
spectra were acquired (Figure 2.5). Both the chemical shifts and the line-shapes of the 
protons on the riminophenazine core exhibited the most significant changes. For instance, 
the peak of H4 at 5.27 ppm demonstrated a line-width of less than 1.5 Hz in the absence 
of HPMCP. When the ratio of HPMCP to CLF increased to 1:1, the line-width 
dramatically increased to more than 36 Hz, and the chemical shift changed to 5.41 ppm. 
As the amount of HPMCP further increased, however, the line-width decreased to 17 Hz 
for a 5:1 ratio of HPMCP to CLF. Similar behavior was observed for the peak of H 6 
located at 6.44 ppm. The line-width of each doublet-doublet component (coupling 
constants 8.2 Hz and 1.1 Hz) was about 1 Hz or less without HPMCP. As the HPMCP: 
CLF ratio increased to 1:1, the doublet-doublet peak coalesced into a single broad peak 
with a 40 Hz line-width, and shifted downfield to 6.58 ppm. Again, when the ratio of 
HPMCP to CLF increased to 5:1, a broad doublet re-appeared at 6.89 ppm with a 19 Hz 
combined line-width. We also noticed that a clear new sharp doublet-doublet appeared at 
8.35 ppm, which coincides with the spectrum of the phthalic acid and CLF mixture 
(Figure A.8). This observation suggests that the binding is between the phthalic acid 
group of HPMCP and CLF.  
2.5.3.2 2D NMR spectra: NOESY and DOSY  
The NOESY of CLF is shown in Figure2.6A. A positive sign (red color) of a NOE cross 
peak (circled red for clarity) was observed between H4 (5.27ppm) and the proton of the 
isopropyl group located at 3.47 ppm, indicating fast tumbling of this part of the molecule. 






the same cross-peak switch sign to negative (same sign as diagonal; Figure2.6B), but also 
more negative cross-peaks in other regions were observed. The change of the cross-peak 
sign suggests CLF molecules tumble more slowly overall and the NOE build up was 
becoming more efficient as a result. For comparison, only positive NOEs among these 
protons were observed even in the presences of higher amount (drug: polymer = 1:1) of 
either HPMC or PVPVA (Figure 2.6C and Figure2.6D). 
To explore the changes associated with molecular mobility, DOSY was recorded for CLF 
with different polymers (Figure A.9).  The apparent self-diffusion coefficient appears at 
7.94×10-10 m2/s for the sample with the 0.5: 1 ratio of HPMCP: CLF. However, the self-
diffusion coefficients for the two samples of CLF with HPMC or PVP/VA at a 1:1 weight 
ratio were recorded as 3.16×10-9 m2/s and 5.01×10-9 m2/s respectively. The sample of 
CLF with HPMC or PVP/VA thus exhibit much higher self-diffusion coefficients than 
that of CLF with HPMCP, presumably due to the different strength of association 








A prerequisite of investigating drug-polymer interactions is to understand the functional 
group involvement of CLF and polymers. Neutral Population Analysis (NPA) was 
conducted to show partial atomic charges of CLF (Figure 2.7A) as a means of further 
delineating the structure and properties of the free molecule (details of charges are listed 
in Table A.1). Nβ from the imine group is the most negatively charged atom (-0.542e) and 
the proton (Hα) from secondary amine group has the highest positive value (+0.425e) 
throughout the molecule. Hence, Nβ could serve as a strong hydrogen bond acceptor, 
while Hα could potentially be an active hydrogen bond donor. Moreover, the short 
distance between the Nβ and Hα (1.987Å) indicates the potential of forming a partial 
intra-molecular hydrogen bond, which could weaken the intermolecular interaction 
between Hα and other hydrogen bond acceptors due to the physical and geometrical 
characteristics of hydrogen bonding.98  
On the other hand, the functional group characteristics of polymers and the potential for 
intermolecular interactions could be evaluated by analyzing the chemical structure of 
HPMC, HPMCP, and PVP/VA (Figure 2.1). Based on the pKBHX scale of functional 
groups, the carboxylic acid of HPMCP and hydroxyl group of HPMC could be 
categorized as strong hydrogen bond donors, while the carbonyl group of PVP/VA was 
treated as a strong hydrogen bond acceptor.99, 100 In addition, experimental data, such as 
the similarity in the CLF NMR chemical shift changes induced by both HPMCP and 
acetic acid (Figure A.7) indicate that the carboxylic acid group of HPMCP is a key 
functional group in forming ionic interactions with CLF. This is further supported by the 






will result in proton transfer.46-48 For this study, it appears likely that proton transfer and 
subsequent ion-pair formation can occur between HPMCP (pKa~3) and CLF (pKa=8.5) 
even in a non-polar solvent (chloroform).101, 102 To be specific, the phthalic acid group 
provides a proton to protonate CLF, gaining negative charge for ionic bonding with the 
now positive CLF, in addition to the potential for hydrogen bonding interactions. 
According to the discussion of the molecular characteristics of each binding moiety, 
variations we can rationalized in drug loading capacities and physical stability upon 
storage for the different dispersions based on the different drug-polymer interaction 
strengths. CLF is expected to form the weakest interactions with PVP/VA since this 
polymer only contains an acceptor group, and hydrogen bonding between CLF and this 
polymer is expected to be hindered by the presence of a partial intra-molecular hydrogen 
bond involving the CLF donor group. The ASDs of CLF and HPMCP demonstrated 
superior drug loading capacities, and this is attributed mainly to the ionic interactions 
formed in the CLF-HPMCP dispersions which are strongly supported by the UV/Vis and 
NMR spectra.  
The color changes and red-shifted UV/Vis absorption spectrum of CLF in the amorphous 
dispersion with HPMCP strongly supports the protonation and charge transfer between 
the CLF and HPMCP leading to strong interactions.103-105 When CLF interacts with the 
carboxylic acid group of HPMCP, protonation of the π-conjugated riminophenazine 
(chromophore) will impact its electronic properties, resulting in the observed color 
change.106, 107 This supposition is strongly supported by the consistent nature of the 






between CLF and HPMCP in the non-polar solvent is thought to correlate well with the 
interaction between the drug and polymer in the ASD.  
Moreover, the observed changes in the 1H NMR chemical shifts and line-shapes strongly 
suggest that CLF exists in more than one state in the presence of HPMCP. Under the 
assumption of fast exchange, a simple two-site equilibrium model is proposed in 
Equation 2.1, in which CLF can exist either in the free-state or as ion-pair formed with 
the carboxylate group of HPMCP (Figure 2.7B). A similar system has been analyzed in 
the literature by applying the theory of dynamic NMR.108 
CLF + HPMCP ⇌ [CLF+ HPMCP-]                       Equation 2.1 
Formation of an ion-pair would lead to a change of electron density, and therefore exhibit 
different chemical shifts of 1H NMR for the two states.81 Basically, the observed proton 
chemical shift is the population average of each individual state and the line-shape is 
expected to be broadened by the exchange between the two states. Furthermore, the 
existence of free and bound-states of CLF can be quantitatively estimated by titration. 
Based on the previous studies of NMR line-shape changes for equilibrium systems, the 
line-width would be expected to be broadest when 1/3 of the CLF exists in the bound-
state with carboxylic acid of HPMCP.109, 110 In the titration study (Figure 2.5A), this 
occurs when the weight ratio of CLF: HPMCP is about 1:1. Due to the limited solubility 
of HPMCP in chloroform, even with the highest concentration of HPMCP (10 mg/mL), 
only about two-thirds of CLF exists in the bound-state. In the current case, the H4 
resonance, a singlet, was selected for the dynamic NMR calculation due to its proximity 
to the center of interaction (Nβ) and lack of spectral interference from other protons 






dissociation rate constant, and chemical shift of bound state, the peak position and line-
width of the H4 resonance are calculated to show good agreement with the experiments, 
which validates the two-site equilibrium model (Figure 2.8). Although the line-shape and 
chemical shifts for H4 are satisfactorily explained, it should be pointed out that this model 
is a rather simplified and approximate one as it does not account for the heterogeneity 
and complexity of the polymer.  
In the free-state, a small molecule, such as CLF (MW 474), is expected to tumble 
relatively rapidly in solution leading to positive proton-proton NOEs. In contrast, when 
associated to a much larger molecule, such as a polymer, the same small molecule would 
tumble more slowly leading to negative NOEs due to a larger correlation time.111 We 
observed that NOEs of CLF (2mg/mL) changed signs from positive to negative when 1 
mg/mL HPMCP was added. Based on the above two-state equilibrium model, NOEs of 
the bound-state CLF with a negative sign become dominant and are clearly visible in 
NOESY (Figure 2.6B) suggesting that a significant portion of  CLF is associated with 
HPMCP. In contrast, HPMC or PVPVA does not appear to strongly associate with CLF, 
because no NOE sign changes were observed for CLF (Figure 2.6C and 2.6D).  
Similarly, we can interpret the DOSY results by applying the two-site equilibrium model. 
In the presence of HPMCP, CLF will spend a significant amount of time in the bound-
state, and therefore its translational movement will be slower than the free-state of the 
drug. In our study, we treat the observed CLF diffusion coefficient as an averaged 
population of self-diffusion constants for the free-state and bound-state CLF. According 
to the DOSY results, the self-diffusion coefficient of CLF and HPMCP complexes is 






of the bound-state complex and a slower average movement of the CLF molecule. 
Therefore, we can claim that the molecular mobility of CLF is significantly reduced due 
to the strong association between CLF and HPMCP. This conclusion is also consistent 
with the fact that ASD of CLF and HPMCP has greater stability and lower crystallization 
tendency during storage.  
After evaluating the interaction type and strength between CLF and HPMCP, we were 
curious about the molecular details of the CLF and HPMCP complex. As discussed 
previously, the carboxylic acid group of HPMCP serves as the key moiety in interacting 
with CLF. For computational modeling, HPMCP was simplified to acetic acid, and 
simulations were performed to probe the possible molecular structure of the CLF and 
carboxylic acid complex. According to a previous report, two potential complexes 
(complex I and complex II) with two different types of interactions are proposed.112 The 
structures and geometrical positions of the two complexes were optimized by the 
methods described in the experimental section (listed in Table A.2 and A.3). To be 
specific, for complex I, protonated Nβ H
+ of CLF interacts with the COO- group by 
electrostatic force. In addition, the complex is stabilized by a bifurcated hydrogen 
bonding system formed between Hα and Hβ and the carboxylate group (Figure 2.7C). In 
complex II, hydrogen bond dimer formation is involved between CLF and the carboxylic 
acid without ionization (Figure 2.7D). At a first glance, it seems that formation of a dimer 
system without protonation would be highly possible in a non-polar solvent (chloroform). 
However, we deem that interactions between CLF and HPMCP should be very similar to 






First, our calculated Gibbs free energy of complex I is 1.24 kcal/mol lower than that of 
complex II (Table A.4, A.6) suggesting the complex I is more thermodynamically 
favorable and stable. Second, with regard to changes in chemical shifts, the simulated 
NMR spectrum of complex I generally agrees well with the experimental NMR spectrum 
(Figure A.10). Specifically, in this study, there is a particular interest in the chemical 
shifts of H4 and H6, because they are located on the π conjugated riminophenazine core 
and have little spectral interference from other signals. For complex I, H4 shifts 
downfield from 5.49 ppm to 6.04 ppm, and H6 changes from 7.43ppm to 7.85ppm in the 
simulated spectrum. In contrast, for complex II, the calculated NMR spectrum 
demonstrates an obvious discrepancy with experiments: H4 shifts downfield 0.18 ppm, 
and H6 is shifted upfield by 0.2 ppm (Table A.8). Apparently, experimental observations 
are more consistent with the simulated spectral changes of complex I. Third, for complex 
I, the strong absorption peak appeared at 583 nm in the simulated visible spectrum, and 
this correlates well with the experimentally observed red-shifted spectrum and 
solution/film color-changes. In contrast, for complex II, the simulated UV/Vis spectrum 
has no significant differences compared to that of pure CLF (Figure A.11). Thus, the 
simulations further support the existence of ionic interactions between CLF and HPMCP 







2.7 Conclusion  
An amorphous solid dispersion system of clofazimine and HPMCP was found to have 
superior drug loading capacity and better physical stability due to strong drug-polymer 
interactions. By studying the drug-polymer interactions in a non-polar solvent system 
prior to forming ASDs, we are able to explain and predict the improved solid state 
performance of dispersions, and this approach is expected to reduce the need for the time-
consuming, traditional polymer screening process. Furthermore, by correlating the 
spectroscopic measurements with quantum chemistry calculations, the functional  groups 
involved in the binding moiety are identified, and ionic interactions are confirmed as the 
dominant force in the CLF and HPMCP complex. Protonation of CLF leads to the 
electron density changes of the riminophenazine core, which result in a corresponding 
downfield shifted 1H NMR spectra and a red-shifted visible spectrum. The line-width 
changes of the NMR spectra reveal an exchange two-site equilibrium model as the 
underlying mechanism of CLF-HPMCP association in a non-polar solvent. Based on this 
equilibrium model, we are able to quantify the free and the bound states of CLF in 
chloroform. Furthermore, the molecular mobility of API molecules and drug-polymer 
association were investigated by NOESY and DOSY. The strong drug-polymer 
association in the CLF-HPMCP complex correlates well with its lower self-assembly 
tendency in the amorphous solid dispersions and its lower tendency to crystallize upon 
storage 
In summary, the ASD system of CLF and HPMCP serves as an example of illustrating 
the utility of ionic interactions in formulations as a means to improve the drug loading 






the underlying interaction strength, interaction types, and functional group involvement 
between drug and polymer at a molecular level. To the best of our knowledge, this is the 
first time whereby solution state NOESY and DOSY results have been correlated to the 
molecular mobility of API molecules in ASDs. These interesting discoveries should 
profoundly impact the selection of appropriate polymers when designing new amorphous 

















Figure 2.2 PXRD for dispersion system of CLF with different polymers (A: HPMCP; B: 








Figure 2.3 UV/ Visible spectra of CLF with different polymers and acetic acid for both 
solution state (dashed line) and solid state (solid line). A) HPMCP; B) HPMC; C) 






























Figure 2.6 2D NOESY of CLF alone (A) and with HPMCP (B), HPMC (C) or PVP/VA 
(D) 
 
Figure 2.7 NPA of charges for CLF (A), Mechanism of CLF interact with carboxylic 







Figure 2.8 Calculated (dash line) and measured (solid) dynamic NMR spectra for H4 (A) 









CHAPTER 3. SOLID-STATE SPECTROSCOPIC INVESTIGATION OF 
MOLECULAR INTERACTIONS BETWEEN CLOFAZIMINE AND 
HYPROMELLOSE PHTHALATE IN AMORPHOUS SOLID DISPERSIONS 
3.1 Abstract 
It has been technically challenging to specify the detailed molecular interactions and 
binding motif between drugs and polymeric inhibitors in the solid state. To further 
investigate drug-polymer interactions from a molecular perspective, a solid dispersion of 
clofazimine (CLF) and hypromellose phthalate (HPMCP), with reported superior 
amorphous drug loading capacity and physical stability, was selected as a model system. 
The CLF-HPMCP interactions in solid dispersions were investigated by various solid 
state spectroscopic methods including ultraviolet-visible (UV/Vis), infrared (IR), and 
solid-state NMR (ssNMR) spectroscopy. Significant spectral changes suggest that 
protonated CLF is ionically bonded to the carboxylate from the phthalyl substituents of 
HPMCP. In addition, multivariate analysis of spectra was applied to optimize the 
concentration of polymeric inhibitor used to formulate the amorphous solid dispersions. 
Most interestingly, proton transfer between CLF and carboxylic acid was experimentally 
investigated from 2D 1H-1H homonuclear double quantum NMR spectra by utilizing the 
ultrafast Magic-Angle Spinning (MAS) technique. The molecular interaction pattern and 
the critical bonding structure in CLF-HPMCP dispersions were further delineated by 






These high resolution investigations provide critical structural information of API-
polymer interaction, which can be useful for rational selection of appropriate polymeric 
carriers which are effective crystallization inhibitors for amorphous drugs. 
3.2 Keywords  
Amorphous; Solid Dispersion; Drug Polymer Interactions; Acid-Base Interaction; Solid-








Amorphous solid dispersion (ASD) formulations, where the active pharmaceutical 
ingredient (API) is molecularly dispersed in a polymeric matrix, are widely applied to 
improve bioavailability for poorly water soluble pharmaceutical entities.64, 65, 67, 113, 114 
However, maintaining the amorphous state of drug substances in ASDs is a challenge, 
whereby intermolecular interactions formed between the API molecule and functional 
groups of the polymer are thought to be of critical importance.66, 70, 115-117 For instance, it 
has been demonstrated that polyvinylpyrrolidone forms strong intermolecular interactions 
with resveratrol in the dispersion, leading to satisfactory physical stability at stressed 
condition;118 while polyvinylpyrrolidone can also show insufficient inhibitory effects on 
itraconazole crystallization due to the absence of drug-polymer interactions.119 Typically, 
stronger drug-polymer intermolecular interactions can more effectively disrupt molecular 
self-assembly of the API in the dispersion, and therefore lead to a relatively stable ASD 
system with a high drug loading. For example, formation of strong association between 
clofazimine (CLF) and hypromellose phthalate (HPMCP) leads to an ASD system with 
superior drug loading capacity and physical stability.120 Acid-base interaction, an 
electrostatic interaction formed by ionized molecules, is perhaps the strongest inter-
molecular association possible between an API and polymeric carrier. The formations of 
such strong intermolecular interactions in dispersions are generally favorable especially 
for high-dose formulations.72-74, 121-123 For instance, ASD systems of lapatinib with 
ionizable polymers illustrated the utility of acid-base interactions in formulations as a 
strategy to enhance the drug loading capacity.102 Hence, understanding the molecular 






design robust formulations of ASDs with satisfactory physical stability at minimal 
polymer concentrations avoiding the reliance on the empirical polymer screening process. 
However, molecular details of drug-polymer interaction patterns are still unclear due to 
the challenges of identifying the interaction type, functional group involvement, and the 
binding motif in amorphous materials.69  
Although our previous research provided an improved understanding of intermolecular 
interaction patterns between CLF and HPMCP in a nonpolar solvent system prior to 
forming the solid dispersion120, knowledge about CLF-HPMCP interactions in the solid 
state is still limited, which necessitates the employment of comprehensive solid state 
spectroscopic investigations. Infrared (IR) spectroscopic analysis, a powerful tool to 
select the appropriate polymer for ASD formulations, can be used to monitor drug-
polymer interactions by evaluating the vibrational changes of involved functional 
group.124-126 Ultraviolet-Visible (UV/VIS) spectroscopy is a useful method to estimate the 
electronic property changes of molecules containing conjugated structures.82, 92, 127 In the 
past decade, solid-state NMR (ssNMR) has been successfully applied to provide atomic-
level structural insights of intra- and intermolecular interactions in ASDs.128-133 The 
molecular proximity between API and polymer has been experimentally detected in 
various dipolar experiments utilizing homo- and heteronuclear correlation. For example, 
2D 1H-1H correlation experiments have observed cross peaks between the –OH and 
aliphatic groups of diflunisal and aromatic groups of PVP, suggesting their close contact 
(~ 3 Å).132 Moreover, the recent advances of ultrafast magic angle spinning (MAS) NMR 
technology enables the 1H detection at a largely improved resolution, allowing a more 






determine convoluted structures.134, 135 The 1H-detection technique under ultrafast MAS 
spinning also makes 2D 1H-1H homonuclear correlation experiments more applicable for 
probing detailed structural information of natural-abundant organic solids.132, 136 
In the present research, taking advantage of aforementioned spectroscopic analyses, the 
goal was to probe the solid-state interaction patterns of CLF and HPMCP dispersions at a 
molecular level and to further elucidate the underlying reaction mechanism. On the basis 
of our previous research about ion-pair formation of CLF and HPMCP in a non-polar 
solvent system, we herein hypothesized the presence of acid-base interactions in CLF-
HPMCP solid dispersions and focused on obtaining direct spectroscopic evidence of such 
an interaction. An objective of particular interest was to combine the molecular-level 
results from ssNMR and computational chemistry to determine the structure or, at a 
minimum, the critical structure elements of the CLF-HPMCP complex. Moreover, 
another goal of this study was to determine an optimized ratio of drug and polymer by 
using multivariate analysis of spectra. The findings of this research can serve as a 
precedent demonstrating the utility of comprehensive spectroscopic investigations on 








3.4 Experimental  
3.4.1 Materials 
CLF (Figure 3.1A) in crystalline form was purchased from Sigma-Aldrich (St. Louis, 
MO). HPMCP (HP-55, Figure 3.1B) was generously provided by Shin-Etsu Chemical 
Co., Ltd. (Tokyo, Japan). Dichloromethane (ChromAR grade) was obtained from 
Mallinckrodt Baker, Inc. (Paris Kentucky). Ethanol (200 proof) was supplied by 
Pharmaco Products, Inc. (Brookfield, CT). Both CLF and HPMCP were individually 
stored in desiccators with calcium sulfate (W.A. Hammond Drierite Co. Ltd, Xenia, OH) 
for at least 7 days at 25°C. The melt-quenching method was employed to prepare a neat 
reference sample of amorphous CLF: the crystalline form of CLF was placed on a 
THMS600 temperature controlled hot-stage (LINKAM scientific, Surrey, UK) at 220 °C 
for approximately 10 minutes and then quench-cooled by liquid nitrogen.  
3.4.2 Preparation of solid dispersion  
Both CLF and HPMCP at the desired dry weight ratios were fully dissolved (visually 
inspected, sonication was applied as needed) in a 50%: 50% (v/v) solvent mixture of 
dichloromethane and ethanol to form homogenous solutions. These uniform single-phase 
solutions were then employed to prepare solid dispersions by using rotary evaporation or 
spin coating to remove the solvents. For rotary evaporation, dichloromethane and ethanol 
were removed by a rotary-evaporator (Buchi, New Castle, DE) under vacuum and 
submersed into a water bath maintained at a constant temperature (~50°C) for 2-3 
minutes. Dispersions of CLF-HPMCP were afterwards exposed to a vacuum at room 
temperature for at least 24 hours to further remove any residual solvents in the powder. 






infrared spectroscopic analysis. Several drops of the solution were placed either on a 
quartz microscope slide or on a barium fluoride (BaF2) infrared substrate (VWR, Radnor, 
PA). Spin coating were performed using a KW-4A spin coater (Chemat Technology Inc., 
Northridge, CA) with a rate of 200 rpm for 20s (for quartz slides) and 100 rpm for 10s 
(for barium fluoride substrate) at ambient temperature to readily remove solvents.90  
3.4.3 Powder X-Ray diffraction (PXRD)  
The X-ray diffraction patterns of CLF-HPMCP solid dispersions prepared by rotary 
evaporation were collected on a Panalytical X’Pert pro X-Ray diffractometer 
(PANalytical Inc., Westborough, MA) with Cu Kα radiation of 1.5406 Å in transmission 
mode. Measurements were conducted at ambient conditions in transmission geometry 
with 2θ ranging from 2° to 40° using a 0.0167° step size. The voltage and the current of 
the generator were set to 45 kV and 40 mA respectively.  PXRD data were processed by 
Panalytical X’Pert Data Viewer (version 1.5) software.  
3.4.4 Solid-State Ultraviolet-Visible (UV/Vis) spectroscopy 
A Cary 300 Bio UV spectrometer coupled with WinUV software (Varian Inc., Palo Alto, 
CA) was employed to analyze dispersions of CLF and HPMCP spin-coated onto quartz 
slides. Data were collected over the wavelength range from 200nm to 800nm, while the 
spectral region of 370nm to 600nm was used for subsequent analyses. Multivariate 
analysis software SIMCA v13 (Umetrics AB, Umeå, Sweden) was applied for principal 
components analysis (PCA). Standard normal variate transformation (SNV) was 






3.4.5 Infrared (IR) spectroscopy  
IR spectra of CLF and HPMCP dispersions were obtained in transmission mode using a 
Bruker Optics IR IFS 66V/S spectrophotometer (Billerica, MA) equipped with globar 
infrared source, KBr beam splitter, and DTGS detector. A scan range from 1000 to 4000 
cm-1 was set with 128 scans co-added and 4 cm-1 resolution. A vacuum was applied to the 
sample and detector compartments to minimize the interference from moisture present in 
air. IR spectra of pure CLF or HPMCP were collected by the same method. Spectra were 
virtually inspected by OPUS software v7 (Bruker Optics, Ettlingen, Germany). PCA of 
infrared spectra were processed using SIMCA v13 (Umetrics AB, Umeå, Sweden).  
3.4.6 Solid-state NMR spectroscopy (ssNMR) 
All ssNMR spectra were acquired on a Bruker HD Avance III triple-resonance 
spectrometer operating at 1H and 13C resonance frequency of 400 MHz and 100 MHz 
respectively. All 13C experiments were carried out by using a Bruker 4 mm triple 
resonance HXY MAS probe tuned to 1H and 13C double-resonance mode, as previously 
described.137 Approximately 90 mg of ASD powder was packed into 4.0 mm MAS 
zirconium rotors for each experiment. Sample temperature is maintained at 293 K using a 
BCU cooling system. One-dimensional (1D) 13C spectra were acquired using the cross-
polarization magic angle spinning (CP-MAS) experiment under a spinning frequency of 
12 kHz.  1H to 13C cross polarization applied a 1.5 ms contact time with a linear ramp on 
the 1H channel and constant field on the 13C channel.  83 kHz SPINAL 1H decoupling 
was used during acquisition.  
1H-detected experiments were carried out using a H/F/X ultrafast spinning probe on 






at a proton frequency of 400 MHz.  The cooling gas streams from BCU-II at a 253 K 
were streamed to control the sample temperature. 2D 1H-1H dipolar double quantum (DQ) 
correction spectra were recorded using back-to-back (BABA) scheme.138 This ssNMR 
method describes a rotor-synchronized pulse sequence which excites DQ coherence from 
1H homonuclear dipolar coupling in the excitation period and reconverted to single 
quantum coherence for detection. For all 2D experiments, the 1H 90o pulses during the 
excitation and reconversion blocks were 1.2 μs.  Other experiment parameters include 32 
scan average with a 2.5 s recycle delay, one rotor cycle BABA recoupling, 12.9 ms 
maximum evolution time in indirect dimension and 9.1 ms during direct acquisition 
period, a 16-step phase cycle and ultrafast MAS frequency of 60 kHz. 
Glycine was used as an external 13C chemical shift reference by setting the carbonyl 13C 
peak at 176.49 ppm. 1H chemical shifts are referenced by setting the single 1H resonance 
of Adamantine at 1.6 ppm on the TMS scale. All spectra are recorded and processed in 
TopSpin 3.5. 
3.4.7 Computational methods 
The density functional theory (DFT) based calculations for both pure CLF and its 
complexes were performed by applying Gaussian 09 software package 91 with the DFT 
level of the hybrid B3PW91 function and 6-311++g(2d,2p) basis set.77, 92, 93 using the 
previously published CLF structure as a starting point94, optimizations were conducted in 
the gas state without any geometrical constraints as a fair comparison to the structure in 
the amorphous solid state. Zero imaginary frequency was achieved in the output of 
frequency analysis of each system. The Gauge-Independent Atomic Orbital (GIAO) 






3.5 Results and Discussion  
3.5.1 Amorphous Drug Loading and Chemical Features  
The X-ray diffraction patterns of powdered CLF-HPMCP dispersions with CLF: HPMCP 
(w/w) ratios increasing from 1: 0.25 to 1: 2 are shown in Figure 3.2. The amorphous form 
of CLF could be effectively maintained for the dispersion with a 0.75: 1 ratio of HPMCP 
to CLF. In comparison to the limited amorphous drug loading reported for CLF 
dispersions prepared with neutral polymeric carriers,120 the ASD of CLF-HPMCP was 
shown to have a superior drug loading capacity (~60%) indicating that HPMCP is an 
effective crystallization inhibitor for amorphous CLF. Hence, formation of strong 
intermolecular interactions is expected between CLF and HPMCP.  
In order to better investigate the specific drug-polymer interaction, understanding the 
chemical features of free drug and polymer molecules is a reasonable starting point. 
Natural Population Analysis (NPA) was applied herein to scrutinize the atomic charges of 
CLF (Figure 3.1C, details of charges are attached in Table A.10-12) as a means to 
identify potential interaction sites of drug molecules.139 In Figure 3.1C, the atomic charge 
of Nα (-5.35e), which is part of the imine group, was shown to have the most negative 
value throughout the CLF molecule, implying a potential for serving as a strong proton 
acceptor. On the other hand, Hβ , located at the secondary amine group, stood out as the 
most positively charged atom (+0.425e), indicating that the NH group is capable of being 
a proton donor. In addition, based on the geometrical characteristics of hydrogen bonds, 
the close atomic range between the Hβ and Nα (1.976 Å) enables the formation of a partial 
intramolecular hydrogen bond.98, 140 The existence of such an intramolecular interaction 






polymeric carriers with chemical structures containing only acceptor groups are expected 
to have limited inhibitory effects on the crystallization of CLF. This expectation is in 
satisfactory agreement with previous research: lacking of proton donor groups to interact 
with Nα, polyvinylpyrrolidone were shown as a poor polymeric inhibitor to disrupting the 
self-assembly of CLF.89  
According to the chemical structure of HPMCP shown in Figure 3.1B, one substituent of 
particular interest is the phthalyl group which is expected to be a key functional group in 
bonding with CLF. To be specific, the carboxylic acid of the phthalyl can not only be a 
strong hydrogen bond donor, but also can become negatively charged by proton donation, 
subsequently forming an ionic interaction. Considering the pKa values of CLF (8.5)
141 
and HPMCP (~3)102,  further support for the formation of  an acid-base interaction can be 
established on the basis of the salt formation rule which enunciates that proton transfer 
likely occurs between acidic/basic components when the ΔpKa value (pKa basic 
component- pKa acidic component) is greater than 2 to 3.
46-48, 101 Therefore, spectroscopic 
evidence of ionic bonding between negatively charged phthalate and protonated CLF 
were sought as described below.  
3.5.2 Solid-State Spectroscopic Investigation of Drug-Polymer Interactions 
3.5.2.1 UV/Vis Spectroscopy   
Pure CLF presents with a red color in both crystalline and amorphous forms, while an 
apparent color change from red to dark purple can be visually inspected when 
formulating CLF with HPMCP as a solid dispersion (Figure A.12). This color-change 






acetic acid/formic acid. Interestingly, no color change can be detected for CLF solid 
dispersions prepared with polymers that lack of carboxylic acid group (e.g. PVP/VA or 
HPMC). These interesting findings further suggest that the carboxylic acid group from 
phthalyl on HPMCP is the key functional group that interacts with CLF in solid 
dispersions.  
Furthermore, significant differences of the UV/Vis spectra between the pure CLF and 
CLF-HPMCP dispersions were observed in the visible wavelength range. To be specific, 
CLF alone shows a broad peak centered at 450 nm. This peak gradually bathochromically 
shifted to 487nm when preparing CLF-HPMCP dispersions with different weight ratios 
(Figure 3.3A). It is important to point out that the HPMCP alone has no visible 
absorption peak in this spectral region. The color-change phenomenon and the 
corresponding red-shifted visible absorption spectra of CLF-HPMCP dispersions are 
directly caused by the impact of electrostatic interactions on chromophore of the drug 
molecule.103-105 In this case, Nα of the imine group is located at the π-conjugated 
riminophenazine core which is the chromophore of the CLF. The proton of polymer 
carboxylic acid group transfers to the Nα, yielding a carboxylate group and a protonated 
imine group. Therefore, protonation of the riminophenazine core leads to electron density 
changes in the conjugated chromophore resulting in the obvious color-change and red-
shifted visible spectra.106, 107  
To further quantitatively investigate the effect of HPMCP on this bathochromic shift, 
spectra of dispersions with CLF: HPMCP (w/w) ratios ranging from 1: 0.1 to 1: 2 were 
subjected to principal components analysis (PCA). The first principal component (PC1) 






value of a component is defined as the projection of a spectrum onto a multidimensional 
space as a single point. In this case, score values of PC1 were applied to represent the 
spectral region with peaks located at different wavelength positions. The score values of 
PC1 were then plotted against HPMCP/CLF (w/w) to probe the best HPMCP content in 
the CLF solid dispersion formulations (Figure 3.3B). Based on Figure 3.3A and 3.3B, no 
significant red-shift was observed for the peak centered at 450nm when the CLF: 
HPMCP (w/w) ratio was less than 1: 0.5, indicating that the low content of HPMCP in 
these dispersions was insufficient to protonate the CLF chromophore. On the other hand, 
the wavelength of the broad peak has the largest bathochromic shift (~37nm) when the 
weight ratio of CLF to HPMCP reaches 1: 1.5, suggesting total protonation of the 
interaction center. The sharpest changes of the PC1 score value were observed for the 
intermediate compositions (CLF: HPMCP= 1: 0.75 or 1) of this titration curve. Similar 
quantitative results of correlating the spectral variables and polymer content of 
dispersions can be found from the mid-IR and ssNMR studies (vide infra). 
3.5.2.2 IR spectroscopy  
IR spectra of dispersions were evaluated herein to delineate how the drug-polymer 
interaction resulted in changes of vibrational modes for the involved chemical moieties of 
CLF or HPMCP. According to Figure 3.4A, a clear new peak (peak A) appears at 3310 
cm-1 in the IR spectra of the CLF-HPMCP dispersions. This new peak corresponds to the 
Nα-H
+ stretching of the protonated imine group. Interestingly, peak A was absent for 
dispersions with ratio of CLF to HPMCP less than 1: 0.5 (w/w) suggesting that the 






to protonate the imine group. As the concentration of the HPMCP in dispersions 
increases, the intensity of peak A was enhanced accordingly. This finding is in a good 
agreement with the UV/vis spectra discussed above.  
HPMCP alone has a fairly broad peak centered at 1724 cm-1 (peak B) assigned to the 
stretching of the carboxylic acid C=O group. The carboxylic acid from the phthalyl 
substituents can be converted to carboxylate group by forming ionic interaction with CLF. 
This interaction is supported by the appearance of peak at 1540 cm-1 (peak D) and 1395 
cm-1 (peak F) which can be assigned to the antisymmetric and symmetric stretching of 
the carboxylate group. A hypsochromic shift of Peak B from 1724 to 1733 cm-1 in the IR 
spectra of dispersions was also noted(Figure 3.4B); and this may be due to some 
accompanying changes in the hydrogen bond interactions of C=O groups. More evidence 
of the existence of acid base interactions between CLF and HPMCP can be found from 
the changes of spectra features in the region of 1650 cm-1 to 1350 cm-1 (Figure 3.5). 
Specifically, Peak C located at 1626 cm-1 corresponds to the stretching of C=Nα from the 
imine group. In the presence of HPMCP, peak C undergoes a bathochromic shift to 1619 
cm-1, indicating that protonation of Nα leads to changes in the vibrational properties of the 
imine group. This observation is consistent with a previous report of a similar red-shift of 
imine peak in the IR spectra of CLF salts prepared with low-molecular weight counter-
ions such as maleic acid or isonicotinic acid.112 Finally, the appearance of an intense new 
peak at 1481 cm-1 (peak E) is assigned to Nα H
+ deformation, further supporting the 
protonation of Nα.  
Spectral regions containing peaks A-F were subjected to PCA to further quantitatively 






score value against the HPMCP/CLF weight ratio for each peak are shown in Figure 3.6 
A-F. Each plot shows good agreement with the score plots obtained from the UV/Vis 
spectra; For the HPMCP/CLF ratio in the range of 0.75 to 1, the steepest changes of the 
PC1 score value were noted; indicating CLF consists of a mixture of the ionized and 
neutral states at these polymer concentrations. A detailed calculation of the molar ratio of 
drug and polymer and how this determines the optimized polymer concentration will be 
further discussed in detail.  
3.5.2.3 Solid state NMR spectroscopy  
Intermolecular geometry between API and polymer carrier have been successfully 
detected by dipolar based ssNMR experiments utilizing cross polarization, spin diffusion 
effect, and multi-quantum correlations.128-130 To further obtain site specific information at 
a molecular level, we have utilized ssNMR to elucidate the structural basis of the 
interactions between CLF and HPMCP.  Figure 3.7 shows the 13C CP-MAS spectra of the 
HPMCP, melt-quenched and as-received CLF. The relatively broad peaks, i.e. 13C peak 
width at full width at half maximum (FWHM) of 4.1-7.1 ppm and 2.8-3.8 ppm 
respectively for polymer and melt-quenched API, indicate the amorphous nature of the 
two samples. In comparison, the crystalline CLF has relatively sharp 13C peak of ~ 1.0 
ppm. It is useful to note the resolved –C=O peak (in red) of HPMCP and isopropyl-C (in 
green) in CLF from all other peaks, providing good probes to detect possible perturbation 
of local structures.  
The spectral comparison of CLF-HPMCP dispersions at various API-to-polymer weigh 






and resonance position largely match with the melt-quenched API, confirming the 
amorphous state. The only exception is the 13C spectrum of the dispersion sample at the 
CLF: HPMCP ratio of 1:0.25, which contains a large amount of sharp peaks from 
crystalline content. This confirms the PXRD finding in Figure 3.2. Interestingly, 
chemical shift changes of –C=O and isopropyl-C peaks, respectively in HPMCP and CLF, 
are observed in Figure 3.8A and B, suggesting the molecular interaction between these 
two groups. Specifically, as summarized in Table A.9, 13C chemical shift of isopropyl-C 
of pure CLF in crystalline and amorphous forms show a peak 49.4 ppm. In dispersion 
samples, this peak shifts to upfield positions, e.g. 47.0 ppm at the CLF: HPMCP ratio of 
1: 9. The chemical shift difference of isopropyl-C between pure CLF and the ASD is 
correlated with the computational results in Table 3.1 for determining a model of the 
CLF-HPMCP complex, which will be discussed more in the next section. Moreover, the 
13C resonance of carboxylic acid C=O in pure polymer is at 169.5 ppm and shifts to a 
new position at 174.2 ppm in CLF-HPMCP dispersions (Figure 3.8B), assigned to the 
carboxylate bound to CLF. This new component accounts for more peak intensity and 
area with respect to the original peak of pure HPMCP at a higher CLP: HPMCP ratio. PC 
analysis of this drug-loading dependent peak change shows sharpest change of the score 
value at the CLF: HPMCP ratio equal to 1 (Figure 3.8C), in good agreement with the 
findings of UV/Vis and IR spectroscopy.  
1H double quantum (DQ) correlation experiment utilizing back-to-back (BABA) 
excitation and reconversion pulse schedule has shown the capability of detecting close 
contacts of up to 5 Å in pharmaceutical solids.132, 136, 142 2D 1H-1H spectra of pure CLF 






between aliphatic and aromatic protons. Hypothetically, the formation of CLF-HPMCP 
ASD involves proton transfer from –COOH of polymer to Nα of CLF. This formation of 
a new Nα and Hα contact, if exists, will impact the local electronic configuration of N-H. 
Therefore, it would be of particular interest to pay attention to peaks of protons attached 
to Nand N (exists only if the proton transfer happens). The proton chemical shift of N-
H in pure CLF has been experimentally measured to be 8.6 ppm in chloroform in our 
previous study, which is presumably overlapped with the aromatic protons in Figure 3.9A. 
Therefore, the possible intramolecular correlations between H and other protons within 
the same CLF molecule will be underneath the aliphatic-aromatic cross peaks. HPMCP 
has no N-H groups and thus no amine proton peak in Figure 3.9B. Very interestingly, a 
pair of new cross peaks at 11.5 ppm and 10.0 ppm respectively appears in the spectrum of 
the HPMCP ASD (50% CLF by weight) in Figure 3.9C, which has equal peak intensity 
as shown in the 1D slice in red. These relatively large chemical shifts can only be 
assigned to protons adjacent to a nitrogen atom in the current molecular systems. 
Considering both the fact that no N-H containing compound has been introduced in 
forming the ASD and characteristic chemical shifts, these two new resonances can be 
assigned to the existing Nβ-Hβ and the newly formed Nα-Hα. As shown in Table 3.2, 
computational data in the next session show a peak shift to downfield for H when bound 
to polymer, resulting in the resolved peak in the spectrum of ASD. The correlation 
between Hα-Hβ in the DQ-SQ BABA spectrum of the CLF-HPMCP complex further 







3.5.3 Understanding the mechanism of CLF-HPMCP interaction from correlating 
ssNMR findings and computational analysis 
The aforementioned experimental investigations provide valuable spectroscopic evidence 
for understanding the molecular interactions with CLF-HPMCP ASDs. Computational 
modeling is applied herein to better interpret these experimental findings, for elucidating 
the interaction mechanism, and for depicting critical structure elements of CLF-HPMCP 
complex. As the carboxylic acid of HPMCP is the key chemical moiety to bond with CLF, 
the HPMCP structure was simplified as acetic acid in the computational modeling for 
ease of calculation.  
Two possible structures of CLF and carboxylic acid complex (complex I and complex II) 
with optimized geometrical positions and different binding motif were proposed herein 
according to a previously published report.112, 120 Briefly, ionic interaction was formed in 
complex I (Figure 3.10A, Table A.11) between the protonated imine group of CLF (NαH
+) 
and the carboxylate group. In addition, NαH
+ and the secondary amide group (NβH) form 
a bifurcated hydrogen bond with the COO- group to further stabilize complex I. On the 
other hand, the bonding motif of complex II (Figure 3.10 B, Table A.12) was proposed as 
forming a hydrogen bond dimer between CLF and HPMCP without proton transfer. The 
atomic distance between Hα and Hβ is 1.702 Å and 2.176 Å in complex I and II 
respectively; hence both are within the detection range of the 1H DQ BABA experiment. 
Simulated NMR chemical shifts of each complex were calculated by methods described 
in the experimental sections (summarized in Table A.10 to A.12). Interestingly, the 
chemical shifts of the simulated NMR spectrum for complex I has a satisfactory 






specific, there is a particular interest in the changes of chemical shifts of the isopropyl 
group in 13C CP-MAS spectra due to its direct connection to the imine group (interaction 
center) and lack of spectral interference from the HPMCP. According to the experimental 
ssNMR results, the chemical shift of the isopropyl group in 13C ssNMR spectrum of pure 
CLF was located at 49.4 ppm, while this peak was shielded to 47.5 ppm for 50% drug 
loading CLF-HPMCP ASD. For the simulated NMR spectrum, we observed that this 
peak upfield shifted from 53.2 to 51.1ppm (Table 3.1) showing a satisfactory concurrence 
with the experimental result. In contrast, peak of isopropyl moiety shows a downfield 
shift for complex II (Table 3.1), exhibiting an obvious discrepancy with experimental 
chemical shift. Moreover, for the 50% drug loading CLF-HPMCP dispersion, the 
chemical shifts of Hα and Hβ are experimentally reported as 11.5 and 10.0 ppm 
respectively in 1H NMR spectra giving a difference of 1.5 ppm. On the other hand, the 
simulated chemical shifts of Hα and Hβ for complex I are calculated to be 15.2 and 13.8 
ppm (Table 3.2), while the calculated chemical shifts of Hα and Hβ become 13.7 and 9.3 
ppm applying the complex II as a model structure (Table 3.2). These calculated results 
give a chemical shift difference of 1.4 ppm and 4.4 ppm for complex I and II respectively. 
The good agreement between the experimental and computational results suggests that 
complex I is a better model to illustrate interactions existed in the CLF-HPMCP ASD 
system. Thus, these simulations further support the presence of and acid-base interaction 
in the CLF-HPMCP ASD system, and indicate that the molecular interaction pattern 
between CLF and HPMCP should be very similar to the bonding motif of complex I. 
Hence, the following detailed molecular structure and binding mechanism is proposed 






on the phthalyl from HPMCP. The intra-molecular hydrogen bond formed between Nα 
and the secondary amide group is cleaved to make NβH as active hydrogen bond donor. 
Therefore, NαH
+ and NβH form a bifurcated hydrogen bond to further enforce the binding 
strength between CLF and HPMCP in ASDs.  
In order to further optimize the HPMCP concentration in the ASD system, the molar ratio 
between the CLF and key substituents of HPMCP (phthalyl group) were calculated on the 
basis of the chemical reaction discussed above (Figure 3.10C). According to the 
certificate of analysis of the HPMCP HP-55 (provided by Shin-Etsu Chemical Co., Ltd.), 
the weight percentage of the phthalyl group is around 33%. Hence, a 1: 1 molar ratio 
between CLF and phthalyl group is achieved when the weight ratio of CLF to HPMCP is 
in the approximate range of 1: 0.75 to 1: 1 (w/w). This molar ratio of CLF to phthalyl 
group be can correlated with the changes observed in the various spectra processing by 
multivariate analysis. To be specific, according to the plots of PC1 score value against 
HPMCP/CLF (w/w) ratio (Figure 3.3B, Figure 3.6A-F, Figure 3.8C), the sharpest PC1 
score value changes were observed for dispersions with molar ratio of CLF: phthalyl is 1: 
1, which suggests that this is the composition where CLF is undergoing a substantial 
change from the neutral to the protonated state. Hence, in this case, an optimized CLF-
HPMCP solid dispersion with sufficient drug-polymer interaction and superior 
amorphous drug loading can be achieve at a 1 to 1 molar ratio between CLF and phthalyl 
group. It is also noteworthy that only half of the CLF present is protonated by the method 
applied in this study at this specific CLF to phthalyl molar ratio due to the limited proton 








This study serves to illustrate the utility of various solid state spectroscopic methods, 
alone and in combination with multivariate analysis, to evaluate the interaction pattern in 
ASDs from a molecular perspective, thereby reducing the reliance on time-consuming 
empirical polymer screening. Ionic interactions are shown to be the dominant forces 
present in ASD systems of CLF and HPMCP. Protonation of the imine group on the 
riminophenazine core result in changes of electronic properties of the chromophore, 
which lead to an obvious color changing phenomenon and a corresponding bathochromic  
peak shift in UV/Vis spectrum. Spectral evidence of protonated imine and ionization of 
the carboxylic acid group from HPMCP can also be found from IR and 13C NMR spectra, 
further confirming the formation of ionic interaction between CLF and the phthalyl group 
of HPMCP. Moreover, the 2D double quantum NMR spectrum of CLF-HPMCP ASD 
provides important structural clues for proton transfer between CLF and HPMCP. To the 
best of our knowledge, it is the first documented study to utilize the ultrafast MAS 
technique (VMAS = 60 kHz) to explore drug-polymer interactions in ASDs. By combining 
computational chemistry with the NMR spectroscopy, molecular details of the CLF-
HPMCP interaction and a possible bonding motif are delineated. We also demonstrated 
that principal components analysis can be utilized to process spectra to further optimize 
the drug and polymer ratio based on the spectral changes. The interesting findings of this 
research should be helpful for scientists to design innovative formulations of amorphous 
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Table 3.1 Calculated NMR chemical shifts (ppm) and experimental chemical shifts (ppm) 
for isopropyl-C (-CH(CH3)2) in pure CLF and CLF-HPMCP complex (1:1, w/w). Refer 
to Figure 3.10 for schematic structures of complexes I and II. 
 Experimental Chemical 
Shifts 
Calculated Chemical Shifts 
Pure CLF CLF+HPMCP Pure CLF Complex I Complex II 
isopropyl-C 49.4 47.5 53.2 51.1 55.32 
 
Table 3.2 Calculated NMR chemical shifts (ppm) and experimental chemical shifts (ppm) 
for Hα and Hβ in CLF-HPMCP complex (1:1, w/w). Refer to Figure 3.10 for schematic 
structures of complexes I and II. 
 Experimental Chemical Shifts Calculated Chemical Shifts 
CLF * CLF+HPMCP ASD Complex I Complex II 
Hα - 11.5  15.2 13.7 
Hβ 8.6 10.0  13.8 9.3 
 
* The experimental chemical shift is taken from solution NMR measurement of pure CLF 


















Figure 3.2 PXRD for CLF-HPMCP dispersion systems (weight ratio of CLF to HPMCP 








Figure 3.3 Solid state UV/ Visible spectra of CLF and HPMCP dispersions with different 
CLF to HPMCP weight ratios (A); the score value of 1st principal component in principal 
components analysis of UV/Vis spectra in the wavelength region of 380 nm to 600 nm 








Figure 3.4 Infrared spectra of CLF-HPMCP with different CLF to HPMC weight ratios 







Figure 3.5 Infrared spectra of CLF-HPMCP with different CLF to HPMC weight ratios 







Figure 3.6 Plots of the score value of the 1st principal component in principal 
components analysis of IR spectra in the regions containing peaks A to F versus the 







Figure 3.7 13C CP-MAS NMR spectra of HPMCP (top), as-received crystalline CLF 









Figure 3.8 13C CP-MAS NMR spectra of CLF-HPMCP dispersions with different API to 
polymer weight ratios (A) and the enlarged spectral region from 157 ppm to 183 ppm (B); 
(C) Plots of the score value of 1st principal component in principal components analysis 








Figure 3.9 2D 1H-1H double quantum-single quantum (DQ-SQ) back-to-back (BABA) 
ssNMR spectra of amorphous CLF (A), HPMCP (B) and CLF-HPMCP ASD with 50% 
drug loading (C). The 1D slice at 21.5 ppm (indirect dimension and DQ frequency) is 
shown in red in (C). 1D projections are shown along with all 2Ds. All spectra are 








Figure 3.10 Models of CLF and carboxylic acid complex I (A) and II (B) for quantum 
chemistry calculation; (C) Molecular mechanism of the solid-state CLF-HPMCP reaction 











CHAPTER 4. IMPACT OF METALLIC STEARATES ON DISPROPORTIONATION 
OF HYDROCHLORIDE SALTS OF WEAK BASES IN SOLID-STATE 
FORMULATIONS2 
4.1 Abstract 
Excipient-induced salt disproportionation (conversion from salt form to free form) in the 
solid state during storage or manufacturing is a severe formulation issue that can 
negatively influence product performance. However, the role of excipient properties on 
salt disproportionation and mechanisms of proton transfer between salt and excipients are 
still unclear. Moreover, knowledge about the formation of disproportionation products 
and the consequent impact of these reactions products on the disproportionation process 
is still inadequate.  In the present study, three commonly used lubricants (sodium stearate, 
calcium stearate, and magnesium stearate) were mixed with a hydrochloride salt as binary 
mixtures to examine their different capabilities for inducing salt disproportionation at a 
stressed storage condition (40°C 65% RH). The overall objective of this research is to 
explore factors influencing the kinetics and extent of disproportionation including surface 
area, alkalinity, hygroscopicity, formation of new species etc. In addition, we also aim to 
clarify the reaction mechanism and proton transfer between the model salt and stearates 
to provide insight into the in-situ formed reaction products. We found that the properties 
                                                 
2
 The content of this chapter is adapted with permission from Haichen Nie, Wei Xu, Jie Ren et al. Impact of 
Metallic Stearates on Disproportionation of Hydrochloride Salts of Weak Bases in Solid-State 






of stearates significantly affect the disproportionation process in the initial stage of 
storage, while properties of the reaction products negatively affect the hygroscopicity of 
the powder mixture promoting disproportionation during longer-term storage. In addition, 
lubrication difference among three stearates was evaluated by performing compaction 
studies. The findings of this study provide an improved understanding of the proton 
transfer mechanism between the ionized form of an active pharmaceutical ingredients and 
excipients in solid dosage forms. It also provides pragmatic information for formulation 
scientists to select appropriate lubricants and other excipients, and to design robust 
formulations.  
4.2 Keywords 
Salt stability, Proton transfer, Surface area, Hygroscopicity, Deliquescence, Solid state 









Many active pharmaceutical ingredients (APIs) can be categorized as weak acids or weak 
bases.1 A large fraction of these weak electrolytes are poorly soluble in aqueous media in 
their neutral form.143, 144 To increase the water solubility and bioavailability of such 
substances, salt formation of ionizable APIs is a preferred formulation strategy.45, 145, 146 
Physicochemical advantages of salt formation include modifying solid-state properties, 
such as melting point and hygroscopicity, to improve the stability during storage and 
manufacturing.120, 147, 148 However, the propensity of conversion from the ionized form of 
drug species to its neutral form is considered as an important potential risk associated 
with employing pharmaceutical salts. This undesirable conversion is generally referred to 
in pharmaceutical reports as disproportionation.52, 53, 56 Many detrimental effects of salt 
disproportionation on pharmaceutical product performance have been reported. For 
instance, conversion of maleate or hydrochloride salts to the respective free base was 
shown to lead to the loss of API with a consequent decrease in tablet potency.12, 54, 55 
Rohrs et al. ascribed a significant decrease in the extent of dissolution of a tablet 
formulation to the disproportionation of delavirdine mesylate to the free base.42 Hence, in 
order to ensure that robust formulations are produced, it is imperative to have a 
comprehensive understanding of the mechanisms of salt disproportionation and to 
scrutinize key factors associated with such reactions. 
Although disproportionation is observed in solid state systems, the presence of water is 
known to be necessary for the disproportionation process, with higher water contents 
driving the process, indicating that it is a solution mediated reaction.12, 52, 57 The pH of 







required to understand the likelihood of disproportionation occurring.15, 56 Herein, only 
the disproportionation of salts of weak bases will be discussed; examples relating to the 
stability of weakly acidic salt can be found in the literature.16, 149, 150 The pH of maximum 
solubility (pHmax), viewed as the threshold value of disproportionation, is determined by 
the dissociation constant (pKa) of the base, the intrinsic solubility of the free base, and 
the salt solubility.17, 151 Solids of both salt and free base are considered to coexist at pHmax 
with the formation of an equilibrium between unionized and ionized drug substance in 
solution. Microenvironment, a theoretical concept, is postulated as an idealistic medium 
for proton transfer in a microscopic water layer on the surface of solid particles. When 
the pH value of microenvironment exceeds the value of pHmax, the salt form can 
potentially reverse back to its free base.18, 60 The microenvironmental pH can be greatly 
impacted by acidity/basicity of excipients in a multicomponent formulation. To be 
specific, excipients with high basicity can elevate the microenvironmental pH value and 
are generally reported as problematic components in formulations containing salts of 
weak bases.58-60 For instance, croscarmellose sodium and di/tribasic sodium phosphate 
were implicated in the conversion of the mesylate salt to the free base form as a result of 
their highly basic nature.42, 52 The pH of a slurry of a given excipient is generally 
employed as an empirical approach to estimate the microenvironmental pH, and to 
provide an indication of the likely drug-excipient compatibility.152, 153 For example, using 
the excipient slurry pH as a starting point, a quantitative model was developed by Merritt 
et al. to predict the salt disproportionation.154 
However, merely considering the slurry pH value of a given excipient is insufficient to 







and slurry pH of excipients were demonstrated as unsatisfactory predictors of salt 
stability in a formulation. Instead, excipients containing proton accepting groups, such as 
carboxylate groups, were found to significantly increase the risk of salt 
disproportionation.41 In addition, particle size and surface area of problematic excipients 
is also a crucial element impacting the salt stability.61 The formulation hygroscopicity is 
another significant factor influencing the disproportionation process. To be specific, the 
hygroscopicity of drug salts is typically affected by counterions employed for salt 
formation, and is a benchmark used during screening to identify the optimal salt form.57, 
155, 156 On the other hand, excipients and disproportionation reaction products can be 
hygroscopic. For instance, in a formulation containing a hydrochloride salt of API, 
magnesium stearate was highlighted as the most problematic excipient due to its unique 
deleterious ability to form magnesium chloride as a disproportionation product. The 
formation of this new highly hygroscopic substance, following acid-base reaction with 
the drug salt, in turn accelerated the disproportionation of the hydrochloride drug salt.41 
Building upon this observation, the current work will seek to further delineate how the 
properties of excipients (such as surface area and hydroscopicity) and the properties of 
reaction products formed following proton transfer impact the disproportionation process.  
The primary objective of the current study was to investigate the impact of excipient 
counterion on the disproportionation reaction, focusing specifically on the excipient 
properties as well as the characteristics of the reaction products. The second objective 
was to further understand the underlying mechanisms of proton transfer and salt 
disproportionation. The hydrochloride salt of pioglitazone, a thiazolidinedione for 







First, hydrochloride salts are still the most predominant salt forms employed for weakly 
basic APIs.15, 157 Second, pioglitazone hydrochloride salt (PIO-HCl) was selected due to 
its reported low pHmax and the tendency to readily undergo disproportionation.
158-160 
Three metallic stearates with different counterions, typically used as lubricants in tablet 
formulations8, 161, were blended with PIO-HCl salt to induce and accelerate the 
disproportionation process. Based on the previously reported analytical approaches of 
quantifying disproportionation of PIO-HCl in tablets,62 we quantified and differentiated 
disproportionation kinetics of PIO-HCl in mixtures with different metallic stearates by 
combining Raman spectroscopy and chemometrics. In addition, the lubrication properties 
of the three metallic stearates were further evaluated to assess the amount of lubricant 








4.4 Experimental Section 
4.4.1 Chemicals  
Pioglitazone hydrochloride (PIO-HCl) salt was supplied by Tokyo Chemical Industry 
(TCI) Co, ltd. (Portland, OR). Pioglitazone free base/neutral (PIO-FB) form was obtained 
from Dr. Reddy's Laboratory (India). The chemical composition and the solid state form 
of the PIO-HCl salt and PIO-FB were confirmed prior to the experiments by Fourier 
transform infrared (IR) spectroscopy (Smiths Detection Inc., MD) and powder X-ray 
diffraction (Panalytical X'pert Pro diffractometer). The IR spectra (Figure A.13) of PIO-
HCl and PIO FB demonstrate satisfactory agreement with literature reports. In addition, 
the X-ray diffractogram (Figure A.14) manifest peak positions for both pioglitazone HCl 
salt and its free base that are consistent with references.162 Magnesium stearate (MgSt) 
was obtained from Mallinckrodt (St. Louis, MO). Sodium stearate (NaSt) and calcium 
stearate (CaSt) were purchased from Acme-Hardesty Co. (Blue Bell, PA).  Chemical 
structures of PIO-HCl salt and different metallic stearates are shown in Figure 4.1. 
Mannitol, for compaction studies, was ordered from SPI Pharm. (Wilmington, DE). 
4.4.2 Sample Preparation of Binary Mixture for Disproportionation Studies 
PIO-HCl salt and each stearate were prepared as binary mixtures at a 90% to 10% ratio 
which is a reasonable representation of the typical ratio of API and lubricant found in a 
pharmaceutical tablet. For instance, a 200 mg tablet with 2-3% lubricant and an API 
potency of 50 mg would not be considered an unusual formulation.41 Prior to blending, 
all materials used in this study were individually stored in desiccators with calcium 
sulfate (W.A. Hammond Drierite Co. Ltd, Xenia, OH) for 7 days at 25°C. Powders of 







at the desired weight ratio in a glovebox (sidENTRYTM) purged with dry nitrogen to 
maintain a low relative humidity (RH) condition. The binary formulations with a targeted 
weight (300 mg) were subjected to additional mixing by a ResodynTM LABRAM acoustic 
mixer (Butte, MT) with 30% intensity for 3 minutes. Each binary mixture of PIO-HCl 
salt and metallic stearates was prepared in triplicate. Samples, in open dish conditions, 
were then placed into a 40°C/65% RH stability chamber and periodically analyzed by 
Raman spectroscopy.  
4.4.3 Sample Preparation of Placebo Formulation for Compaction Studies 
Placebo formulations were prepared for tablet compaction to investigate the different 
lubrication effects of various stearates. Each metallic stearate was added with diluents in 
a ratio of 0.5: 99.5 or 1: 99 (w/w) respectively as a placebo mixture. Powder samples 
were gravimetrically dispensed into glass vials and then subjected to a TURBULA®T2F 
Shaker-Mixer (Glen Mills Inc., Clifton, NJ) for mixing (1 minute).  In order to ensure 
enough friction between compacts and die-wall to differentiate the lubricating capacity of 
the different stearates, mannitol was selected as a diluent in placebo formulation due to 
the rugged nature of its surface.163-166 
4.4.4 Raman Spectroscopy Bulk Measurement  
A Kaiser Raman RXN1 Workstation (Kaiser Optical Systems, Inc., Ann Arbor, MI) 
equipped with a PhAT™ large volumetric bulk sampling probe was used to conduct 
Raman spectroscopy bulk measurements. HoloGrams™ v4.1 software was employed for 
data acquisition. The PhAT probe, coupled to the base unit via a fiber bundle, delivered 
the excitation energy from a 785 nm high power NIR diode laser (InvictusTM) located 







measurements. A 6 mm laser spot was generated by employing a 250 mm focal length 
lens. In order to ensure spectral quality, calibration of the laser excitation wavelength 
(cyclohexane; ASTM standard), spectrograph wavelength (neon atomic lines; ASTM 
standard), and instrument spectral response (white-light source; NIST standard) were 
performed. Taking into account the penetration of the PhAT Raman measurement, 
powder samples were carefully placed into a specially designed sample holder with 
controlled thickness for reproducibility. The CCD was cooled to -40°C and a dark 
subtraction was automatically applied to each spectrum to mitigate the baseline offset.  
Data acquisition time for each measurement was set as 10 seconds and 6 accumulations 
were averaged for all the samples. All Raman spectral data were processed by Grams AI 
(Thermo, Inc. Waltham, MA) for visual inspection. Multivariate analysis software 
SIMCA v13 (Umetrics AB, Umeå, Sweden) was used for chemometric analyses. 
4.4.5 Slurry pH of Stearates 
The slurry pH values of stearates were evaluated by preparing a 10% (w/v) slurry by 
weight of each stearate in water. After 90 minutes of forming the slurry, pH was 
potentiometrically measured by a calibrated Accumet® Research AR15 pH meter 
equipped with Accumet® electrode (Fisher Scientific, Pittsburgh, PA). The slurry pH 
values after 90 minutes and the values after 720 minutes were identical. 
4.4.6 Specific Surface Area Measurement 
The specific surface area of each stearate was measured using a Micromeritics TriStar 
3000 automatic physisorption analyzer operated in the 11 point Brunauer–Emmett–Teller 
(BET) analysis mode.167 Powder samples were loaded into glass sample tubes and 







measurement. Afterward, samples were vacuum outgassed for 60 minutes at room 
temperature until a stable baseline pressure was detected. The nitrogen adsorption 
isotherm was then generated in a bath of liquid nitrogen (77.4 K) using nitrogen dosing at 
the relative pressure range (p/po) range of 0.05-0.30.  
4.4.7 Particle Morphology 
Particle morphology of each stearate was evaluated by a Quanta FEG 250F (Field 
Electron and Ion Co., Hillsboro, OR) environmental Scanning Electron Microscopy 
(SEM). SEM was operated at 2.0 kV beam energy in a high vacuum condition. A small 
amount of sample powder was poured from a spatula onto double-sided conductive 
carbon tape mounted on aluminum stubs for the SEM analyses. 
4.4.8 Dynamic Vapor Sorption Measurements 
A Q5000SA Dynamic Vapor Sorption (DVS) (TA Instruments, New Castle, DE) was 
employed to measure the isohumidity moisture sorption at 40°C/65%RH. A sample of 
approximately 10 mg was pre-weighed and carefully dispensed into a crucible. All 
samples were dried at 50°C at the beginning of the experiments for 60 minutes until the 
change of %weight was less than 0.01 over a five minute period. Afterward, data 
acquisition to determine the percentage weight change was conducted at 40°C/65%RH 
condition for 2880 minutes. All the moisture sorption data were processed by the 
Universal Analysis 2000 (version 4.5A) software. 
4.4.9 Powder X-Ray diffraction (PXRD)  
The X-ray diffraction patterns of raw material, initial binary mixtures, and the stressed 
binary mixtures were collected on a Panalytical X’Pert pro X-Ray diffractometer 







reflectance mode. All the measurements were conducted at ambient conditions in Bragg–
Brentano geometry with 2θ ranging from 4° to 80° using a 0.0167° step size. The voltage 
and the current of the generator were set to 45 kV and 40 mA respectively.  PXRD data 
were processed by Panalytical X’Pert Data Viewer (version 1.5) and X’Pert High Score 
Plus (version 4.1) software.   
4.4.10 Tablet Compaction 
Tablet compaction was carried out using a Huxley-Bertram compaction simulator 
(Huxley Bertram Engineering, Ltd., Cambridge, UK), with 9.525 mm round flat punches 
following a two-stage displacement-controlled compression profile. The fill depth was 
adjusted to achieve 300mg tablet weight. The punch motion was set up as follows. The 
upper punch applies a pre-compression and a main-compression to the powder bed, while 
the lower punch stays stationary during compression. In both pre- and main- compression, 
the upper punch moves down following a sine-wave, waits a certain time lapse 
(simulating a dwell time), and moves up following a symmetric sine-wave. After main 
compression, the lower punch moves up at a constant speed to eject the tablet out-of-die. 
Two punch speeds were used to make tablets in order to evaluate strain-rate effect on 
compaction performance. In the low-speed case, the upper punch moved at a maximum 
speed of 120mm/s with 32ms dwell time in both pre- and main- compression, and the 
lower punch ejected tablets at ~25mm/s. In the high-speed case, the entire punch profile 
was accelerated 8X with 960mm/s maximum punch speed, 4ms dwell time, and 
~200mm/s ejection speed. The low and high speeds were designed to cover the range of 
realistic punch speeds on a high rotary tablet press. 13 tablets were made for each placebo 







2.2mm to achieve a range of compression pressures between 80MPa and 400MPa. 
During the compression and ejection process, the compaction simulator recorded force 
and displacement of both punches at a data acquisition rate of 2,060 Hz for low-speed, 
and 16,480 Hz for high-speed punch motion. 
The ejected tablets were kept for about 10 minutes in room temperature (23oC) and low 
humidity (22%RH) before being tested for weight (m), thickness (t), diameter (D), and 
breaking force (F). An automatic tablet tester (Dr. Schleuniger® Pharmatron SmartTest, 
Switzerland) was used for these measurements. Tablet tensile strength (TS) was then 












4.5 Results and Discussion  
4.5.1 Properties of drug substances and metallic stearates 
Raman spectra of pioglitazone (HCl salt and free base) and three metallic stearates are 
shown in Figure 4.2. A specific spectral region (1560-1660 cm-1) was used for evaluation 
for the following two reasons: first, stearates are Raman inactive in this spectral range, 
while distinct Raman peaks of both PIO-HCl and PIO-FB are clearly visible. These 
strong Raman peaks enable us to discriminate the drug substance from the different 
lubricants in mixtures. Second, in spite of overlapping peaks in this spectral region, the 
peak pattern differences between PIO-HCl and PIO-FB can be readily discerned without 
using multivariate analysis. To be specific, PIO-FB demonstrates a single peak located at 
1610 cm-1, while a doublet peak was observed for PIO-HCl in the region 1600-1650 cm-1. 
A plausible explanation for these spectral differences is that the vibrational modes of the 
pyridine ring are changed after protonation.169-171 To rule out the possibility of laser-
induced form conversion, pure PIO-HCl and its mixture with stearates were exposed at 
the same set laser power for 10mins. No data drift were observed for the specified 
spectral region (Figure A.15).  
SEM images of three different metallic stearates are shown in Figure 4.3A-C. Although 
the particle size of the three stearates are in the similar range (10-30 µm), a greater 
number of fine particles of NaSt (Figure 4.3A) were observed under the microscope. For 
particle morphology, MgSt (Figure 4.3B) and CaSt (Figure 4.3C) are characterized as 
flake-shaped particles, while NaSt present as nonspherical granule-like particles with an 
irregular shape. The different particle shape and particle size of NaSt mostly likely 







axis), the BET surface area of NaSt (51.3 m2/g) is almost five times greater than that of 
MgSt (10.1 m2/g) and CaSt (13.9 m2/g). The measured slurry pH value of each stearate is 
also shown in Figure 4.4 (left Y axis), and provides an indication of their potential to 
elevate the microenvironmental pH.12  Basic pH values were observed for all three 
metallic stearates whereby MgSt (8.23) and CaSt (8.28) have similar slurry pH value, and 
NaSt (9.51) has the highest slurry pH value. The alkaline nature of the metallic stearates 
can be partially ascribed to the existence of basic impurities in the stearates. For instance, 
magnesium oxide is well documented as a basic impurity of MgSt, CaSt has calcium 
hydroxide as an impurity while sodium hydroxide has been reported as an impurity in 
NaSt.8, 63, 172, 173 The slurry pH values of all three stearates are much higher than the pHmax 
(2.8) of PIO-HCl salt indicating the potential for inducing salt disproportionation. 
Intuitively, based on the above observations, NaSt is expected to be the most problematic 
excipient in the formulation of hydrochloride salts due to its high specific surface area 
and strong alkalinity. However, some counterintuitive results were observed from 
disproportionation studies indicating that other factors need to be considered (vide infra).   
4.5.2 Chemometric models and Raman calibration curves 
Based on the aforementioned spectral region, chemometric models for calibration 
samples were established to obtain a validated calibration curve to quantify the salt 
disproportionation in mixtures. A series of samples with different PIO-HCl salt to PIO-
FB ratio was prepared to generate a calibration curve ranging from 50% PIO-HCl (50% 
PIO-FB) to 100% PIO-HCl (0% PIO-FB). Each calibration standard was freshly prepared 
in triplicate and stored in desiccators with calcium sulfate at ambient temperature prior to 







samples over the selected spectral region. A decreasing intensity of the higher 
wavenumber peak (peak II) with an increasing amount of PIO-FB can be observed from 
Figure 4.5A. Based on the spectral difference, a chemometrics model could be built to 
directly discern and quantify the existence of PIO-FB.  
The spectra of the calibration sample were preprocessed by standard normal variate 
transformation (SNV), a mean centering and auto-scaling algorithm, to eliminate the 
multiplicative effects generated from light scattering and particle size variations of 
powdered sample.174-177 Pretreated spectra were then subjected to principal components 
analysis (PCA). The PCA results suggested that the first two components capture over 
99.7% of the spectral variation. According to the loading plots of PCA (Figure A.16), 
loadings of first principal component (PC1) and second principal component (PC2) both 
demonstrate the spectral variation from peak I and peak II. It is noteworthy that PC 1 
captures 99.2% spectral variations, and hence makes a much larger contribution to the 
model than that of PC2. Moreover, in the PC1-PC2 score plot (Figure 4.5B), no outliers 
were detected in the Hotelling’s T2 ellipse at 95% confidence region. Calibration standard 
of each level segregates into discriminating clusters along PC1 (X-axis). Hence, selecting 
PC1 as the only principal component for the partial least squares (PLS) models is 
reasonable to avoid over-fitting. The selection of principal component is further 
confirmed by applying the “leave-one-out” cross validation (a trade-off between the 
goodness of fitting and prediction), which is discussed as follows.   
Based on the above analysis, PLS calibration (blue dots) was established by employing 
PC1 as the major principal component (Figure 4.5C). The small value of root mean 







fitting of the model and predictive power.178 In addition, the reasonable values of R2Y 
and Q2 suggest that the PLS model is appropriate to quantify the amount of PIO-FB.179 
Furthermore, this PLS calibration curve was applied for validation (red dots in Figure 
4.5C) using another group of samples (each level of the standard prepared in triplicate). 
The consistency between the calibration points and the validation points further implies 
the robustness of applying this PLS model. Moreover, a low value of the root mean 
squares error of prediction (RMSEP) further indicates the accuracy and good quantitative 
performance of this calibration model.180 On the basis of the Raman spectral differences 
and the validated chemometric model, the disproportionation of PIO-HCl could be 
quantified.  
4.5.3 Quantitation of disproportionation in binary mixtures 
Binary mixtures containing PIO-HCl and each stearate were prepared in a 9:1 ratio (w/w) 
and stressed at a high humidity condition (40°C and 65% RH) for a period of up to 30 
days. The levels of disproportionation (% conversion) were quantified by combining the 
Raman spectroscopy and aforementioned PLS model (Figure 4.6). Less than 1% of form 
conversion was observed for the neat PIO-HCl salt stressed at 40°C and 65% RH for 30 
days. On the other hand, at the same stress condition, a considerable amount of form 
conversion was observed for PIO-HCl in the mixtures with metallic stearates indicating 
that all three stearates are capable of inducing the disproportionation of PIO-HCl salt. 
Differences in both the kinetics and the extent of disproportionation were obvious among 
the blends containing different stearates. For the mixtures containing MgSt or NaSt, the 
extents of disproportionation (% conversion) reached a plateau within 2 days, while the 







PIO-HCl and CaSt, indicating slower disproportionation kinetics. Additional points were 
collected over the first 72 hours (Figure 4.6A) in order to further differentiate variations 
in disproportionation kinetics between samples containing MgSt (blue dots) and NaSt 
(grey dots). In Figure 4.6A, it can be observed that the highest extent of 
disproportionation was achieved within 12 hours for the mixture of PIO-HCl and NaSt 
indicating the fastest disproportionation rate. For the mixture of PIO-HCl and MgSt, the 
plateau disproportionation value was reached after 36 hours. Based on the plateau value 
of disproportionation at 30 days for each blend, the blend of PIO-HCl and NaSt had the 
lowest level (13%) of disproportionation, whereas higher percentages conversion to PIO-
FB were observed for blends in presence of MgSt (20%) or CaSt (18%). Clearly, 
according to the above disproportionation results for binary mixtures of PIO-HCl and 
metallic stearates, considering factors such as excipient surface area and excipient slurry 
pH are insufficient to understand differences in the rate and extent of disproportionation, 
in particular due to two counterintuitive observations. First, although CaSt and MgSt 
have similar particle sizes and morphologies, specific surface area, and slurry pH values, 
there is a considerable differences in disproportionation kinetics observed between the 
MgSt blends and CaSt blends. Second, NaSt has the highest surface area and alkalinity, 
whereas the mixture of PIO-HCl was shown to have the lowest extent of 
disproportionation. Hence, it is necessary to take into account of the moisture sorption 
profiles for both the initial components and the powder mixtures as another important 







4.5.4 Moisture sorption 
Salt disproportionation, which is conversion from the ionized state of a molecule to its 
neutral form via proton transfer, is considered a solution mediated reaction. Hence, the 
presence of water in the powder sample, even a small amount of adsorbed water on the 
surface of solids, is crucial to form the microenvironment and to promote the interactions 
between the API salt and reactive excipients. In this case, factors of particular interest are 
the hygroscopicity of the PIO-HCl salt, the moisture uptake of each stearate, and the 
water sorption of binary mixtures of PIO-HCl and stearates at the stressed condition.  
The hygroscopicity of a salt is considered as an important criterion in salt screening, 
since hygroscopic salts often have stability issues. In the present study, based on the 
moisture sorption isotherm (40°C), little water uptake was observed (<0.1%) up to 95% 
RH for the PIO-HCl salt (Figure A.17). In addition, the water sorption curves of PIO-HCl 
and PIO-FB at the stressed storage condition of this study (40°C and 65% RH) 
demonstrate minimum percent weight changes over a period of 48 hours (Figure A.18). 
It is also necessary to explore the moisture uptake of the additives used to form the binary 
mixture and moisture sorption profiles for each stearate are shown in Figure 4.7A. At the 
condition of 40°C/65% RH, the plateau values of the percentage weight change for all 
stearates were reached within 10 minutes. The plateau values of percentage water gained 
for NaSt and MgSt are 1.18% and 0.81% respectively, while the % water in CaSt is only 
0.16% at the same storage condition. The hygroscopic characteristic of NaSt can be 
partially attributed to its high surface area. It is well documented that powder samples 
with high surface areas are typically more hygroscopic due to enhanced surface 







material when comparing among three stearates. At 40°C/65% RH, the equilibrium water 
content in CaSt is only one seventh of the amount of water in NaSt, and five times less 
than the adsorbed water presented in MgSt. The hygroscopic variations among the 
stearates are thus lead to the different amount of adsorbed water on the surface solid 
particles. It has been suggested that the amount of adsorbed water on the surface of 
crystalline solids determines the molecular mobility of solvated species, which in turn 
can react with other mobilized species in the near vicinity.182-186 Accordingly, it is 
expected that this factor influenced the initial rate of disproportionation observed herein. 
For instance, the PIO-HCl and CaSt mixture had the slowest disproportionation kinetics 
due to the limited hygroscopicity of CaSt. In contrast, PIO-HCl and NaSt was observed to 
have the highest disproportionation rate, which can be partially ascribed to the more 
hygroscopic nature of NaSt. However, as shown in Figure A.19, none of the stearates are 
very hygroscopic at the storage conditions employed. Hence, even the presence of small 
amount adsorbed moisture on the surface of the solids is sufficient to trigger the reaction 
of proton transfer. This finding is also consistent with other publications which associated 
chemical instability issues with the existence of low level of adsorbed water layers on the 
solid surfaces.187-189 
It is perhaps of most significance to investigate the percentage water gained in binary 
mixtures of PIO-HCl (90% w/w) and stearates (10% w/w) at the storage condition 
directly relevant to the disproportionation process. The percentage weight change of each 
blend at 40 °C/65% RH plotted as a function of time is shown in Figure 4.7B. It can be 
observed that the plateau value of % water for the mixture of PIO-HCl and NaSt was 







hours for the mixture of PIO-HCl and MgSt. For the blend of PIO-HCl and CaSt, 
equilibrium was not reached within 48 hour, and the moisture sorption is still increasing. 
It is noteworthy that the kinetics of the water sorption roughly mirrors the 
aforementioned kinetics of disproportionation (Figure 4.6A). To be specific, for PIO-HCl 
with MgSt or NaSt, the time of reaching equilibrium with respect to water sorption is 
similar to the time taken to achieve the highest extent of form conversion. For PIO-HCl 
and CaSt, increasing trends were observed both in water sorption profile and 
disproportionation kinetics. This interesting finding not only further confirms the vital 
role of moisture in disproportionation, but also suggests that water sorption kinetics at the 
storage condition of interest can be used to evaluate the disproportionation kinetics. A 
similar observation was reported by Hsieh et al. when assessing the disproportionation 
kinetics of benzocaine mesylate.61 Interestingly, although a significant water gain was 
absent in the moisture sorption profiles of pure MgSt (Figure 4.7A) and pure PIO-HCl 
(Figure A.18), a considerable water uptake (5.3% w/w) was noted in the water sorption 
profile of the mixture (blue line in Figure 4.7B). This observation was originally reported 
by John, et. al.41 where it was discovered that the increased hygroscopicity of the 
formulation could be attributed to a chemical interaction between MgSt and the weakly 
basic HCl salt. The byproduct of this MgSt induced disproportionation of PIO-HCl salt is 
the generation of deliquescent MgCl2. Building upon this observation, we deliberately 
selected stearate lubricants with different cation to further assess the impact of excipient 
counterion on the disproportionation reaction. For mixtures containing CaSt, it is also 
suspected that highly hygroscopic reaction products that can undergo deliquescence at 







hygroscopic material. At 40 °C and 65% RH, based on the results of water gained for 
each neat component, the % water adsorbed by the mixture of PIO-HCl and CaSt in a 9 to 
1 ratio is expected to be lower than 0.1% if there is no chemical reaction between two 
species. However, 0.63% adsorbed moisture was detected in the powder mixture over 48 
hours of stressed storage. In addition, it was noted that the equilibrium of moisture uptake 
was not reached in 48 hours for the blend of PIO-HCl and CaSt, as evidenced by the 
upward-trend shaped water sorption curve. In contrast, no synergistic moisture sorption 
was observed in a powder blend containing PIO-HCl and NaSt.  These interesting 
findings suggest that different reaction products, with varying hygroscopicities, can be 
formed via proton transfer between the PIO-HCl and the different stearates in the 
following manner. 
During the process of converting the PIO-HCl to PIO-FB, protons transfer from the 
ionized drug (PIO-HCl) to proton acceptors present in the metallic stearates (carboxylate 
groups). In other words, in order to ensure the overall charge neutrality of the chemical 
reaction190, cations of the metallic stearates have to combine with chlorine anions to form 
inorganic metallic chloride salts as reaction products. The reaction scheme between PIO-
HCl and metallic stearates is summarized in Figure 4.8. Thus, magnesium chloride 
(MgCl2), calcium chloride (CaCl2), and sodium chloride (NaCl) were formed as 
disproportionation products when MgSt, CaSt, NaSt respectively were blended with PIO-
HCl salt and subjected to stress storage conditions. It is well known that both MgCl2 and 
CaCl2 undergo deliquescence, whereby the salt dissolves upon exposure to ambient 
relative humidity forming a salt solution, at relative humidities that are lower than the 







humidity (DRH) of MgCl2 is reported as 31%.
191 For CaCl2, the DRH value was 
estimated ~20% by applying both conductivity and hygrometer methods.192, 193 In 
contrast, NaCl does not undergo deliquescence until exposure to a much higher RH and 
the DRH of NaCl is 75% RH at 40 °C.194 
In order to further confirm the formation of metallic chloride as a disproportionation 
product, PXRD was employed, scanning a wide angular range (2 theta range from 4° to 
80°) to detect the existence of inorganic salts.195 PIO-HCl and stearates mixtures were 
prepared in a 1:1 ratio, exposed at 40°C 65% RH for 24 hours, and subsequently 
subjected to PXRD to obtain a diffractogram. Although the diffractograms of pure PIO-
HCl, PIO-FB, and NaSt demonstrated no strong peaks at the high 2 theta range, several 
new peaks in this region were clearly observed in the stressed mixture of PIO-HCl and 
NaSt (Figure 4.9A). These intense peaks (located at 31.7°, 45.5°, 56.6°, 66.2°, and 73°) 
correspond to peaks reported in the diffractogram of NaCl.196 In contrast, no peaks 
representative of MgCl2 or CaCl2 could be detected (Figure 4.9B) for PIO-HCl blends 
with MgSt or CaSt, which can be accounted for on the following basis. First, the low 
DRH of MgCl2 and CaCl2 is expected to result in a loss of crystallinity during storage and 
analysis due to deliquescence and hence an absence of peaks. Second, relatively small 
amounts of MgCl2 or CaCl2 are anticipated to form in the powder mixtures, and the 
intensities of the peaks at high two theta values are relatively weak based on their 







4.5.5 Impact of excipients properties on kinetics and extent of PIO-HCl 
disproportionation  
Based on the above discussion, the main properties of excipients and reaction products 
influencing the kinetics and the extent of salt disproportionation are summarized in this 
section. During the initial stage of stressed storage at 40°C 65% RH, disproportionation 
of PIO-HCl in binary mixtures is determined by the properties of the additives (stearates) 
including their alkalinities, hygroscopicities, and specific surface areas. The alkalinity 
and the hygroscopicity of each stearate directly influence the microenvironmental pH of 
each blend of PIO-HCl and stearate. Although the microenvironmental pH in powder 
blends is generally difficult to characterize59, the alkalinity of pure component (evaluated 
by slurry pH value) provides a reasonable indicator of the likelihood of creating a 
favorable microenvironmental pH to induce PIO-HCl salt disproportionation. On the 
other hand, the hygroscopicitiy of each stearate impacts the mobilization of reactive 
species via solvation at the surface, at least at the initial stage of the reaction. Clearly, 
more hygroscopic stearates adsorb more water from the environment, and more solvated 
species can be potentially formed as a result, depending on the location and physical state 
of the sorbed water. Following the sorption of water, in the mixture of PIO-HCl with a 
basic stearate, the microenvironmental pH of the blend exceeds the pHmax of PIO-HCl 
(2.8). Consequently, conversion from PIO-HCl salt to its neutral form occurs during the 
initial stage of stressed storage.14, 199 The specific surface areas of reactants also have 
been reported to impact the chemical relativity.200-202 In this case, we observe that 
specific surface areas of stearates also extensively affect the salt disproportionation 







area will lead to the greater area of contact with the PIO-HCl, as well as leading to a 
larger extent of surface water adsorption. These results are consistent with a previous 
study in which it was noted that mesylate salts with higher surface area per unit mass 
were observed to undergo a larger extent of disproportionation.61 For the systems studied 
herein, NaSt has the highest specific surface area, hygroscopicity, and alkalinity. 
Therefore, during the initial stages of storage, the binary mixture of PIO-HCl and NaSt 
demonstrate greater rate and extent of disproportionation.  
However, as the disproportionation reaction proceeds at 40°C 65% RH for longer periods 
of time, different metallic chlorides are accumulated as reaction products in the mixtures, 
and these new components start to influence the water sorption behavior of the powder 
blends. To be specific, the aforementioned in-situ formation of MgCl2 and CaCl2 lead to a 
significant increase in the amount of water sorbed by the powders due to their 
deliquescence with the subsequent formation of a solution phase within the powder 
mixture.38, 203 Consequently, the bulk water now present in the powder blends is expected 
to further facilitate the disproportionation reaction to a greater extent, as is 
experimentally observed. Therefore, during the later stages of storage at stressed 
condition, it is clear that the extent of disproportionation is dominated by the 
hygroscopicity of the products formed via proton transfer. 
4.5.6 Compaction study and composition suggestions in formulation 
In addition to the previously discussed physicochemical factors that influence HCl salt 
disproportionation, the amount of a given problematic excipients will also have an impact. 
Thus, a greater weight fraction of a given problematic excipient in the powder mixture 







various stearates studied herein in terms of achieving a sufficient lubrication effect was 
unknown. MgSt is frequently used as a lubricant, but the other metallic stearates have 
been less studied in this context. Therefore, 0.5% and 1% of each metallic stearate was 
added as a lubricant for a placebo mannitol formulation,  evaluating both high speed 
(Figure 4.10A) and low speed compaction,  (Figure 4.10B) to discriminate the different 
lubrication effects. It was observed that CaSt has the worst lubrication effect during the 
compaction of placebo formulation tablets. For instance, severe breakage issues, such as 
sticking, were observed for tablets employing 0.5% w/w CaSt in the placebo formulation. 
In addition, according to Figure 4.10, both high-speed and low-speed compactions for 
formulations with 0.5% CaSt exhibit extensive friction during the ejection, indicating 
insufficient lubrication effects. In contrast, satisfactory lubrication effect for formulations 
containing MgSt or NaSt are observed based on their ejection forces. It is noteworthy that, 
based on the high speed compaction study (Figure 4.10A), the ejection force of the 
formulation containing 0.5% w/w NaSt is equivalent to the ejection force of formulation 
containing 1% w/w MgSt, implying that NaSt has the best lubrication effect, probably 
due to its high surface area. This interesting result suggests that a lower weight fraction of 
NaSt in the tablet formulation is required to achieve an acceptable lubrication effect. 
When formulating susceptible HCl salts, employing a lower weight fraction of a stearate 
would be expected to reduce the extent of HCl salt disproportionation. Hence, as 
compared to CaSt and MgSt, NaSt can be potentially used as a more favorable lubricant 
in formulations containing HCl salt due to the lower required amount. However, 
according to previous reports, different lubricants can impact the mechanical strength of 







stearates was investigated. At both low and high compaction speed, no significant 
differences of tablet tensile strength (MPa) were observed among the formulations with 
different stearate in the 100-400MPa compressive stress range (Figure A.20). These 
results suggest that employing CaSt, MgSt, and NaSt as lubricants in a formulation lead 









Three metallic stearates (MgSt, CaSt, and NaSt) can induce a significant extent of PIO-
HCl salt disproportionation in powder blends stored at 40°C/65% RH condition. The 
differing properties of the three metallic stearates result in different kinetics and extent of 
PIO-HCl salt disproportionation. During the initial stages of stressed storage, the extent 
and kinetics of PIO-HCl salt disproportionation in the mixture of PIO-HCl and stearates 
is dominated by the hygroscopicity, alkalinity, and surface area of each stearate. Hence, 
during the initial period of storage, blends of NaSt and PIO-HCl have the largest rate due 
to large surface area, high hygroscopicity, and strong alkalinity of NaSt.  In contrast, the 
mixture of CaSt and PIO-HCl demonstrates the slowest rate of disproportionation due to 
the non-hygroscopic nature of CaSt. 
However, the reaction products were also found to influence the progression of 
disproportionation. The metallic chlorides, formed as reaction products, exhibit different 
tendencies to undergo deliquescence at the storage conditions employed. Since both 
CaCl2 and MgCl2 can readily deliquesce, blends of PIO-HCl and MgSt/CaSt 
demonstrated a greater extent of disproportionation during the later period of storage 
when the reaction products had formed. Hence, it can be concluded that with the 
accumulation of the reaction products, their hygroscopicity becomes a dominant factor in 
facilitating additional disproportionation. These observations, together with initial studies 
demonstrating that NaSt shows adequate lubrication properties when present at a low 
amount, suggest that alternative lubricants with a lower propensity to induce 
disproportionation than the commonly employed MgSt, might need to be considered to 
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Figure 4.1 Chemical structure of Pioglitazone HCl salt (A) and metallic stearates: 

















Figure 4.3 SEM images of metallic stearates: sodium stearate (A); magnesium stearate 








Figure 4.4 BET specific surface area (right Y axis) and slurry pH value (left Y axis) of 








Figure 4.5 Raman spectra of calibration (50% PIO-HCl to 100% PIO-HCl) standards 
over the spectral range 1560cm-1 to 1660cm-1 (A); PCA of calibration standards (B); PLS 









Figure 4.6 Extent of disproportionation (% Conversion) of PIO-HCl salt in a binary 









Figure 4.7 (A) Water sorption curves of pure CaSt (Red), pure MgSt (Blue), and pure 
NaSt (grey) at 40°C 65% RH over the period of 50 minutes. (B) Water sorption curves of 
binary mixture of PIO-HCl and stearates in a 9:1 ratio: PIO-HCl and CaSt mixture (red); 









Figure 4.8 Mechanism of proton transfer between PIO-HCl and Metallic Stearates 
 
 
Figure 4.9 Wide-angular diffractogram of PIO-HCl, PIO-FB, NaSt, MgSt, CaSt, and the 








Figure 4.10 Ejection forces of high speed compaction (A) and low speed compaction (B) 








CHAPTER 5. CRYSTALLINE SOLID DISPERSION-A STRATEGY TO 
SLOWDOWN SALT DISPROPORTIONATION IN SOLID STATE 
FORMULATIONS DURING STORAGE AND WET GRANULATION 
5.1 Abstract 
Salt disproportionation (a conversion from the ionized to the neutral state) in solid 
formulations is a potential concern during manufacturing or storage of products 
containing a salt of the active pharmaceutical ingredient (API) due to the negative 
ramifications on product performance. However, it is challenging to find an effective 
approach to prevent or mitigate this undesirable reaction in formulations. Hence, the 
overall objective of this study is to seek a practical formulation strategy to reduce the risk 
of salt disproportionation in pharmaceutical products. Crystals of pioglitazone 
hydrochloride salt were dispersed into polymeric matrices as a means of preventing the 
pharmaceutical salt from direct contact with problematic excipients. It was found that the 
level of salt disproportionation could be successfully reduced during storage or wet 
granulation by embedding a crystalline salt into a polymeric carrier. Furthermore, the 
impact of different polymers on the disproportionation process of a salt of a weakly basic 
API was investigated herein. Salt disproportionation was significantly affected by the 
physicochemical properties of different polymers in formulation including hygroscopicity, 
acidity of substituents, and inhibitory effects on the crystallization of the neutral form of 







on the stability of a salt in solid formulations. Moreover, adding pH modifier into 
granulation fluid was found to be another useful method to retard the salt 
disproportionation. Combining the developed salt protection approach and the 
granulation fluid with pH modification, salt disproportionation can be significantly 
reduced during the wet granulation process. These interesting discoveries enable salt 
disproportionation to be mitigated during storage or processing, which provide critical 
information that will allow pharmaceutical scientists to develop appropriate formulations 
with improved drug stability.  
5.2 Keywords 
Salt stability, solid dispersion, acid-base interaction, HPMCAS, PVPVA, inhibitory effect, 
pH modifier, hygroscopicity, crystal growth, microenvironmental pH, pioglitazone 









Salt formation is a crucial formulation strategy to increase the bioavailability of ionizable 
active pharmaceutical ingredients (APIs) with poor aqueous solubility. 45, 145, 146 In 
addition, salt formation can also be applied to avoid polymorphism and to improve the 
stability and manufacturability of APIs by changing their solid-state properties.120, 147, 148 
However, the ionized form of drug substances can be metastable and have a propensity of 
converting to its neutral form, which can be considered a critical potential risk, narrowing 
the application of pharmaceutical salts. This unwanted conversion of drug salt to its 
neutral form is termed salt disproportionation in pharmaceutical literature.16, 52, 53, 56 
Prasugrel hydrochloride salt, a platelet inhibitor, severs as a recent example of salt 
disproportionation showing salt-to-base conversion within a pharmaceutical tablet.206, 207 
Salt disproportionation has been reported to negatively influence the performance of 
pharmaceutical products. For instance, Erlotinib HCl salt disproportionate to its free base 
resulting in a rapid precipitation followed by a decreasing of dissolution rate in simulated 
intestinal fluid.208 Therefore, it is imperative to develop formulation approaches to 
prevent or, at minimum, slowdown salt disporportionation to ensure that robust 
formulations are produced.  
In order to effectively inhibit salt disproportionation, it is a prerequisite to understand the 
following three key factors influencing the disproportionation process. The first of these 
factors is the presence of water, since salt disproportionation is reported to be a solution 
mediated reaction.12, 42, 57 For solid dosage forms, the presence of residual water from 
manufacturing or after moisture sorption from the atmosphere is almost inevitable, and 







solid surface, which can mediate disproportionation.15 Second, microenvironmental pH, 
affected by the acidity/alkalinity of the excipient used in formulation, is another 
important factor impacting salt stability.58-60 For salt of a weak base, salt 
disproportionation can potentially occur when the pH of microenvironment surpasses the 
pH of maximum solubility (pHmax).
14, 18, 60, 151 Hence, modifying the microenvironmental 
pH is a feasible approach to reduce the risk of salt disproportionation. For instance, 
microenvironmental pH can be decreased by avoiding alkaline excipients such as metallic 
stearates or croscarmellose sodium.153, 154, 209 Moreover, pH modifers, such as maleic acid 
or tartaric acid, can be added into solid formulations to further adjust the pH value of 
microenvironment.12, 210 Third, the greater area of contact between the drug salt and 
problematic excipients was reported to significantly accelerate the disproportionation 
reaction (e.g. for miconazole and benzocaine salt).61 Therefore, reducing the exposure of 
the salt surface to the surface of the problematic excipient can be potentially used as a 
means to decrease the extent of salt conversion.  
In the present study, the overall aim was to develop effective formulation approaches to 
slow down salt disproportionation in a solid formulation during storage and 
manufacturing. Pioglitazone hydrochloride (PIO-HCl), a thiazolidinedione for type II 
diabetes treatment158, 160, was employed herein as model compound for two reasons. First, 
the hydrochloride salt is one of the most commonly used salt forms for weakly basic 
APIs.15, 157 Second, PIO-HCl has a low reported pHmax and was shown to readily 
disproportionate when interacting with problematic excipients (e.g. croscarmellose 
sodium).41, 209 According to the previously developed analytical approaches of detecting 







chemometrics were combined herein to monitor the conversion of PIO-HCl to its free 
base.62 In this study, polymers were formulated with crystalline PIO-HCl salt to form 
crystalline solid dispersion (CSD) to slow down disproportionation of the drug salt. 
Embedding the PIO-HCl crystals into a polymeric matrix serves as an approach to protect 
the API by minimizing the contact surface between the drug salt and problematic 
excipients. In addition, acidic substituents present in some polymers, such as the phthalyl 
group of hypromellose phthalate, can also function as a pH modifier to adjust the 
microenvironmental pH. Employing different polymers in solid formulations could have 
different effects on salt disproportionation due to the different physicochemical properties 
of the polymers including factors such as functional group chemistry and hygroscopicity. 
Hence, the first objective of this study was to investigate the impact of different polymer 
on salt disproportionation in solid formulations. Hypromellose acetate succinate 
(HPMCAS) and vinylpyrrolidone-vinyl acetate (PVPVA) are selected due to their very 
different chemistry and hygroscopicity211, 212 and used to produce either physical mixtures 
(PMs) or CSDs with PIO-HCl. Salt disproportionation in PMs and CSDs was monitored 
following exposure to high relative humidity (RH) storage conditions. The second goal 
was to further investigate salt disproportionation in the presence of bulk water. During 
aqueous wet granulation, disproportionation of PIO-HCl was compared when using 
acidic polymers versus adding pH modifiers to the granulation fluid. The findings of this 
research provide feasible approaches for slowing down salt disproportionation during 
storage and wet granulation, as well as a mechanistic understanding of the impact of 








5.4 Experimental  
5.4.1 Chemicals 
PIO-HCl salt was ordered from Tokyo Chemical Industry (TCI) Co, ltd. (Portland, OR). 
PIO free base was supplied by Dr. Reddy's Laboratory (India). Sodium croscarmellose 
(CCNa) was obtained from Mallinckrodt (St. Louis, MO). HPMCAS-LF was provided by 
Shin-Etsu Chemical Co., Ltd. (Tokyo, Japan).  PVPVA was generously provided by 
BASF SE (Florham Park, NJ). Succinic acid and maleic acid were purchased from 
Sigma-Aldrich (St. Louis, MO) and Acros Organics (Fisher scientific Co. NJ) 
respectively. Chemical structures of PIO-HCl and various excipients used in this study 
are shown in Figure 5.1A-F. Weight percentage of each substituents present in 
HPMCAS-LF is listed in Figure 5.1C according to its certificate of analysis. Mannitol, 
used as a diluent for wet granulation studies, was ordered from SPI Pharm. (Wilmington, 
DE). 
5.4.2 Sample preparations of CSDs and PMs 
PIO-HCl salt and polymers were individually stored in desiccators with calcium sulfate 
(W.A. Hammond Drierite Co. Ltd, Xenia, OH) for at least 5 days at 25°C prior to use. 
HPMCAS or PVPVA was first dissolved into an excess amount of acetone (Avantor 
Performance Materials, Center Valley, PA) to form a homogenous polymer solution 
(sonication was applied as needed). Afterwards, approximately 2/3 of the acetone in the 
polymer solution was removed under a reduced pressure by a rotary-evaporator (Buchi, 
New Castle, DE) immersed into a water bath maintained at a constant temperature 
(~50°C) for 2-3 minutes until a viscous solution formed. PIO-HCl salt in crystalline form 







1:1 drug and polymer weight ratio. The remaining acetone was rotary evaporated under 
the same conditions for another 2-3 minutes. CSDs were afterwards placed under vacuum 
at ambient temperature for a minimum of 48 hours to remove residual solvent. Samples 
of salt-polymer physical mixtures were prepared by gravimetrically dispersing powders 
of PIO-HCl and each polymer (HPMCAS or PVPVA) into a 20 mL scintillation glass 
vial at 1:1 (w/w) weight ratio in a glove box (sidENTRYTM) purged with dry nitrogen to 
maintain a low relative humidity (RH) condition. Physical mixtures were then subjected 
to additional mixing by a ResodynTM LABRAM acoustic mixer (Butte, MT) with 30% 
intensity for 5 minutes. 
5.4.3 Preparation of samples for disproportionation studies at 40°C/75%RH storage 
condition 
The prepared 50% drug loading CSDs and PMs of PIO-HCl were individually placed in 
desiccators with calcium sulfate for at least 36 hours at ambient temperature prior to 
blending. Samples of CSDs or PMs were then gravimetrically mixed with CCNa as 
powder mixtures at an 80% to 20% weight ratio in the glove box with purge dry nitrogen. 
A ResodynTM LABRAM acoustic mixer was employed for 3 minutes of additional 
mixing at 30% intensity. Samples were then placed into a 40°C/75% relative humidity 
(RH) stability chamber in open dish conditions for stress storage. It is noteworthy that the 
designed weight ratio of PIO-HCl to CCNa is 2 to 1, which is a realistic representation of 
typical API and disintegrant ratio found in formulation of conventional pharmaceutical 
tablet. For example, a 200 mg tablet with 10% disintegrant and a 50 mg API potency and 







5.4.4 Preparation of samples for disproportionation studies at different RH conditions 
Stability chambers with different RH at 25°C were prepared by filling DURAN® 
dessicators (Fisher Scientific, Pittsburgh, PA) with different saturated salt solutions. 
Subsequently, the desiccators were sealed from the outside environment for at least 3 
days prior to use. Saturated salt solutions of magnesium nitrite and potassium chloride 
were prepared to control relative humidity (RH) at 52% and 86% respectively. Blends of 
CSDs and CCNa were prepared in a 1:1 (w/w) ratio and subjected to 3 minutes additional 
mixing using a LABRAM acoustic mixer (30% intensity). Afterwards, samples 
containing salt CSDs of HPMCAS and PVPVA were stored at 86% RH and 52% RH 
respectively. 
5.4.5 Powder X-Ray diffraction (PXRD)  
The X-ray diffraction patterns of CSDs and PMs were collected on a Panalytical X’Pert 
pro X-Ray diffractometer (PANalytical Inc., Westborough, MA) with Cu Kα radiation of 
1.5406 Å in transmission mode. Samples were measured at ambient conditions in 
transmission geometry with 2θ ranging from 2° to 40° using a 0.0167° step size. The 45 
kV voltage and 40 mA current of the generator were set respectively.  PXRD data were 
processed by Panalytical X’Pert Data Viewer (version 1.5) software. 
5.4.6 Raman Spectroscopy Bulk Measurement  
Raman spectra were obtained using a Kaiser Raman RXN1 Workstation (Kaiser Optical 
Systems, Inc., Ann Arbor, MI) equipped with a PhAT™ bulk volumetric sampling probe. 
HoloGrams™ v4.1 software was employed for data acquisition. The excitation energy 
was transferred from a 785nm high power NIR diode laser (InvictusTM) located within the 







mW, and a 6mm laser spot was generated by employing a 250 mm focal length lens. In 
order to ensure spectral quality, calibration of the laser excitation wavelength 
(cyclohexane; ASTM standard), spectrograph wavelength (neon atomic lines; ASTM 
standard), and instrument spectral response (white-light source; NIST standard) were 
performed. Taking into account the penetration of the PhAT Raman measurement, 
powder samples were carefully placed into a specially designed sample holder with 
controlled thickness for reproducibility. The CCD was cooled to -40°C and a dark 
subtraction was automatically applied to each spectrum to mitigate the baseline offset.  
Data acquisition time for each measurement was set as 10 seconds and 6 accumulations 
were averaged for all the samples. Collected Raman spectra were then processed by 
Grams AI (Thermo, Inc. Waltham, MA) for visual inspection.  
5.4.7 Dynamic Vapor Sorption (DVS) Measurements 
Moisture sorption isotherms of PIO-HCl CSDs were obtained at 25°C employing a 
Q5000SA Dynamic Vapor Sorption (DVS) equipped with an auto-sampler (TA 
Instruments, New Castle, DE). About 10 mg of a CSD powder sample was pre-weighted 
and gently dispensed into a crucible. All samples were dried at 50°C at the beginning of 
the experiments for 60 minutes until the weight changes were less than 0.01% over 5 
minutes. Moisture sorption data were then collected at conditions ranging from 5% to 95% 
RH with a step size of 5% change in humidity. Less than 0.01% weight change over 5 
minutes with a maximum dwell time of 240 minutes were set as equilibrium criteria for 
samples at different humidity step. The data of moisture sorption isotherms were 







5.4.8 Polarized Light Microscopy (PLM) 
A BX51P polarizing microscope (Olympus Corporation of the Americas, MA) equipped 
with a 10X objective and a Nikon DS-Ri1 high-resolution digital camera (Nikon 
Instruments Inc., Tokyo, Japan) was employed to collect images of both pure PIO-HCl 
crystalline and the powder samples of salt-polymer CSDs placed on glass slides (VWR, 
Radnor, PA). Polarized light microscopy was also applied to monitor the crystallization 
in film samples of PIO-polymer amorphous solid dispersions which were prepared by a 
solvent evaporation method. To be specific, PIO-free base and polymer (HPMCAS or 
PVPVA) with a 1 to 1 dry weight ratio were fully dissolved213 (visually inspected) in a 
50%: 50% (v/v) solvent mixture of dichloromethane and methanol to form a set of 
homogenous solutions (sonication was applied as needed). Several drops of the solution 
were added to a microscope slide and readily removed by using a KW-4A spin coater 
(Chemat Technology Inc., Northridge, CA) with a rate of 500 rpm for 20s at ambient 
temperature. The Images acquired by polarized light microscopy were further processed 
by NIS-Elements software package (Version 4.4, Nikon Instruments Inc., Tokyo, Japan) 
5.4.9 High-Shear Wet Granulation 
The lab scale high-shear granulator used in this study was constructed from a 300 mL 
food processor equipped with an electric high-shear chopper. A spray nozzle was inserted 
into drilled hole on the top the granulator. The nozzle was connected to a 10 mL s yringe 
loaded into a pulsating syringe pump (Harvard Apparatus, Holliston, MA). Prior to 
granulation, pure PIO-HCl salt and PM or CSD of PIO-HCl and HPMCAS were 
respectively blended with mannitol (diluent) and CCNa (disintegrant) in the designed 







NJ) for 3 minutes. Three formulations in 20g batch size (Table 5.1) were then loaded into 
the granulator for wet granulation. Purified water and 10 mg/mL maleic acid or succinic 
acid solutions were employed as granulation fluids. Samples with 15%, 25%, and 35% 
(w/w) granulation fluid addition were analyzed by Raman spectroscopy. 
Table 5.1 Three Formulations used for wet granulation studies 
 
 















CCNa 0.5 CCNa 0.5 CCNa 0.5 







5.5 Results and Discussion 
5.5.1 Sample characterization and calibration curve 
The chemical composition and the crystalline form of PIO-free base and PIO-HCl salt 
were confirmed by Fourier transform infrared spectroscopy (Smiths Detection Inc., MD) 
and PXRD respectively. Both the IR spectra (Figure A.13) and X-ray diffractograms 
(Figure A.14) of PIO-HCl and PIO free base showed satisfactory agreement with 
reference data.162 In order to prepare CSDs of PIO-HCl salt, it is a prerequisite to form a 
suspension system where the polymer is fully dissolved, but where PIO-HCl remains as 
undissolved crystalline salt. Acetone, which can readily dissolve both HPMCAS and 
PVPVA, was selected as the solvent to prepare the suspensions of drug salt in the 
polymer, because PIO-HCl is almost insoluble in acetone.214 After the solvent was 
removed, PIO-HCl crystals should be dispersed within a polymer matrix. Based on the 
PLM images of pure PIO-HCl (Figure 5.2A)and its CSDs, the crystalline nature of PIO-
HCl in the CSD can be confirmed; birefringence of PIO-HCl crystals can be clearly 
observed under polarized light for CSDs prepared in PVPVA (Figure 5.2B) or HPMCAS 
(Figure 5.2C). In addition, the X-ray diffraction pattern of the PIO-HCl CSD with 
PVPVA showed good agreement with the diffractogram of the corresponding physical 
mixture (Figure 5.3A). Similarly, the X-ray diffractograms of the CSD and physical 
mixtures of PIO-HCl and HPMCAS (Figure 5.3B) are consistent. The results of PLM and 
PXRD indicate that the crystalline form of PIO-HCl salt was maintained during sample 
preparation.  
Raman spectra of all the substances used in the solid state formulations are shown in 







salt and free base). In the spectral range of 1500 to 1800 cm-1, there are two distinct and 
strong API peaks located at 1609.4 cm-1 (Peak I) and 1638.3 cm-1 (Peak II) with minimal 
spectral interference from the excipients. These two API peaks enable us not only to 
readily discriminate the API from the excipients, but also to differentiate the neutral form 
of PIO from its salt form. To be specific, the spectrum of PIO-HCl salt contains both 
Peak I and II, while PIO free base spectrum only contains Peak I. Therefore, a calibration 
curve can be generated on the basis of this spectral difference to quantitatively study PIO-
HCl disproportionation in mixtures.  
A series of calibration sets were prepared by mixing PIO-HCl salt and free base in a 
known weight percentage ranging from 100% PIO-HCl (0% PIO free base) to 10% PIO-
HCl (90% PIO free base). Each calibration sample was prepared in triplicate and 
evaluated by bulk Raman measurement. Spectra of the 33 calibration standards in the 
specific spectral region are shown in Figure 5.5A. It can be clearly observed from Figure 
5.5A that the intensity of peak II increases with an increasing weight percentage of PIO-
HCl (red arrow indicates the increasing amount of PIO free base). A calibration curve 
with good linearity was established (Figure 5.5B) by plotting the intensity ratio of Peak I 
and II as a function of the weight percentage of PIO-HCl salt in the mixtures. The 
calibration curve was further validated by using another set of samples (each level of the 
validation standards was prepared in triplicate). Good consistency between the calibration 
points (blue) and the validation points (red) are shown in Figure 5.5B demonstrating the 
accuracy and robustness of the calibration curve. Moreover, this calibration model shows 
a low value of root mean squares error of prediction (RMSEP) calculated using the 







enable the quantitative investigation of PIO-HCl salt disproportionation in solid 
formulations during storage and manufacturing (Vide infra).  
5.5.2 Salt disproportionation at high RH storage 
The level of disproportionation (% conversion of salt) following storage at high RH 
condition was quantified by Raman spectroscopy. Croscarmellose sodium (CCNa) was 
used in all solid formulations as a representative problematic excipient that can induce 
the disproportionation of PIO-HCl salt, based on the presence of a proton accepting group 
and a relative high alkalinity.41, 62, 154 Blends prepared by mixing CCNa with PM or CSD 
of PIO-HCl and PVPVA were stressed at high relative humidity (40°C and 75%RH) 
condition for a period up to 3 days. Samples stored for longer time periods could not be 
analyzed due to the formation of sticky agglomerates caused by the hygroscopic nature of 
PVPVA. A considerable amount of salt disproportionation (>10% conversion) was 
observed for both PM and CSD of PIO-HCl and PVPVA (Figure 5.6A). To be specific, 
more than 20% disproportionation was observed in the PM of PIO-HCl and PVPVA after 
storage at 40°C/75%RH for 1 day. Approximately 15% of PIO-HCl disproportionation 
was detected in the salt-PVPVA dispersion stored at the same high RH condition for 2 
days. Clearly, the CSD of PIO-HCl and PVPVA has a lower level of salt 
disproportionation than in the corresponding PM samples, presumably because the 
polymer coated the PIO-HCl crystals, acting as a physical barrier to protect the salt from 
interacting with the problematic excipient (i.e. CCNa). Similarly, using HPMCAS to 
form a CSD can also potentially reduce the exposure of PIO-HCl to CCNa, and in turn 
slow down salt disproportionation in solid formulation. As shown by Figure 5.6B, less 







while the PM samples were shown to have around 10% salt disproportionation over a 
period of 7 days. This result suggests that dispersing a crystalline salt into a polymeric 
carrier can be utilized as a means of API protection to reduce the extent of salt 
disproportionation. 
It is noteworthy that different extents and kinetics of salt disproportionation were 
observed between samples prepared with different polymers. To be specific, a significant 
amount (~23%) of disproportionation with a rapid rate was observed in the PIO-HCl and 
PVPVA physical mixture, while the mixture of PIO-HCl salt and HPMCAS shows a 
lower level (< 10%) and a slower rate of salt-to-base conversion. Similarly, the dispersion 
with PVPVA has a higher extent and faster kinetics of disproportionation than the salt-
HPMCAS dispersion. Three aspects relating to difference in polymer properties most 
likely contribute to these observations. First and foremost, HPMCAS and PVPVA have 
different hygroscopicities. Based on the previously reported isotherm of pure PVPVA 
and HPMCAS, the amount of water sorbed by PVPVA at 75% RH is almost five times 
higher than that sorbed by HPMCAS.212, 215, 216 The greater hygroscopicity of PVPVA 
most likely provides more water to the crystal surface. As salt disproportionation is a 
solution mediated reaction, the role of water present in the formulation is of significance 
to mediate the transfer of protons from the ionized drug molecule to the proton accepting 
group. Therefore, samples prepared with PVPVA which contain a greater amount of 
water can presumably increase the proton diffusivity between PIO-HCl and CCNa, and in 
turn to accelerate the salt disproportionation process. Second, the high weight percentage 
of succinyl group, an acidic substituent present in HPMCAS, can reduce the 







lowering the microenvironmental pH is favorable to avoid the occurrence of salt-to-base 
conversion.14 Hence, the extent of PIO-HCl salt disproportionation is reduced when 
formulating PIO-HCl salt with HPMCAS as a PM or CSD. Third, it is speculated that 
PVPVA and HPMCAS can have a different inhibitory effects on the crystallization of 
PIO free base during the salt-to-base conversion, which may impact the observed kinetic 
differences. In order to evaluate the inhibitory effects of each polymer on the 
crystallization of free base, amorphous solid dispersions (ASDs) of PIO free base were 
prepared as thin films using HPMCAS (Figure 5.7A) or PVPVA (Figure 5.7B) as the 
polymeric carrier. Polarized light microscopy was then conducted on both the freshly 
prepared ASD thin films and the same samples stressed at 40°C/75%RH for 24 hours. In 
Figure 5.7A-B, no evidence of birefringence was observed under polarized light for 
freshly prepared samples confirming their amorphous nature. After stressing these 
amorphous thin films for 24 hours, birefringence were observed both in dispersions of 
PIO-HPMCAS (Figure 5.7C) and PIO-PVPVA (Figure 5.7D). Clearly, smaller crystals 
are present in the dispersion of PIO and HPMCAS (Figure 5.7C) indicating that 
HPMCAS has a better inhibitory effect on the crystallization of PIO free base. However, 
in considering the impact on crystallization kinetics, it should be noted that there are 
different amounts of water present in various solid dispersions, because of the different 
hygroscopicities of the polymers. It has been reported previously that the amount of water 
plays an important role in affecting nucleation, crystal growth, and salt 
disproportionation.61, 217 Typically, a higher amount of sorbed water around solid surfaces 
would be expected to enhance mobility leading to crystallization as well as increased 







polymeric inhibitor on of PIO-HCl salt disproportionation under a condition where the 
water content was similar was investigated.  
5.5.3 Salt disproportionation at conditions with normalized water content 
In order to find storage conditions whereby the CSDs had an equivalent water content, 
the water sorption isotherms for the two systems were compared. Based on the data 
shown in Figure 5.8A, it is apparent that exposing the salt-PVPVA dispersion to storage 
conditions of 25°C/52% RH will lead to the approximately the same water content (~4%) 
as storage of the salt-HPMCAS dispersion at 25°C/86% RH. These results are consistent 
with the previously reported moisture sorption isotherms of PVPVA and HPMCAS.212, 215, 
216 Hence, PVPVA CSD and HPMCAS CSD were stored at 25°C/52% RH and 25°C/86% 
RH respectively for 20 days to quantitatively study the PIO-HCl salt disproportionation 
in the dispersions at an equivalent water content, again utilizing Raman spectroscopy. 
Based on the disproportionation profiles (Figure 5.8B), it is apparent that the dispersion 
with HPMCAS has slower conversion kinetics and a lower level of PIO-HCl salt 
disproportionation over the period of up to 20 days. To be specific, differences of 
percentage conversion between the two CSDs can be clearly discerned after 7 days. For 
example, the % conversion in the salt-PVPVA CSD is almost 5% higher than that in salt-
HPMCAS CSD after 10 days of storage. The extent of disproportionation in the PVPVA 
CSD (>10%) is approximately twice that observed for the HPMCAS CSD (~4%) after 20 
days. These results suggest that HPMCAS has a greater ability to reduce PIO-HCl salt 
disproportionation than PVPVA, at an equivalent water content. Thus, the acidity of 
HPMCAS is perhaps of greatest significance in impacting PIO-HCl salt 







microenvironmental pH, and consequently decrease the extent of PIO-HCl salt 
disproportionation. Further evidence supporting the role of HPMCAS as a pH modifier 
which hinders salt disproportionation is provided by wet granulation studies discussed 
subsequently. 
The inhibitory effects of polymeric carriers on the crystallization of PIO free base might 
be considered as another factor influencing PIO-HCl disproportionation. In order to 
investigate the impact of different polymers on the crystallization of PIO free base with a 
normalized water content in the system, ASD thin films of PIO-HPMCAS and PIO-
PVPVA were stressed at 25°C/86% RH and 25°C/52% RH respectively for 48 hours. In 
Figure 5.9A and B, the absence of birefringence under polarized light indicated that the 
freshly prepared films contained amorphous drug. For the stressed film samples, the PIO-
HPMCAS dispersion showed the presence of small crystals on the surface of the film 
(Figure 5.9C), while larger needle shape crystals were observed in the PIO-PVPVA 
dispersion (Figure 5.9D). These results suggest that using HPMCAS as a polymeric 
carrier can more effectively disrupt the crystalline self-assembly of PIO free base, and 
impede the conversion from PIO-HCl salt to its free base as a result. Probing the 
individual chemical features of PIO and polymeric carriers can provide a possible 
explanation for this observed difference in inhibitory effect on PIO crystallization. To be 
specific, the carboxylic acid from the succinyl group of HPMCAS can function as a 
strong hydrogen bond donor, while the carbonyl group from the PVPVA can function as 
a strong hydrogen bond acceptor. Based on the chemical features of PIO free base, there 
are more hydrogen bond acceptors existed in its structure. For instance, the nitrogen on 







acceptors in the pKBHX database.
99, 100 Furthermore, the nitrogen located on the pyridine 
ring of PIO can also be protonated by a strong acid (such as HCl) to form a PIO salt, 
suggestive of its potential as a good hydrogen bond acceptor. Therefore, stronger 
intermolecular interaction would be expected between PIO free base and HPMCAS. 
Generally, stronger drug-polymer intermolecular interactions lead to more effective 
inhibition of API crystal growth in an ASD. For instance, it has been demonstrated that 
formation of more extensive hydrogen bonds between felodipine and 
polyvinylpyrrolidone appear to be linked to a slower crystal growth rate.218 A similar 
phenomenon was observed for bifonazole, whereby stronger intermolecular drug and 
polymer interaction led to reduced crystal growth.75 
5.5.4 Salt disproportionation during the wet granulation 
Introducing bulk water to solid formulations during wet granulation would be expected to 
increase the susceptibility of systems undergoing solution mediated reactions such as salt 
conversion or hydrolytic degradation.219, 220 The disproportionation extent of each 
formulation following wet granulation is shown in Figure 5.10 as a function of the 
amount of added water. In this case, we observed a higher extent and a faster kinetics of 
PIO-HCl disproportionation with exposure to larger quantities of water during processing 
relative to storing at high RH, further highlighting the significance of water to the 
disproportionation process. Applying pH modifiers in a formulation has been reported to 
lower the risk of unwanted acid-base reactions and improved stability of the salt.210, 220 In 
the present study, low molecular weight pH modifiers were incorporated into the 
granulation fluid as a means to lower the extent of PIO-HCl salt disproportionation. For 







In the absence of low molecular weight pH modifiers or acidic polymers, the largest 
extent of disproportionation was observed (formulation 1, Figure 5.10A, black line). 
However, when using 10mg/mL maleic acid (red line) or succinic acid (blue line) 
solution as the granulation fluid, the percentage of conversion was significantly reduced 
by 10% indicating that adding pH modifier in granulation fluid is an effective strategy to 
lower the risk of disproportionation for a weakly basic salt. No significant differences of % 
conversion were observed in Figure 5.10A between the using maleic acid and succinic 
acid suggesting that both compounds can effectively adjust the microenvrionmental pH to 
slow down disproportionation of PIO-HCl salt. At 35% (w/w) granulation fluid addition, 
it is noteworthy that the % weight of succinic acid or maleic acid used is only 0.36% 
(w/w) of the entire solid formulation. The extent of disproportionation is expected to be 
further reduced with an increasing amount of pH modifier, which will be investigated in 
the future studies.  
In Figure 5.10B, formulation 2 (PIO-HCl and HPMCAS mixtures) granulated with pure 
water (blue line) was shown to have a lower level of salt disproportionation than 
formulation 1 (black line). Hence, even without using an acidic granulation fluid, the 
extent of conversion in formulation 2 was observed to be similar to that of formulation 1 
with a pH modifier in granulation fluid (red line). Based on the certificate of analysis of 
HPMCAS-LF, the weight percentage of succinyl group is 14.6%, and the moles of 
carboxylic acid group from the succinyl substituent of HPMCAS can be calculated 
accordingly; this turns out to be very similar to the number of moles of carboxylic acid 







suggest that HPMCAS can be applied as pH modifier in solid formulations to slow down 
salt disproportionation.  
Furthermore, using the CSD of PIO-HCl and HPMCAS (formulation 3) can further 
reduce the extent of disproportionation during wet granulation. From Figure 5.10C, it can 
be seen that the percentage conversion in formulation 3 (blue line) was 10% less than that 
in formulation 1 (black line) after 25% (w/w) water addition. Moreover, differences in 
PIO-HCl disproportionation between formulation 3 (salt-HPMCAS CSD) and 
formulation 2 (salt-HPMCAS PM) in wet granulations are also apparent. Clearly, the 
CSD of with HPMCAS (blue line) have a lower extent of salt-to-base conversion than 
PMs of salt and HPMCAS (red line). For instance, at 25% and 35% (w/w) water 
additions, larger than 5% differences of salt disproportionation extent were observed 
between dispersion and physical mixture. Interestingly, combining the CSD approach 
with HPMCAS in the solid blend and maleic acid in the granulation fluid (purple line), 
led to minimal disproportionation (<3%) during granulation, further highlighting that 










Dispersing crystalline PIO-HCl salt in a polymeric carrier (HPMCAS or PVPVA) can 
serve as an innovative formulation strategy to protect the PIO-HCl salt from interacting 
with problematic excipients (i.e. CCNa), which in turn slows down and reduces the extent 
of salt-to-base conversion during high RH storage or wet granulation. Compared to 
PVPVA, HPMCAS was found to be more effective at reducing the extent of the PIO-HCl 
disproportionation reaction. This was attributed to a lower hygroscopicity, the presence 
of acidic functional groups, as well as a better inhibitory effect on PIO free base 
crystallization. This study thus provides mechanistic insight into the impact of polymer 
physicochemical properties on the disproportionation reaction.  
Using low molecular weight pH modifiers dissolved in the granulation fluid can serve as 
an alternative approach to reduce the extent of disproportionation of PIO-HCl following 
wet granulation. HPMCAS was also successfully used as a pH modifier to improve salt 
stability in solid formulation following wet granulation, showing as effective as succinic 
acid/maleic acid solutions. Furthermore, by combining the crystalline salt-HPMCAS 
dispersion with an acidic granulation fluid, the extent of PIO-HCl disproportionation was 
minimized, allowing wet granulation to be successfully performed. The formulation 
approaches developed herein thus can be applied to reduce salt disproportionation during 








Figure 5.1 Chemical structure of pioglitazone HCl salt (A); croscarmellose sodium (B); 
HPMCAS whereby the weight percentage of substituents are listed (C); PVPVA (D); 








Figure 5.2 Polarized light microscope images of pioglitazone HCl salt (A), CSD of PIO-










Figure 5.3 X-ray diffactogram of CSD and PM of PIO-HCl and PVPVA (50%: 50% w/w) 








Figure 5.4 Raman spectra of API and excipients over the spectral range 200cm-1 to 
2000cm-1, the expanded spectral region (1500-1800cm-1) is shown in the window 








Figure 5.5 Raman spectra of the calibration samples (10% PIO-HCl to 100% PIO-HCl) 
over the spectral range 1500-1800 cm-1, Peaks I and II are labeled (A) Calibration curve 
generated by plotting peak intensity ration (Peak II/Peak I) against the % PIO-HCl salt in 








Figure 5.6 Disproportionation rate and extent of PMs and CSDs of PIO-HCl and PVPVA 
stored at 40°C/75%RH for 3 days (A); Disproportionation rate and extent of PMs and 










Figure 5.7 Polarized light microscope images of amorphous solid dispersion (ASD) of 
PIO-free base and HPMCAS (A); ASD of PIO free base and PVPVA (B); ASD of PIO-
free base and HPMCAS stressed at 40°C/75%RH for 24 hours (C); ASD of PIO-free base 










Figure 5.8 Moisture sorption isotherms of CSD of PIO-HCl and PVPVA (Blue) and CSD 
of PIO-HCl and HPMCAS (Red) at 25°C (A); Disproportionation studies of CSD of PIO-
HCl and PVPVA (Blue) storing at 25°C/52% RH and CSD of CSD of PIO-HCl and 








Figure 5.9 Polarized light microscope images of amorphous solid dispersion (ASD) of 
PIO-free base and HPMCAS (A); ASD of PIO free base and PVPVA (B); ASD of PIO-
free base and HPMCAS stressed at 25°C/85%RH for 48 hours (C); ASD of PIO-free base 








Figure 5.10 Disproportionation studies in wet granulation including using maleic acid 
and succinic acid solution as granulation fluid (A); disproportionation of the salt and 
HPMCAS physical mixtures (B); disproportionation of salt-HPMCAS CSD in 







CHAPTER 6. ANALYTICAL APPROACHES TO INVESTIGATE SALT 
DISPROPORTIONATION IN TABLET MATRICES BY RAMAN 
SPECTROSCOPY AND RAMAN MAPPING3  
6.1 Abstract 
It has always been challenging to use spectroscopic methods to analyze salt 
disproportionation in a multi-component tablet matrix due to the spectral interference 
generated by the various excipients. Although combining Raman spectroscopy and 
chemometrics can be a powerful approach to study the extent of salt disproportionation, it 
was found in the present study that bulk measurements and chemometric modeling have 
obvious limitations when the targeted component is present at low levels in the tablet. 
Hence, a two-step Raman mapping approach was developed herein to investigate salt 
disproportionation in tablets with a low drug loading (5% w/w). The first step is to locate 
the area of interest where the drug particles reside throughout the tablet surface by using 
a statistically optimized sampling method termed deliberate sub-sampling. The second 
step, referred to herein as close-step mapping, utilize a step by step mapping of the 
targeted area to find more details of salt disproportionation in the tablet regions where the 
drug is concentrated. By using this two-step Raman mapping approach, we successfully 
detected the existence of minor species embedded in multi-component low drug loading 
                                                 
3
 The content of this chapter is adapted from Journal of Pharmaceutical and Biomedical Analysis, Vol. 118, 
Haichen Nie et al., Analytical approaches to investigate salt disproportionation in tablet matrices by Raman 







tablet matrices, where bulk measurements from routine techniques usually lack of 
sensitivity. This approach will help formulation scientists detect and understand salt 
disproportionation and in situ drug-excipients compatibility issues in low dose solid 
dosage formulations. 
6.2 Keywords 
Salt stability; Pioglitazone; low drug loading; drug excipient compatibility; statistically 










Most drug substances are reported to be either weak acids or weak bases.1 Formulating 
poorly water-soluble weak acids or weak bases into salts can not only increase 
bioavailability, but also improve many other physicochemical properties.35, 45, 156 Hence, 
salt formation of active pharmaceutical ingredients (APIs) is recognized as one of the 
most widely used formulation approaches.15 However, a potential risk of employing salt 
formation is that salt forms of APIs have a propensity to revert back to the unionized 
form/free base, a process termed salt disproportionation.52, 53 Disproportionation, a proton 
exchange involving an acid base reaction, can be significantly influenced by several 
factors including the physicochemical properties of excipients, drug loading, and storage 
conditions.61 Theoretically, the tendency for disproportionation can be anticipated based 
on assessment of the microenvironment and knowledge of the salt pHmax, based on the 
assumption that disproportionation is a solution mediated process.15, 154 It has been 
reported that salt disproportionation has detrimental effects on pharmaceutical product 
performance including loss of potency, increased tablet hardness, and reduced dissolution 
rate and bioavailability.12, 42, 54-56 Therefore, it is essential to develop a mechanistic 
understanding of how excipients lead to disproportionation and, perhaps more 
importantly, develop more sensitive approaches to detect disproportionation. 
A variety of analytical methods have been employed to reveal influential factors in 
disproportionation. Raman spectroscopy was shown to be a useful tool to quantify the 
free base and to study effects of excipients on the integrity of salts of weak bases in a 
binary mixture.52 For example, coupling multivariate analysis with vibrational 







calcium salt of atorvastatin to disproportionate at elevated temperature and humidity. 16 
John et al. illustrated that the proton accepting and hygroscopic capacity of excipients 
have significant impact on salt disproportion in powder blends.41 However, there are 
limited studies of salt disproportionation in tablet matrices containing commonly used 
components due to the analytical interference from excipients as well as challenges with 
limits of detection (LOD) when the drug is present at a low weight percent, as is common 
in tablet formulations. Therefore, development of an applicable analytical method with an 
improved LOD is highly desirable to detect the existence of low-level unwanted species 
in multi-component systems.   
Taking advantage of higher Raman scattering coefficients of active pharmaceutical 
ingredients (APIs) compared to those of typical excipients, Raman mapping is capable of 
detecting low levels of APIs and related substances by generating a chemical map with 
high lateral resolution.221-225 For instance, Widjaja et al. successfully targeted magnesium 
stearate, a minor component in a model pharmaceutical tablet, by applying Raman 
microscopy and multivariate analysis.226 Šašić et al. demonstrated the spatial distribution 
of alprazolam in commercial tablets with API contents lower than 1%  (w/w) by 
combining Raman mapping with chemometrics.227 It has been reported that a minor 
amount of a polymorph, as low as 0.025% w/w, in a low-content API formulation was 
detectable by an innovative method which combined Raman mapping with statistically 
optimized sampling.228, 229 Applying a similar method to salt disproportionation studies 








The primary objective of this study is to develop applicable methodologies for 
conventional Raman mapping to detect minor components resulting from 
disproportionation and to understand the “in-situ compatibility issues” between drug and 
excipients in a pharmaceutical tablet with low drug loading. In addition, by using 
chemometrics and Raman spectroscopy, we are expecting to further explore the impact of 
commonly used excipients and storage conditions on the kinetics of salt 
disproportionation in tablets. Pioglitazone (PIO) hydrochloride (HCl) salt, a compound 
with high efficacy and tolerability to treat type II diabetes, was selected as a model 
compound for disproportionation studies, based on previous reports of the existence of 
free base in the bulk powder of the salt and the low calculated pHmax value. 
41, 159, 160, 162 
In this study, we used chemometric modeling and bulk Raman measurement of 30% drug 
loading (DL) tablets to reveal the kinetics of disproportionation for PIO-HCl at different 
storage conditions. We also applied a statistical sampling method (deliberate sub-
sampling) to identify the suspected disproportionation area on the surface of 5% DL 
tablet. After identification of regions of interest (drug particles dispersed in the tablet 
matrix), a close-step mapping approach was conducted on the area of interest to further 
investigate the disproportionation of PIO-HCl in a low content API tablet. By using the 
proposed methods, we could successfully discern the minor component in a 
multicomponent matrix, which was difficult to achieve by using bulk Raman 







6.4 Experimental Section 
6.4.1 Chemicals  
Pioglitazone hydrochloride salt was purchased from TCI Co, ltd. (Portland, OR). 
Pioglitazone neutral forms/free base were obtained from Dr. Reddy's Laboratory (India). 
Magnesium Stearate (Mgst) was obtained from Mallinckrodt (St. Louis, MO). Sodium 
Croscarmellose (CCNa) and Avicel PH-101 were purchased from FMC Biopolymers 
(Philadelphia, PA). Crospovidone was supplied by ISP Tec. (International Specialty 
Products, Wayne, NJ). Mannitol was ordered from SPI Pharm. (Wilmington, DE). 
Anhydrous Dibasic Calcium Phosphate (A-TAB) was purchased from JRS Inc. (Patterson, 
NY).  Chemical structures of API and excipients used in this study are shown in the 
supporting information (Figure A.21 A-D).  
6.4.2 Tablets Preparation 
Formulations of calibration tablets and the tablets for stability tests are listed in the 
supporting documents (Table A.14 to A.16). Powders of API and excipients were 
gravimetrically dispensed (+/- 2% weight standard deviation) into a 20ml glass vial by a 
Symyx Powdernium powder dispensing robot. The weighed powders were mixed by a 
LABRAM mixer (Butte, MT) with 30% intensity for 3 minutes. 100 mg of the mixture 
was carefully poured into a 7.14 mm diameter tablet die held in place with a flat-faced 
lower punch. Afterwards, the flat-faced upper punch was gently placed on the powder 
bed. Axial pressure (200 MPa) was applied to the powder bed by a single station MTS 
Alliance RT equipped with a 50 kN (variation +/- 1N) loading cell (MTS Systems 







were subjected to stability studies at 40°C/75% R.H. (relative humidity) or 40°C/35% 
R.H. chambers in an open dish condition.  
6.4.3 Raman Spectroscopy Bulk Measurement 
Raman spectroscopy bulk measurements were conducted by employing a 785nm Kaiser 
Raman RXN1 Workstation (Kaiser Optical Systems, Inc., Ann Arbor, MI) equipped with 
a PhAT™ large volumetric bulk sampling probe utilizing HoloGrams™ v4.1 software for 
data acquiation. The PhAT probe was connected to the base unit via a fiber bundle (1 
fiber excitation, 50 fiber collections) to deliver the excitation energy from the Invictus™ 
diode laser located within the base unit. Laser power was set electronically to 400 mW 
for the bulk measurement. A 250 mm focal length was employed to generate a 6mm laser 
spot. Utilizing both the Kaiser Hololab™ calibration accessory and a Raman calibration 
standard, calibrations of the spectrograph wavelength (neon atomic lines; ASTM 
standard), laser excitation wavelength (cyclohexane; ASTM standard) and instrument 
spectral response (white-light source; NIST standard) were performed to ensure spectral 
quality. Taking into account the penetration of the PhAT Raman measurement, powder 
samples (each component of tablets) were placed into a beaker with controlled thickness 
(20mm) for reproducibility. The tablets were placed on specially designed tablet holder 
which could be affixed to the stage of the workstation. To mitigate the baseline offset due 
to dark noise from the camera, the CCD was cooled to -40°C and a dark subtraction was 
automatically applied to each spectrum. Data acquisition time for Raman spectroscopic 
bulk measurements was set as 10 seconds and 6 accumulations were averaged for all the 







MA) for visual inspection. Multivariate analysis software SIMCA v13 (Umetrics AB, 
Umeå, Sweden) was used for chemometric analyses. 
6.4.4 Raman Microscopy 
Kaiser Raman RXN1 workstation, along with both Kaiser HoloMap and HoloGrams 
software packages, were used for Raman mapping experiments. To avoid sample damage, 
the Invictus laser power was set to 50% of the maximum (200 mW). A single mode 
excitation fiber, a multimode collection fiber (100 µm), and a 50× microscope objective 
were used to increase spatial resolution of Raman imaging. The size of the laser spot on 
the surface of sample was measured before the experiments by direct visualization and 
measurement under the optical microscope with the laser powered up. The visual laser 
spot size was found to range from 10-15 μm on the tablet surface. Samples were placed 
on a tablet holder affixed to a motorized stage (Prior Scientific, Fulbourn, United 
Kingdom). The steps of the stage translation were set in the HoloMap software before 
scanning the tablets, and the XY coordinate of each point was recorded in the system. 
Raman spectral acquisition parameters for each spot were set as a 10 seconds acquisition 
time with 6 accumulations. Analyses of the mapping results were carried out by HoloMap 












6.5 Results and Discussions  
6.5.1 Characterization of initial tablet components  
In order to verify the purity of pioglitazone neutral form and its hydrochloride salt, 
transmission powder X-ray diffraction (Panalytical X'pert Pro diffractometer) and Fourier 
transform infrared spectroscopy (Smiths Detection Inc., MD) were employed.  The X-ray 
diffraction patterns (Figure A.22A) demonstrate that peak positions of pioglitazone HCl 
salt and its free base are consistent with literature reports. The IR spectra (Figure A.22 B) 
of PIO-HCl and PIO free base also show good agreement with the previous study.162  
Based on these analyses, we can confirm that both chemical composition and solid state 
form of the API were pure prior to the tableting process.  
Raman spectra of all tablet ingredients are shown in Figure 6.1, including pioglitazone 
(HCl salt and free base), mannitol, Mgst, crospovidone, A-TAB, Avicel, and CCNa. In 
this study, we are focusing on 1500-1800 cm-1 spectral range for two reasons. First and 
foremost, in this specific spectral region, both pioglitazone salt and free base are Raman 
active, while all the excipients used in our formulation are largely Raman inactive. The 
strong and distinct API peaks in this spectral range enable us to directly discriminate the 
API from the excipients used in this study. Secondly, although the spectra of pioglitazone 
salt and free base are overlapped in the emphasized region, the spectral differences are 
significant enough to be readily discerned without applying any multivariate analysis. To 
be specific, pioglitazone HCl salt demonstrates a doublet located at 1600-1650 cm-1, 
while pioglitazone free base shows a singlet in the same region. A possible explanation 
for this spectral difference is that the protonation of pioglitazone changes the vibrational 







the impacts of laser on the disproportionation of PIO-HCl salt, both PIO-HCl salt and its 
mixture with excipients found to expedite disproportionation, CCNa and Mgst, were 
exposed at the laser with same power set for 10 minutes. No drift in the data was 
observed in the spectral region of interest for both bulk measurement (Figure A.23 A-C) 
and microscopic measurements (Figure A.23 D-F). 
6.5.2 Raman spectroscopy  
6.5.2.1 Theoretical section 
In this section, based on the result of Raman bulk measurements, the chemometric 
models for calibration tablets with high API content (30% DL) and low API content (5% 
DL) were established. According to the statistical parameters of these chemometric 
models, we will discuss whether the proposed approaches are appropriate for the tablets 
with different drug loadings.  
As summarized in Table A.15, standard tablets with 30% (w/w) drug loading were 
prepared for generating a calibration curve ranging from 100% PIO-HCl (0% PIO free 
base) to 80% PIO-HCl (20% PIO free base). The excipients used in the calibration tablets 
were reported as inert ingredients which would not cause disproportionation of PIO-HCl 
salt.41 Each calibration standard was scanned five times with the macroscopic Raman 
system. In Figure 6.2A, 18 randomly selected Raman spectra (out of 30 total) showing 
the spectral region of interest are presented. From Figure 6.2A, it is clear that the 
intensity of peak I and peak II decrease with an increasing amount of PIO free base 
(whereby the red arrow indicates increasing free base). Therefore, even without a 







are significant enough for us to build chemometric models and directly discern the 
existence of PIO free base in the Raman spectrum.  
In order to eliminate the multiplicative interferences from light scattering and particle 
size variations for solid state samples, standard normal variate (SNV) transformation was 
employed to pre-process the spectra of calibration tablets.174, 175 Principal Component 
Analysis (PCA) was conducted for the pre-treated 30 spectra, and the results 
demonstrated that over 96.5% of the spectral variation was captured in the first two 
principal components. No outliers are observed in the Hotelling’s T2 ellipse at 95% 
probability level (Figure 6.2B). All calibration standards form unique and discriminating 
clusters along the first two principle components. PC1 is the dominant factor describing 
the interclass differences, while PC2 captures the variation within each class. Although 
most of the classes could be separated by PC1 with satisfaction, 99% PIO-HCl and 100% 
PIO-HCl samples show overlap suggesting some level of sub-sampling/ inhomogeneity. 
This drawback indicates that the Raman bulk measurement and/or the chemometric 
model have limitations in detecting the existence of low levels of distinct species. From 
the loading plot of the PCA (Figure A.24), we observed that the loadings from PC1 and 
PC2 are very similar and represent contributions from variations of peaks I, II, and II. 
Moreover, PC1 captures 82% of the total variance, which is much larger than that of PC2 
(14.2%). Therefore, it is reasonable to choose PC1 as the only principal component for 
the partial least square (PLS) models in order to avoid over fitting. 230, 231 This decision is 
also supported by “leave-one-out” cross validation to get a tradeoff between the goodness 







On the basis of above analysis, PLS calibration with PC1 as the principle component was 
carried out for 30% DL tablets and the results are plotted in Figure 6.3A. A low value of 
root mean squares error of cross validation (RMSECV) indicates the balance between 
predictive power and fitting. The reasonable values of R2Y and Q2 suggest that the PLS 
model is applicable and appropriate to evaluate the amount of PIO free base for 30% DL 
tablets. In this study, one side of each calibration tablet was scanned to generate the PLS 
calibration curve. The other side of the each calibration tablet was then scanned to 
validate the PLS model. It is clear that the validation outcomes match well with the 
calibration results (Figure 6.3A). The low value of the root mean squares error of 
prediction (RMSEP) not only suggests that this PLS model is robust, but also indicates 
the good uniformity and homogeneity across samples.   
Similarly, PCA and PLS models were developed for 5% DL calibration tablets using the 
same pre-processing methods over the identical spectral region. For PCA, all levels are 
not well separated in the PC1-PC2 score plot (Figure 6.2D) due to the weak signal of the 
specific peaks in the focused spectral region (Figure 6.2C), and there are clear outliers. 
As for the PLS model, PC1 and PC2 were selected as the principal components, based on 
the cross-validation. The RMSEE (root mean squares error of estimation) of 5% DL 
calibration curve is significantly lower than that of the 30% DL calibration curve 
indicating a poor fit (Figure 6.3B and Table A.17). In addition, the value of RMSEP is 
over 75 for the PLS calibration curve of 5% DL standards (Figure 6.3B and Table A.17), 
confirming the poor predictive power of this model. Thus, the approach of combining the 
bulk Raman measurements and chemometric models is insufficient to characterize low 







with low API content might lead to poor prediction of the degree of salt disproportion, 
which could in turn lead to failure of such tablets. Hence, a statistically based sampling 
method termed “deliberate sub-sampling” (vide infra) was used to investigate the 
existence of the neutral form of pioglitazone in a tablet matrix with 5% DL.   
6.5.2.2 Disproportionation kinetic studies for 30% DL tablets 
Understanding the disproportion kinetics of the 30% DL tablet would be useful for 
estimating the amount of the free base present in the low drug loading tablets with the 
same ratio of drug and disproportionating agents and the storage condition. According to 
the previous discussion, it is appropriate to investigate the disproportional kinetics of 30% 
DL PIO-HCl tablets by bulk Raman measurements with the models outlined above. 
Tablets containing PIO-HCl salt and disproportionating agents were stressed at 40°C/75% 
R.H. and 40°C/35% R.H. for 14 days. Based on the above validated PLS model for 30% 
DL tablets, the kinetics of disproportionation for stressed tablets are shown in Figure 6.4. 
Both the rate and the extent of disproportionation for tablets stressed at 40°C/75% R.H. 
(solid line) are higher than for tablets exposed at 40°C/35% R.H. (dashed line). This 
observation is consistent with the consensus that salt disproportionation is a solution 
mediated reaction and indicates that the relative humidity is a dominate factor for PIO-
HCl disproportionation.6 A-Tab, Mgst, and CCNa all led to the disproportionation of 
PIO-HCl in tablets stressed at both 40°C/75% R.H. and at 40°C/35% R.H., which can be 
attributed to the following factors: First, A-tab, Mgst and CCNa have the potential to 
produce a high pH microenvironment based on results of slurry pH tests. The slurry pH 







the pHmax of PIO-HCl salt (pHmax=3), which indicates that A-Tab, Mgst and CCNa can 
cause disproportionation of the PIO-HCl salt.8, 232, 233 Second, the HPO4
2-
 group of A-Tab 
and the COO- group of Mgst and CCNa are proton acceptors. These proton acceptors 
could acquire a certain amount of protons and convert the pioglitazone from its 
hydrochloride salt form to its free base from.42, 154 Third, Mgst, CCNa, and A-Tab are 
hygroscopic ingredients. Hence, these three excipients can lead to the presence of water 
in the tablet which will promote the salt disproportion reaction, when exposed to high 
relative humidity conditions.234, 235 
For Mgst and A-Tab, MgCl2 and CaCl2 are formed as products of the disproportionation 
reaction, based on the need to maintain charge neutrality (Figure A.21 F and G). It should 
be pointed out that both magnesium chloride and calcium chloride are deliquescent at low 
R.H. conditions.236 Hence, the deliquescence of MgCl2 or CaCl2 could reduce the critical 
R.H. for the system and accelerate the rates of disproportionation.237 In addition, tablets 
formulated with Mgst demonstrated a faster and greater extent of disproportionation than 
other samples due to the existence of alkaline impurities in Mgst. It has been reported that 
magnesium oxide exists as the major basic impurity in the Mgst, which could further  
enhance the alkalinity of the microenvironment and provide additional proton 
acceptors.63 It is important to note that, the disproportionation of PIO-HCl in tablet 
matrices has not been observed without exposure to stressed conditions due to the limit of 
detection provided by Raman spectroscopy. Disproportionation under ambient conditions 
might occur and perhaps can be detected with a more sensitive analytical technique. 







6.5.3 Raman Microscopy 
6.5.3.1 Mapping method and proof-of-concept study 
Given the aforementioned issues with the Raman bulk measurements for detecting 
disproportionation in low content API multi-component tablet matrices, we decided to 
use Raman mapping as an analytical method to study the disproportionation of the 5% 
DL Pioglitazone tablets. Tuning the laser spot to a few microns can significantly improve 
the spatial resolution of the imaging, effectively concentrating the sample which in turn 
enables Raman microscopy to discern the presence of the unwanted species at low 
content level. However, one drawback of applying conventional Raman mapping method 
is the long acquisition time.238 If we want to scan the entire tablet surface, step by step, to 
determine the existence of any neutral form of pioglitazone, the size of laser spot and 
exposure time described in the experimental section, we need to collect about 250,000 
spectra to cover a 5mm×5mm tablet surface, resulting in a total data acquisition time of  
155 days for one tablet. Therefore, a statistical sampling approach must be applied to 
efficiently locate the area of interest within a reasonable analytical period. Šašić’s 
research on low-level polymorph detection provided a solution for our time-consuming 
problem; in this study, the authors used statistically optimized sampling methods.228 
Specifically, the method stipulated that the minimal number of spectra that need to be 
acquired to statistically guarantee detection of a minor component is set as five multiples 
of the intuitive minimal number of spectra which is related to the approximated 







A calibration tablet, 5% DL with 20% PIO free base, was used as an example to illustrate 
this sampling method. In this case, PIO free base is the targeted species and is present at a 
concentration of 1% of the total weight of the tablet. Therefore, 100 spectra acquired 
from the entire tablet surface would be the intuitive minimal number of spectra to yield at 
least one spectrum of the PIO free base. Based on the calculation of a binomial 
distribution probability, acquiring 100 spectra for this calibration tablet can only provide 
limited probability (63.39%) of detecting PIO free base. However, when we acquire five 
times the intuitive minimal number of spectra (in this case 500 spectra), the probability of 
detecting the targeted substance would dramatically increase from 63.39% to 99.34%. 
Hereby, we define this approach as “deliberate sub-sampling”. On the other hand, the 
close step-by-step mapping is termed as close-step mapping and is differentiated from the 
deliberate sub-sampling method.  After locating a spot of interest via deliberate sub-
sampling (in this case, particles of pioglitazone), the close-step mapping method is 
applied in the vicinity of the area of interest to gain a more detailed picture of salt 
disproportionation. 
As a proof-of-concept study, we first applied the deliberate sub-sampling and close-step 
mapping methods to the above mentioned calibration tablet (Figure 6.5). A total 529 
spectra (23×23 spots) were collected across the entire tablets surface (5mm×5mm) with a 
step size of 227μm, to generate the maps of the deliberate sub-sampling (Figure 6.5A). 
The API concentrated area could be unambiguously identified as the “hot pixel” regions 
(Figure 6.5A1), by analyzing the spectral range with characteristic drug peaks (shaded 
area, 1500-1800cm-1). In contrast, regions with a higher concentration of excipients are 







were then analyzed via a close-step mapping approach (shown as an orange square for 
clarity), and a detailed map is generated (Figure 6.5B).  The spectrum of spot B1 shows a 
doublet in the spectra region 1600-1650cm-1(Figure 6.5B1). This doublet coincides with 
the spectrum of PIO-HCl salt (Figure 6.1). On the other hand, the spectrum of spot B2 
shows a singlet in the same spectra region (Figure 6.5B2), which matches with the 
spectrum of PIO free base. These observations further supported the fact that the 
proposed approach is sound and capable of detecting both the PIO-HCl salt and the PIO 
free base in a low-content API tablet matrix. In summary, this method for 5% DL PIO 
tablets can be described as a two-stage approach. First, we use a deliberate sub-sampling 
method to look for the areas where the pioglitazone resides. Secondly, once piogl itazone 
rich regions are identified, a closed step mapping of this area is conducted to discern the 
form of pioglitazone present. Noteworthy, for calibration tablets, the PIO-HCl salt and 
PIO free base are most often spatially separated in the tablet matrix, because we 
intentionally spike the free base of PIO into the powder mixture. The results of close-step 
mapping for the stressed tablets naturally present a different scenario. Specifically, it is 
reasonable to assume that the PIO free base will reside spatially adjacent to the PIO-HCl 
salt from which is came. Hence, intensity of the peak II and peak III are used to further 
identify the disproportionation of PIO-HCl salt, which will be illustrated in the following 
section. 
6.5.3.2 Disproportionation studies for 5% DL tablets 
In this study, we used 5% DL tablets formulated with inert excipients and Mgst (model 







compatibility and salt disproportionation within a multi-component tablet matrix 
(detailed formulations are listed in Table 2S). Deliberate sub-sampling and close-step 
mapping were conducted on both the freshly prepared model tablets and the same model 
tablets stressed at 40°C/75% R.H. for 12 hours. Before scanning the model tablets, it is 
necessary to estimate the minimal number of acquired spectra for deliberate sub-sampling. 
The kinetics study for the 30% DL tablets (Figure 6.4) provides the information that 
about 10% PIO-HCl converted to the PIO Free base for the tablets in presence of Mgst or 
CCNa. The 5% DL tablets were exposed to the same stressed conditions and have a 
similar ratio of drug to disproportionating agents. Hence, it is reasonable to assume that 
10% PIO-HCl would convert to its neutral form after 12 hours for the 5% DL tablets. 
Based on the previous discussion about the deliberate sub-sampling, 1024 spectra (32×32 
spots, step size =161.2 μm) were collected throughout the surface of the model tablet to 
ensure a high probability of finding one interesting spot for close-step mapping. The 
deliberate sub-sampling results for both the model tablets and stressed model tablets are 
shown in the supporting information (Figure A.25 to Figure A.28), and the areas targeted 
for close-step scanning are marked for clarity.  
The close-step mapping for initial model tablet 1 is shown in Figure 6A. The spectrum of 
A2, a hot pixel located at the edge of the API concentrated area, shows that peak II has a 
lower intensity than peak III. As the spectrum of pure PIO-HCl is expected to 
demonstrate similar intensity for peak II and peak III (Figure 6.1), the spectral 
discrepancy between A2 and pure PIO-HCl indicates the existence of PIO free base in the 
API concentrated area. This observation indicates that disproportionation of PIO-HCl salt 







ambient conditions, we did not observe any disproportionation of the 30%DL tablet 
formulated with Mgst by the combined chemometrics and Raman bulk measurements due 
to poor detection limits for low content substances. 
For the stressed model tablet 1 (Figure 6.6B), the spectrum (Figure 6.6B1 and 6.6B2) 
from the API concentrated area displays lower intensity for peak II suggesting that the 
larger amount of PIO-HCl salt has converted to its free base. It has also been observed 
that the peak II of B2 has slightly lower intensity than that of B1. A possible explanation 
is that surface of the API particle is coated with Mgst, which contributes to a faster 
disproportionation rate at the surface than for the material in the core. The results of 
close-step mapping (Figure 6.7) for model tablet 2 could be interpreted in a same way. 
Based on the mapping results of the initial model tablet 2 (Figure 6.7A), we did not 
observe PIO free base at ambient conditions probably due to higher critical R.H. for 
disproportionation of this system. For the stressed model tablet 2 (Figure 6.7B), the 
spectrum of B2, at the edge of API concentrated area, shows a lower intensity of peak II, 
indicating the occurrence of disproportionation.  
Although the approaches we have proposed in this study could be applied to detect the 
existence of a minor component with satisfaction, we came to realize that this Raman 
mapping method is best suited to qualitatively detect the targeted substances, rather than 
for quantification for the following two reasons. First, the deliberate sub-sampling 
method was derived from a binomial distribution, which means that it is only able to 
conceptually tell a “yes” or “no” for the targe t species. Second, in this study, the close-
step mapping only analyzed a 200 μm×200 μm area out of a 5mm×5mm tablet surface. It 







components generally have a wide distribution over the tablet surface and the core. In 
addition, although the analytical time to generate the imaging is significantly reduced by 
the employment of deliberate sub-sampling, it is important to point out that it is still a 
very time consuming process. With the development of non-linear optical imaging 
approaches, broadband coherent anti-stokes Raman scattering (BCARS) microscopy can 
provide a possible remedy to further resolve our time-consuming problem by taking 
advantage of its fast acquisition time and high spatial resolution.239 Using BCARS to 









This study demonstrated that Raman bulk measurements combined with chemometrics 
are appropriate to analyze the kinetics of disproportionation for 30% DL PIO-HCl tablets. 
A-Tab, Mgst, CCNa all has the potential to facilitate disproportionation of PIO-HCl due 
to their high alkalinity and capacity to accept protons. At 40°C/75 R.H., approximate 10% 
of PIO-HCl formulated with Mgst or CCNa converts to PIO free base in 12 hours. In 
addition, this is the first time it has been reported that A-tab can lead to 
disproportionation of pioglitazone hydrochloride. Hence, formulation scientists should 
exert caution when formulating salts of weak bases with A-Tab, Mgst, and CCNa due to 
the potential risk of disproportionation.  
Deliberate sub-sampling and close-step mapping methods were applied for low drug 
loading (5% DL) PIO-HCl tablets. Applying the deliberate sub-sampling method, we 
successfully detected the suspected area of disproportionation for both calibration and 
stressed tablets. This statistically optimized sampling method is very effective and was 
able to significantly reduce the data analysis time. Utilizing the proposed two-step 
mapping approach, the presence of PIO free base was observed in a model tablet exposed 
at ambient conditions, which could not be detected by Raman bulk measurements. This 
important finding suggests that the proposed method has the potential to detect minor 
species in a multi-component tablet matrix. Moreover, this finding also indicates that 
Mgst could lead to the disproportionation of PIO-HCl even at ambient conditions (below 
the reported critical R.H.). To the best of our knowledge, this is the first time that Raman 
mapping has been employed to study salt disproportionation in a multi-component tablet 







disproportionation, which is a minor component embedded in a tablet, will help 
formulation scientists better understand in situ drug-excipients compatibility. Hence the 
findings of this study could profoundly impact the formulation design of dosage forms 
containing pharmaceutical salts. 
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Figure 6.2 Raman spectra of 30% DL calibration tablets over the spectral range 1500cm-1 
to 1800cm-1 (A); PCA model for 30%DL calibration tablets (B); 
Raman spectra of 5% DL calibration tablets over the spectral range 1500cm-1 to 1800cm-1 










Figure 6.3 PLS model for 30%DL calibration tablets (A); PLS model for 5%DL 











Figure 6.4 Kinetics of disproportionation for 30% DL Pio-HCl tablets stressed at 


















Figure 6.5 Raman imaging of calibrated tablets (5% DL, 80% Pio-HCl salt) deliberate 













Figure 6.6 Raman close-step mapping for Pio-HCl tablet formulated with Mgst (model 














Figure 6.7 Raman close-step mapping of Pio-HCl tablet formulated with CCNa (model 
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Figure A. 1 PXRD stability data for dispersion system of CLF with different polymers 
stressed at 40°C 75%RH conditions (A: HPMCP; B: HPMC and C: PVPVA). Percentage 

















Figure A. 3 1D 1H NMR for CLF in DMSO, 298K 
 
 









Figure A. 5 2D HSQC of CLF in DMSO, 298K 
 
 










Figure A. 7 1D 1H NMR of CLF with acetic acid and HPMCP in CDCl3, 298K 
 
 



































Figure A. 12 Pictures of Pure CLF and amorphous solid dispersion of CLF and HPMCP 











Figure A. 13 Infrared spectra of PIO-HCl salt and PIO-FB 
 
 








Figure A. 15 API and metallic stearates mixtures exposed at same laser power source 
(described at experimental section) for 10mins (A: pure PIO-HCl sample; B: PIO-HCl 


















Figure A. 17 Moisture absorption profile of PIO-HCl at the % RH range of 30% to 95% 
 
 
Figure A. 18 Water sorption curves of pure PIO-HCl (Red) and pure PIO-FB (Blue) at 








Figure A. 19 Water sorption curves of pure CaSt (Red), pure MgSt (Blue), and pure NaSt 









Figure A. 20 Tensile strength of high speed compacted tablets (A) and low speed 










Figure A. 21 Chemical structure of Pioglitazone and excipients and the 











Figure A. 22 (A) PXRD of Pio-HCl salt and Pio free base, (B) FT-IR of Pio –HCl salt 












Figure A. 23 PIO-HCl salt and its mixtures with disproportionation agents exposed at 
same laser power source (described at experimental section) for 10mins (A-C is bulk 
measurement, D-F is microscopic measurement, A and D are pure PIO-HCl sample, B 



















Figure A. 25 Raman imaging deliberate sub-sampling for Pio-HCl tablet formulated with 











Figure A. 26 Raman imaging deliberate sub-sampling for Pio-HCl tablet formulated with 









Figure A. 27 Raman imaging deliberate sub-sampling for Pio-HCl tablet formulated with 












Figure A. 28 Raman imaging deliberate sub-sampling for Pio-HCl tablet formulated with 











Table A. 1 Optimized Cartesian coordinates, natural population analysis, and isotropic 
magnetic shielding tensors of pure CLF, calculated at the level of B3PW91 with 6-







shielding tensor(ppm) X Y Z 
Cl 8.57929 0.70438 0.20117 -0.00125 708.9403 
Cl -6.96678 -2.33405 0.30340 0.01827 690.4833 
N 0.08787 2.77828 -0.16436 -0.45669 -60.7806 
N -2.17413 1.14860 -0.02273 -0.38952 103.7129 
C -0.92483 0.56464 -0.04051 0.31490 47.4209 
C 1.52816 0.91705 -0.11050 -0.27753 84.1422 
N 2.93334 -1.07215 -0.07029 -0.53210 136.1622 
C 0.21950 1.47720 -0.10523 0.15735 31.1400 
C -2.33307 2.52604 -0.08258 0.28526 51.4044 
C 5.25061 -1.37969 -0.56999 -0.14170 60.0886 
N 0.88340 -2.62405 -0.02109 -0.54172 -52.8164 
C 0.57893 -1.36804 -0.02587 0.23097 30.7503 
C 1.73853 -0.42938 -0.05779 0.18777 40.4934 
C 4.23871 -0.59566 -0.00222 0.12600 43.0956 
C -3.83940 -0.05297 1.29676 -0.14130 49.6256 
C -1.16773 3.32165 -0.15777 0.06111 44.9712 
C -3.33343 0.30745 0.05487 0.09306 45.0816 
C -0.73263 -0.78672 -0.01272 -0.40698 94.4555 
C -4.96075 -0.86602 1.37776 -0.23558 49.9542 
C 5.92598 0.98447 0.70899 -0.22138 52.6299 
C 4.59800 0.58765 0.64988 -0.22382 63.8541 
C -1.30440 4.71687 -0.22263 -0.18716 53.0886 
C -2.54884 5.31069 -0.21148 -0.22846 59.6242 
C 6.90764 0.19823 0.12901 -0.07236 49.7895 
C -3.59224 3.13477 -0.06974 -0.29401 68.8093 
C -5.55877 -1.31023 0.20735 -0.04361 38.7639 
C -0.13835 -3.65427 -0.00754 -0.07321 133.2955 
C 6.57683 -0.99110 -0.50432 -0.24630 52.2951 














shielding tensor(ppm) X Y Z 
C -3.93856 -0.14334 -1.11078 -0.19026 49.5801 
C -5.06015 -0.95700 -1.03814 -0.21844 50.0098 
C -0.52460 -4.02093 -1.44221 -0.57691 164.3251 
C 0.39540 -4.86815 0.74601 -0.54806 161.0774 
H 1.28777 -5.26013 0.25364 0.19533 30.3906 
H -0.35451 -5.66062 0.78141 0.19683 30.5956 
H 0.66214 -4.60308 1.77003 0.20628 30.5534 
H -1.58611 -1.44538 0.01012 0.22822 26.2069 
H 2.34094 1.62215 -0.18724 0.22782 24.2707 
H -0.39768 5.30516 -0.28056 0.22595 23.5507 
H -4.48607 2.53033 -0.01053 0.22748 24.9227 
H 7.34686 -1.60505 -0.95025 0.22989 24.0039 
H -1.04025 -3.30939 0.51360 0.17123 28.1268 
H 6.19296 1.89939 1.21954 0.23000 23.8707 
H -3.53510 0.14234 -2.07321 0.23669 23.9729 
H -5.36488 -1.15025 2.33901 0.23575 23.5576 
H 3.85293 1.18866 1.14832 0.22732 23.5758 
H -2.63930 6.38780 -0.26157 0.21693 24.0465 
H -3.35890 0.30274 2.19856 0.22912 23.9343 
H -4.67402 4.97063 -0.12331 0.21620 24.1657 
H 4.98938 -2.30260 -1.07268 0.21225 24.3498 
H -5.54039 -1.31191 -1.93897 0.23652 23.5464 
H 2.78999 -2.07853 -0.14492 0.42531 22.2766 
H -0.92438 -3.15754 -1.97566 0.20332 30.8624 
H -1.28074 -4.80821 -1.44536 0.20497 30.6935 








Table A. 2 Calculated energies of the pure CLF under temperature of 298.15 Kelvin and 
pressure of 1.00 atm 
 
Zero-point correction 0.429324 (Hartree/Particle) 
Thermal correction to Energy 0.457493 
Thermal correction to Enthalpy 0.458437 
Thermal correction to Gibbs Free Energy 0.366616 
E(RB3PW91) -2181.35315634 
Sum of electronic and zero-point Energies -2180.923832 
Sum of electronic and thermal Energies -2180.895663 
Sum of electronic and thermal Enthalpies -2180.894719 









Table A. 3 Optimized Cartesian coordinates, natural population analysis, and isotropic 
magnetic shielding tensors of the complex I, calculated at the level of B3PW91 with 6-







shielding tensor(ppm) X Y Z 
Cl -7.68268 2.64768 -0.45174 -0.00075 705.2324 
Cl 7.17515 -2.48455 -0.40050 0.02692 684.9506 
N 0.51282 3.09341 0.30079 -0.39130 -81.9411 
N 2.63927 1.30794 0.07801 -0.34344 77.7577 
C 1.36211 0.83669 0.00573 0.35090 48.3249 
C -1.04231 1.33572 0.05530 -0.29844 81.8958 
N -2.63278 -0.44875 -0.21798 -0.60517 120.4140 
C 0.28504 1.80723 0.12344 0.13202 35.6761 
C 2.90156 2.65391 0.26316 0.28644 53.1113 
C -4.88142 -0.04005 0.52789 -0.20570 54.4976 
N -0.53641 -2.25168 -0.38380 -0.50466 92.1246 
C -0.25735 -0.96541 -0.21961 0.27256 30.0124 
C -1.36257 0.01151 -0.12317 0.21630 39.3163 
C -3.79630 0.34009 -0.26384 0.14992 41.9198 
C 4.26926 0.10794 -1.28879 -0.19059 51.0405 
C 1.79247 3.53023 0.37386 0.06702 42.5922 
C 3.73947 0.38496 -0.03665 0.09557 45.7090 
C 1.06770 -0.50154 -0.15360 -0.39590 92.8903 
C 5.33132 -0.77703 -1.40377 -0.21410 49.9191 
C -5.11964 2.13798 -1.18354 -0.22338 53.6051 
C -3.93024 1.42845 -1.12795 -0.21341 58.8601 
C 2.03534 4.90627 0.56499 -0.18075 51.1835 
C 3.31770 5.38915 0.64194 -0.21137 55.8608 
C -6.18354 1.75042 -0.38271 -0.05897 46.5212 
C 4.20657 3.15780 0.34257 -0.28432 66.0951 
C 5.84363 -1.37176 -0.25938 -0.04011 37.4957 
C 0.45578 -3.32092 -0.51204 -0.05234 135.8688 
C -6.07604 0.66094 0.46761 -0.21900 51.3938 







Table A. 3 continued 
 
C 4.25530 -0.21192 1.10505 -0.19075 51.7584 
C 5.31660 -1.09852 0.99496 -0.21349 49.3221 
C 0.90767 -3.81564 0.86104 -0.58829 166.1825 
C -0.13119 -4.44234 -1.35932 -0.58488 165.5475 
H -1.01868 -4.86459 -0.88703 0.21843 29.9838 
H 0.60687 -5.23563 -1.47809 0.21370 30.6200 
H -0.41083 -4.08107 -2.34916 0.21350 30.3694 
H 1.87454 -1.21230 -0.21129 0.23982 25.6546 
H -1.82017 2.07560 0.16438 0.24890 23.8469 
H 1.17551 5.55772 0.64793 0.23204 23.2013 
H 5.05260 2.49144 0.25865 0.23294 24.4683 
H -6.91316 0.36559 1.08478 0.23081 23.8628 
H 1.31343 -2.91120 -1.04810 0.19810 28.1313 
H -5.22168 2.97850 -1.85578 0.22979 23.9119 
H 3.83194 0.01344 2.07483 0.24060 24.0498 
H 5.75562 -1.00064 -2.37218 0.23923 23.4544 
H -3.11358 1.71269 -1.77727 0.22825 23.7395 
H -1.51532 -2.58537 -0.31011 0.44172 19.7410 
H 3.49355 6.44646 0.78904 0.22192 23.6783 
H 3.85665 0.58121 -2.16976 0.23951 23.8431 
H 5.41579 4.88992 0.59048 0.22106 23.7955 
H -4.77370 -0.88898 1.19281 0.24937 23.3384 
H 5.72905 -1.57063 1.87516 0.23968 23.4162 
H -2.82566 -1.46574 -0.10169 0.44616 17.9317 
H 1.31447 -3.00405 1.46488 0.21122 30.4587 
H 1.67948 -4.57799 0.74726 0.21224 30.7786 
H 0.06889 -4.25416 1.40305 0.21621 30.6544 
O -3.12998 -3.13781 -0.17097 -0.84572 12.6727 
O -3.67180 -2.93390 1.99006 -0.75581 -53.5009 
C -3.69265 -3.54152 0.90946 0.79687 2.6289 
C -4.44041 -4.86116 0.79853 -0.69004 160.8492 
H -3.75885 -5.64702 0.46829 0.21453 29.6330 
H -4.88711 -5.14224 1.74960 0.20817 30.0257 








Table A. 4 Calculated energies of complex I under temperature of 298.15 Kelvin and 
pressure of 1.00 atm 
 
Zero-point correction 0.493224 (Hartree/Particle) 
Thermal correction to Energy 0.527141 
Thermal correction to Enthalpy 0.528085 
Thermal correction to Gibbs Free Energy 0.423258 
E(RB3PW91) -2410.44999132 
Sum of electronic and zero-point Energies -2409.956767 
Sum of electronic and thermal Energies -2409.922850 
Sum of electronic and thermal Enthalpies -2409.921906 








Table A. 5 Optimized Cartesian coordinates, natural population analysis, and isotropic 
magnetic shielding tensors of the complex II, calculated at the level of B3PW91 with 6-







shielding tensor(ppm) X Y Z 
Cl -7.62533 -2.75090 0.73472 0.00098 706.8703 
Cl 7.15649 2.40229 0.80066 0.02011 689.2134 
N 0.48551 -3.05212 -0.56459 -0.45022 -63.1730 
N 2.61988 -1.30663 -0.12907 -0.37890 97.3801 
C 1.33530 -0.81785 -0.09539 0.32393 47.5082 
C -1.07402 -1.31372 -0.24807 -0.31041 83.7448 
N -2.65550 0.44474 0.17418 -0.64242 138.6902 
C 0.26094 -1.78336 -0.31906 0.14526 32.5930 
C 2.87903 -2.64530 -0.38608 0.28257 51.6839 
C -4.96503 0.01516 -0.40207 -0.19617 54.6151 
N -0.63826 2.25853 0.18023 -0.55326 -21.8689 
C -0.29773 1.00316 0.09816 0.19885 25.9122 
C -1.38680 -0.00482 -0.00070 0.34719 35.7815 
C -3.81324 -0.34951 0.29421 0.14634 42.9609 
C 4.16476 -0.18059 1.38923 -0.14319 50.1542 
C 1.77398 -3.49993 -0.60624 0.06369 44.4889 
C 3.71606 -0.40693 0.09505 0.07859 44.7204 
C 1.04321 0.50332 0.10699 -0.40931 92.3096 
C 5.22649 0.68471 1.61068 -0.23392 50.0142 
C -5.02333 -2.19763 1.27444 -0.22371 53.3444 
C -3.85878 -1.45829 1.14143 -0.20866 56.2635 
C 2.01356 -4.85892 -0.87169 -0.18315 52.6240 
C 3.29663 -5.35756 -0.91679 -0.22470 58.9171 
C -6.15559 -1.81960 0.56847 -0.05788 46.5206 
C 4.17942 -3.15989 -0.43076 -0.29135 67.8840 
C 5.82303 1.31357 0.52735 -0.04408 38.5555 
C 0.38586 3.27434 0.42886 -0.06536 131.4664 
C -6.13773 -0.71180 -0.26351 -0.22142 52.2908 







Table A. 5 continued 
 
C 4.31783 0.22812 -0.98302 -0.14709 50.4861 
C 5.38032 1.09442 -0.76914 -0.23324 49.8214 
C 1.00085 3.78026 -0.87860 -0.59412 166.0610 
C -0.22971 4.41810 1.22974 -0.58205 162.8510 
H -1.01322 4.92035 0.66063 0.20447 30.2959 
H 0.53484 5.15648 1.47779 0.20614 30.6565 
H -0.66586 4.04998 2.15882 0.21029 30.4883 
H 1.85317 1.20502 0.21699 0.23028 26.0279 
H -1.84824 -2.05561 -0.37381 0.23146 24.4635 
H 1.15316 -5.49421 -1.03751 0.22426 23.5290 
H 5.02564 -2.51005 -0.26008 0.22802 24.8067 
H -7.02677 -0.42198 -0.80601 0.23035 23.8821 
H 1.18545 2.84713 1.04285 0.18177 28.1862 
H -5.05277 -3.05340 1.93442 0.23060 23.9296 
H 3.95885 0.04503 -1.98710 0.23026 24.0234 
H 5.58601 0.86667 2.61353 0.23639 23.5191 
H -2.98521 -1.73741 1.71406 0.23072 23.6848 
H -1.81525 3.02184 -0.72985 0.49902 17.0173 
H 3.46678 -6.40618 -1.12237 0.21782 23.9939 
H 3.68694 -0.68004 2.22161 0.22991 23.8960 
H 5.39097 -4.88751 -0.72561 0.21708 24.1064 
H -4.94313 0.87896 -1.05121 0.23016 24.3045 
H 5.85804 1.59271 -1.60069 0.23644 23.5051 
H -2.79620 1.44815 0.25272 0.44157 22.3667 
H 1.44303 2.96524 -1.45270 0.20634 30.7271 
H 1.78168 4.51325 -0.66834 0.20898 30.7645 
H 0.24291 4.26019 -1.49930 0.21016 30.6897 
O -2.37996 3.60819 -1.34706 -0.73162 81.7044 
O -3.98548 3.13516 0.12970 -0.67013 -73.1908 
C -3.59931 3.74262 -0.85437 0.81942 3.1301 
C -4.44833 4.70749 -1.62740 -0.68713 164.1599 
H -4.46325 4.42834 -2.68122 0.23493 29.3933 
H -5.45840 4.72086 -1.22948 0.22666 29.9144 









Table A. 6 Calculated energies of the complex II under temperature of 298.15 Kelvin and 
pressure of 1.00 atm 
 
Zero-point correction 0.492050 (Hartree/Particle) 
Thermal correction to Energy 0.526187 
Thermal correction to Enthalpy 0.527132 
Thermal correction to Gibbs Free Energy 0.420792 
E(RB3PW91) -2410.44555476 
Sum of electronic and zero-point Energies -2409.953505 
Sum of electronic and thermal Energies -2409.919367 
Sum of electronic and thermal Enthalpies -2409.918423 









Table A. 7 Optimized Cartesian coordinates and isotropic magnetic shielding tensors of 




Coordinates(Angstroms) Isotropic magnetic 
shielding tensor(ppm) X Y Z 
Si 0.000000 0.000000 0.000000 339.1847 
C 0.000000 0.000000 1.881823 186.9601 
H 0.882586 -0.509561 2.275011 31.6975 
H 0.000000 1.019123 2.275011 31.6975 
H -0.882586 -0.509561 2.275011 31.6975 
C 0.000000 -1.774199 -0.627274 186.9601 
H -0.882586 -2.314755 -0.277918 31.6975 
H 0.000000 -1.805193 -1.719175 31.6975 
H 0.882586 -2.314755 -0.277918 31.6975 
C -1.536502 0.887100 -0.627274 186.9601 
H -1.563343 1.921719 -0.277918 31.6975 
H -1.563343 0.902597 -1.719175 31.6975 
H -2.445930 0.393035 -0.277918 31.6975 
C 1.536502 0.887100 -0.627274 186.9601 
H 2.445930 0.393035 -0.277918 31.6975 
H 1.563343 0.902597 -1.719175 31.6975 
H 1.563343 1.921719 -0.277918 31.6975 
 
Table A. 8 Changes of calculated NMR chemical shifts (ppm) and experimental 
chemical shifts (ppm) for H4 and H6 
 
 Experimental chemical Shifts Calculated chemical Shifts 
Pure CLF CLF+HPMCP Pure CLF Complex I Complex II 
H4 5.27 5.76 5.49 6.04 5.67 













ASDs (CLF:HPMCP ratio) Pure CLF 
1:9 1:2 1:1 1:0.75 1:0.25 Crystalline API Amorphous API 









Table A. 10 Optimized Cartesian coordinates, natural population analysis, and isotropic 
magnetic shielding tensors of pure CLF, calculated at the level of B3PW91 with 6-













shift X Y Z 
Cl1 6.96497 -2.34197 -0.32879 0.02925 684.8764 NA 
Cl2 -8.57554 0.70736 -0.23235 0.01003 702.7735 NA 
N3 -0.88997 -2.61850 0.04165 -0.53475 -53.8368 NA 
N4 -2.93251 -1.06522 0.09037 -0.53186 136.5883 NA 
N5 -0.08004 2.77901 0.17890 -0.43855 -67.3732 NA 
N6 2.17885 1.14646 0.02566 -0.39714 106.6676 NA 
C7 0.73308 -0.78703 0.02359 -0.40561 94.9237 91.6519 
C8 -0.58112 -1.36475 0.04245 0.23413 31.0403 155.5353 
C9 -1.73767 -0.42301 0.07650 0.18750 40.8414 145.7342 
C10 -1.52396 0.92228 0.13004 -0.27136 83.4594 103.1162 
C11 1.31285 4.71451 0.23240 -0.17810 52.2162 134.3594 
C12 2.55709 5.30792 0.21552 -0.22462 59.9295 126.6461 







Table A. 10 continued 
 
C14 3.59927 3.13294 0.06680 -0.29557 70.0641 116.5115 
C15 2.34046 2.52537 0.08590 0.28238 52.0423 134.5333 
C16 1.17527 3.31999 0.16717 0.06405 44.6101 141.9655 
C17 -0.21429 1.47936 0.11987 0.15622 31.4721 155.1035 
C18 0.92747 0.56326 0.04996 0.31299 47.8462 138.7294 
C19 3.33476 0.30494 -0.05829 0.09855 44.6241 141.9515 
C20 3.95150 -0.14401 1.10216 -0.19063 49.7003 136.8753 
C21 5.07165 -0.95874 1.02288 -0.21842 50.4750 136.1006 
C22 5.56153 -1.31863 -0.22447 -0.04390 38.3801 148.1955 
C23 4.95145 -0.87663 -1.38984 -0.23556 50.3588 136.2168 
C24 3.83184 -0.06229 -1.30192 -0.14158 49.7901 136.7855 
C25 -4.23700 -0.58926 0.01154 0.12714 43.4411 143.1345 
C26 -4.59169 0.59467 -0.64137 -0.22216 64.4502 122.1254 
C27 -5.91905 0.98986 -0.71254 -0.21743 52.7197 133.8559 
C28 -6.90790 0.20370 -0.14449 -0.06959 48.9103 137.6653 
C29 -6.57979 -0.98559 0.49011 -0.24258 52.5142 134.0614 
C30 -5.25433 -1.37317 0.56853 -0.14137 61.0764 125.4992 
C31 0.12219 -3.65546 0.02557 -0.07123 133.3554 53.2202 
C32 0.49790 -4.03316 1.46009 -0.57428 164.0618 22.5138 
C33 -0.42059 -4.85916 -0.73792 -0.54563 160.8518 25.7238 
H34 -2.78534 -2.07209 0.15561 0.42390 22.2777 9.4342 
H35 1.58396 -1.44914 -0.00262 0.22289 26.3378 5.3741 
H36 -2.33220 1.63154 0.21359 0.22775 24.2757 7.4362 
H37 0.40414 5.29869 0.29507 0.22498 23.5408 8.1711 
H38 2.64791 6.38500 0.26600 0.21104 24.1627 7.5492 
H39 4.68131 4.96904 0.11610 0.20944 24.3270 7.3849 
H40 4.49269 2.52816 0.00209 0.22101 25.1028 6.6091 
H41 3.55494 0.14617 2.06626 0.23060 24.0911 7.6208 
H42 5.56080 -1.31214 1.91960 0.23044 23.6688 8.0431 
H43 5.34833 -1.16631 -2.35262 0.22966 23.6824 8.0295 
H44 3.34194 0.29098 -2.19976 0.22317 24.0678 7.6441 
H45 -3.84019 1.19567 -1.13028 0.22296 23.6485 8.0634 
H46 -6.18398 1.90522 -1.22343 0.22404 23.9850 7.7269 








Table A. 10 continued 
 
H48 -4.99614 -2.29540 1.07458 0.20398 24.5435 7.1684 
H49 1.03022 -3.31620 -0.48989 0.16656 28.1798 3.5321 
H50 0.90414 -3.17632 1.99924 0.20208 30.8910 0.8209 
H51 1.24420 -4.82998 1.46537 0.20156 30.7521 0.9598 
H52 -0.38385 -4.38428 1.99934 0.20653 30.8080 0.9039 
H53 -0.68327 -4.58298 -1.75976 0.20715 30.5338 1.1781 
H54 -1.31887 -5.24361 -0.25102 0.19585 30.3752 1.3367 





















Table A. 11 Optimized Cartesian coordinates, natural population analysis, and isotropic 
magnetic shielding tensors of the complex I, calculated at the level of B3PW91 with 6-














shift X Y Z 
Cl1 -7.68973 2.59461 -0.28619 0.01038 696.5541 NA 
Cl2 7.19769 -2.42208 -0.29395 0.03868 679.1959 NA 
N3 0.45827 3.08564 0.21370 -0.38762 -79.9411 NA 
N4 2.60951 1.32132 0.05758 -0.36142 85.6160 NA 
C5 1.33703 0.83257 -0.03633 0.34576 48.6174 137.9582 
C6 -1.07280 1.30971 -0.04538 -0.30475 83.0503 103.5253 
N7 -2.63466 -0.49662 -0.32422 -0.59176 114.9628 NA 
C8 0.24511 1.79563 0.04645 0.13322 35.2700 151.3056 
C9 2.85408 2.67550 0.23352 0.27675 54.1428 132.4328 
C10 -4.82386 -0.06207 0.58080 -0.19641 52.3357 134.2399 
N11 -0.52633 -2.27513 -0.42697 -0.49515 75.7003 NA 







Table A. 11 continued 
 
C13 -1.37805 -0.02224 -0.21450 0.22467 37.2488 149.3268 
C14 -3.80763 0.28630 -0.30826 0.14521 42.8044 143.7712 
C15 4.27656 0.12192 -1.26391 -0.19211 51.0684 135.5072 
C16 1.73177 3.53654 0.31015 0.06698 42.6147 143.9609 
C17 3.71986 0.41242 -0.02609 0.10349 45.2341 141.3415 
C18 1.06279 -0.50786 -0.18545 -0.40264 94.4669 92.1087 
C19 5.35069 -0.75157 -1.34971 -0.21531 50.3404 136.2352 
C20 -5.19326 2.05184 -1.19155 -0.22324 54.2212 132.3544 
C21 -4.00399 1.34032 -1.19985 -0.20883 57.9018 128.6738 
C22 1.95527 4.91608 0.49196 -0.17579 50.8742 135.7014 
C23 3.23011 5.41708 0.59150 -0.21274 57.1417 129.4339 
C24 -6.19236 1.69836 -0.29673 -0.05262 44.2766 142.299 
C25 4.14996 3.19550 0.33459 -0.28880 67.9637 118.6119 
C26 5.85358 -1.32601 -0.19037 -0.04153 37.2474 149.3282 
C27 0.46870 -3.34430 -0.49617 -0.04974 135.4767 51.0989 
C28 -6.01807 0.64250 0.58466 -0.21517 51.1016 135.474 
C29 4.32973 4.55141 0.51173 -0.17967 55.0444 131.5312 
C30 4.22692 -0.16479 1.12992 -0.19250 51.8555 134.7201 
C31 5.30046 -1.03976 1.05015 -0.21446 49.6521 136.9235 
C32 0.81994 -3.83867 0.90681 -0.58666 165.7214 20.8542 
C33 -0.07118 -4.46162 -1.38164 -0.58532 165.6767 20.8989 
H34 -1.01055 -4.84897 -0.98699 0.22972 29.5884 2.1235 
H35 0.65261 -5.27565 -1.43156 0.20613 30.8115 0.9004 
H36 -0.25676 -4.10219 -2.39412 0.21096 30.4695 1.2424 
H37 1.87710 -1.21212 -0.21247 0.23119 25.9399 5.772 
H38 -1.86043 2.04230 0.04038 0.25028 24.0612 7.6507 
H39 1.08342 5.55400 0.54934 0.22992 23.2958 8.4161 
H40 5.00554 2.53813 0.27569 0.22444 24.7750 6.9369 
H41 -6.80627 0.37688 1.27526 0.22619 23.9324 7.7795 
H42 1.36538 -2.94211 -0.97175 0.18773 28.2659 3.446 
H43 -5.34977 2.86725 -1.88385 0.22367 24.0160 7.6959 









Table A. 11 continued 
 
H45 5.79505 -0.98497 -2.30695 0.23313 23.5792 8.1327 
H46 -3.23400 1.59432 -1.91614 0.22137 23.9475 7.7644 
H47 -1.52337 -2.63027 -0.35941 0.44542 16.4745 15.2374 
H48 3.38815 6.47833 0.73149 0.21485 23.8959 7.816 
H49 3.87168 0.57892 -2.15732 0.23235 23.9890 7.7229 
H50 5.33460 4.94554 0.58995 0.21302 24.0852 7.6267 
H51 -4.65855 -0.88448 1.26783 0.25462 23.3364 8.3755 
H52 5.70563 -1.49588 1.94232 0.23377 23.5437 8.1682 
H53 -2.80780 -1.52136 -0.23279 0.45104 17.8959 13.816 
H54 1.20392 -3.02926 1.52880 0.20741 30.6047 1.1072 
H55 1.57907 -4.62043 0.85131 0.20572 30.8970 0.8149 
H56 -0.06341 -4.24818 1.39764 0.22470 30.3969 1.315 
O57 -2.99334 -3.21001 -0.27527 -0.84325 13.3272 NA 
O58 -3.34450 -2.89198 1.91053 -0.71498 -77.6898 NA 
C59 -3.52743 -3.51391 0.86194 0.79028 3.8583 182.7173 
C60 -4.45110 -4.71988 0.83368 -0.68484 161.3616 25.214 
H61 -3.91436 -5.59330 0.45919 0.21009 29.7610 1.9509 
H62 -4.84727 -4.92731 1.82485 0.21013 30.0182 1.6937 









Table A. 12 Optimized Cartesian coordinates, natural population analysis, and isotropic 
magnetic shielding tensors of the complex II, calculated at the level of B3PW91 with 6-














shift X Y Z 
Cl1 7.63172 2.73651 0.94989 0.00879 702.6859 NA 
Cl2 -7.12110 -2.37487 1.00961 0.03139 682.8733 NA 
N3 -0.48982 3.02874 -0.70692 -0.43263 -69.3083 NA 
N4 -2.61503 1.30366 -0.15830 -0.38928 101.4706 NA 
C5 -1.32754 0.81620 -0.12685 0.32230 48.1676 138.408 
C6 1.07810 1.31116 -0.33150 -0.26860 81.7244 104.8512 
N7 2.66909 -0.42407 0.16729 -0.59303 137.0895 NA 
C8 -0.25889 1.77365 -0.40775 0.14513 32.7391 153.8365 
C9 -2.88054 2.63099 -0.47166 0.27958 52.2527 134.3229 
C10 5.03673 -0.09657 -0.17296 -0.13779 55.5216 131.054 
N11 0.65563 -2.24392 0.20949 -0.57577 -26.5639 NA 








Table A. 12 (continued) 
C13 1.39956 0.01503 -0.03302 0.16608 36.9535 149.6221 
C14 3.82183 0.36364 0.33766 0.12812 43.5886 142.987 
C15 -4.12384 0.23175 1.43309 -0.14386 50.5064 136.0692 
C16 -1.77868 3.47238 -0.74947 0.06598 44.2732 142.3024 
C17 -3.70364 0.41441 0.12236 0.08465 44.3640 142.2116 
C18 -1.02996 -0.49446 0.12092 -0.44763 92.4056 94.17 
C19 -5.17766 -0.62669 1.71046 -0.23386 50.4494 136.1262 
C20 4.97315 2.28405 1.25041 -0.21991 54.1653 132.4103 
C21 3.80876 1.55627 1.06520 -0.21651 59.9425 126.6331 
C22 -2.02297 4.81702 -1.07358 -0.17436 51.6441 134.9315 
C23 -3.30640 5.31440 -1.11945 -0.22182 59.2879 127.2877 
C24 6.16632 1.81744 0.72119 -0.06060 47.0489 139.5267 
C25 -4.18077 3.14362 -0.51636 -0.29379 69.2656 117.31 
C26 -5.80001 -1.29655 0.66657 -0.04448 38.0320 148.5436 
C27 -0.35982 -3.25317 0.50994 -0.07670 131.2554 55.3202 
C28 6.20481 0.62318 0.01938 -0.23863 52.6836 133.892 
C29 -4.38582 4.47226 -0.83782 -0.18423 55.7792 130.7964 
C30 -4.33106 -0.26163 -0.91577 -0.14846 50.4607 136.1149 
C31 -5.38618 -1.12113 -0.64632 -0.23314 50.4793 136.0963 
C32 -1.02843 -3.78023 -0.76289 -0.58935 166.0912 20.4844 
C33 0.28893 -4.38408 1.30300 -0.58543 162.4106 24.165 
H34 1.04788 -4.89355 0.70791 0.20576 30.2247 1.4872 
H35 -0.46229 -5.11943 1.59719 0.20167 30.7499 0.962 
H36 0.76688 -3.99943 2.20413 0.21645 30.4368 1.2751 
H37 -1.83448 -1.19537 0.26991 0.22476 26.1754 5.5365 
H38 1.84434 2.05154 -0.50327 0.23355 24.2329 7.479 
H39 -1.16261 5.43903 -1.28270 0.22342 23.5042 8.2077 
H40 -5.02394 2.50310 -0.30003 0.22128 24.9871 6.7248 
H41 7.14126 0.25837 -0.37902 0.22297 24.0814 7.6305 
H42 -1.13426 -2.81409 1.14905 0.18073 28.2866 3.4253 
H43 4.95503 3.20480 1.81680 0.22354 24.0719 7.64 
H44 -3.99444 -0.11334 -1.93345 0.22411 24.0976 7.6143 









Table A. 12 (continued) 
H46 2.88982 1.91116 1.50925 0.22526 23.7496 7.9623 
H47 1.77135 -3.04730 -0.79974 0.50070 18.0122 13.6997 
H48 -3.47959 6.35256 -1.37068 0.21188 24.1169 7.595 
H49 -3.62584 0.76150 2.23450 0.22372 24.0690 7.6429 
H50 -5.39677 4.85773 -0.86938 0.21019 24.2989 7.413 
H51 5.06450 -1.03755 -0.70344 0.22688 23.8688 7.8431 
H52 -5.88312 -1.65106 -1.44662 0.23039 23.6628 8.0491 
H53 2.80912 -1.42907 0.21988 0.44248 22.3972 9.3147 
H54 -1.48965 -2.97376 -1.33409 0.20223 30.7555 0.9564 
H55 -1.80302 -4.50610 -0.50837 0.20372 30.8726 0.8393 
H56 -0.29808 -4.27354 -1.40507 0.21738 30.5834 1.1285 
O57 2.25257 -3.64880 -1.45896 -0.72505 84.6437 NA 
O58 4.02807 -3.12504 -0.20844 -0.65473 -83.8943 NA 
C59 3.52853 -3.75029 -1.12389 0.81521 5.7669 180.8087 
C60 4.28836 -4.71073 -1.99297 -0.68404 164.4378 22.1378 
H61 4.20021 -4.41262 -3.03827 0.23050 29.5077 2.2042 
H62 5.33267 -4.73315 -1.69672 0.22473 29.9314 1.7805 










Table A. 13 Optimized Cartesian coordinates and isotropic magnetic shielding tensors of 




Coordinates(Angstroms) Isotropic magnetic 
shielding tensor(ppm) X Y Z 
Si 0.00000 0.00000 0.00000 339.4622 
C 1.08666 1.08666 1.08666 186.5756 
H 1.72988 0.48240 1.72988 31.7119 
H 1.72988 1.72988 0.48240 31.7119 
H 0.48240 1.72988 1.72988 31.7119 
C -1.08666 -1.08666 1.08666 186.5756 
H -1.72988 -0.48240 1.72988 31.7119 
H -1.72988 -1.72988 0.48240 31.7119 
H -0.48240 -1.72988 1.72988 31.7119 
C -1.08666 1.08666 -1.08666 186.5756 
H -0.48240 1.72988 -1.72988 31.7119 
H -1.72988 0.48240 -1.72988 31.7119 
H -1.72988 1.72988 -0.48240 31.7119 
C 1.08666 -1.08666 -1.08666 186.5756 
H 1.72988 -1.72988 -0.48240 31.7119 
H 0.48240 -1.72988 -1.72988 31.7119 









Table A. 14 Formulation of calibration tablets 
5% DL formulation 30%DL formulation Drug mixture 





Drug mixture 5 Drug mixture 30 100 0 
Mannitol 45 Avicel 32 99 1 
Avicel 45 Mannitol 32 97.5 2.5 






Table A. 15 Formulation of 30% DL tablets for disproportionation studies 











one HCl 30 
Pioglitaz
one HCl 30 
Pioglitaz
one HCl 30 
Pioglitaz
one HCl 30 
Mannitol 30 Mannitol 33 A-TAB 32 Mannitol 32 
Avicel 30 Avicel 33 Avicel 32 Avicel 32 
crospovid














Table A. 16 Formulation of 5% tablets for disproportionation studies 
5% DL formulation for mapping studies 
Material %wt./wt. Material %wt./wt. 
Pioglitazone HCl 5 Pioglitazone HCl 5 
Mannitol 47 Mannitol 45 
Avicel 47 Avicel 45 
ccNa 1 crospovidone 4.5 
 Mgst 0.5 
 
 
Table A. 17 Parameters of PLS model for 30%DL and 5%DL tablets 
 
30%DL  5% DL  
Number of Principle component 1 3 
Range of Raman shift (cm-1) 1500-1800 1500-1800 
R2X 0.823 0.682 
R2Y 0.996 0.984 
Q2 0.996 0.972 
RMSEE 0.436 0.982 
RMSECV 0.454 1.278 
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